<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>Operator_BCSC1819_S12_C21IDX_p431-470_3P</title>
		<link href="Operator_BCSC1819_S12_C21IDX_p431-470_3P-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="Operator_BCSC1819_S12_C21IDX_p431-470_3P" lang="en-US">
		<div id="_idContainer000" class="_idGenObjectStyleOverride-1">
			<p class="em-only_endmatter-title ParaOverride-1">Index</p>
			<p class="em-only_endmatter-idx1">(<span class="italic">f</span> <span class="symbol">=</span> figure; <span class="italic">t</span> <span class="symbol">=</span> &#173;table)</p>
			<p class="em-only_endmatter-idx-alpha"><span class="italic">ABCA4</span> gene</p>
			<p class="em-only_endmatter-idx2">retinopathy caused by, 31</p>
			<p class="em-only_endmatter-idx2">Stargardt disease caused by, 271</p>
			<p class="em-only_endmatter-idx1"><span class="italic">ABCC6</span> gene, 87</p>
			<p class="em-only_endmatter-idx1">Abetalipoproteinemia, 289–290</p>
			<p class="em-only_endmatter-idx1">Absolute scotomas, 327</p>
			<p class="em-only_endmatter-idx1">Abusive head trauma, 365–366, 366<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">ACCORD trial, 98</p>
			<p class="em-only_endmatter-idx1">Acetazolamide, 305, 393</p>
			<p class="em-only_endmatter-idx1">Achromatopsia, 250, 250<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Acquired vasoproliferative lesions, 168</p>
			<p class="em-only_endmatter-idx1">Acute exudative polymorphous vitelliform <br />maculopathy, 287</p>
			<p class="em-only_endmatter-idx1">Acute idiopathic maculopathy (AIM), 228–229</p>
			<p class="em-only_endmatter-idx1">Acute macular neuroretinopathy (AMN), 228, <br />229<span class="italic">f,</span> 277</p>
			<p class="em-only_endmatter-idx1">Acute posterior multifocal placoid pigment epitheliopathy (APMPPE), 220<span class="italic">t,</span> 221<span class="italic">f,</span> <br />221–222</p>
			<p class="em-only_endmatter-idx1">Acute ret&#173;i&#173;nal necrosis (ARN), 236, 236<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Acute syphilitic posterior placoid chorioretinitis (ASPPC), 241</p>
			<p class="em-only_endmatter-idx1">Acute zonal occult outer retinopathy (AZOOR)</p>
			<p class="em-only_endmatter-idx2">description of, 226–228, 227<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">electro-&#173;oculography of, 51</p>
			<p class="em-only_endmatter-idx1">Acyclovir</p>
			<p class="em-only_endmatter-idx2">acute ret&#173;i&#173;nal necrosis treated with, 236</p>
			<p class="em-only_endmatter-idx2">herpetic retinitis treated with, 238<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">progressive outer ret&#173;i&#173;nal necrosis syndrome treated with, 236</p>
			<p class="em-only_endmatter-idx1">Adaptation</p>
			<p class="em-only_endmatter-idx2">dark</p>
			<p class="em-only_endmatter-idx3">in electro-&#173;oculography, 50</p>
			<p class="em-only_endmatter-idx3">in full-&#173;field (Ganzfield) electroretinography, 42</p>
			<p class="em-only_endmatter-idx2">light</p>
			<p class="em-only_endmatter-idx3">in electro-&#173;oculography, 50</p>
			<p class="em-only_endmatter-idx3">in full-&#173;field (Ganzfield) electroretinography, 42</p>
			<p class="em-only_endmatter-idx1">Adaptive optics imaging, 33</p>
			<p class="em-only_endmatter-idx1">Adaptive optics scanning &#173;laser ophthalmoscope, of macula, 13<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Adult-&#173;onset foveomacular vitelliform dystrophy, 272, 276</p>
			<p class="em-only_endmatter-idx1">Adult-&#173;onset vitelliform lesions, 272, 273<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Adult-&#173;onset vitelliform maculopathy</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography of, 68</p>
			<p class="em-only_endmatter-idx2">spectral-&#173;domain optical coherence tomography of, 67–68, 68<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">A2E, 31</p>
			<p class="em-only_endmatter-idx1"><span class="italic">Aedes aegypti</span> mosquito, 247</p>
			<p class="em-only_endmatter-idx1">Afferent pupillary defect, 352</p>
			<p class="em-only_endmatter-idx1">Aflibercept</p>
			<p class="em-only_endmatter-idx2">branch ret&#173;i&#173;nal vein occlusion treated with, 135</p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal vein occlusion treated with, 135</p>
			<p class="em-only_endmatter-idx2">diabetic macular edema treated with, 113</p>
			<p class="em-only_endmatter-idx2">macular telangiectasia type 1 treated with, 161</p>
			<p class="em-only_endmatter-idx2">neovascular age-&#173;related macular degeneration treated with, 82–83</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal vein occlusion treated with, 135</p>
			<p class="em-only_endmatter-idx1">African Americans. <span class="italic">See also</span> Race</p>
			<p class="em-only_endmatter-idx2">sickle cell hemoglobinopathies and, 149, 154</p>
			<p class="em-only_endmatter-idx2">systemic lupus erythematosus in, 230</p>
			<p class="em-only_endmatter-idx1">Age</p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal vein occlusion and, 133</p>
			<p class="em-only_endmatter-idx2">central serous chorioretinopathy and, 189</p>
			<p class="em-only_endmatter-idx2">choroidal thickness affected by, 19, 212</p>
			<p class="em-only_endmatter-idx2">posterior vitreous detachment associated with, 307–308</p>
			<p class="em-only_endmatter-idx1">Age-&#173;Related Eye Disease Study (AREDS), 64, 69–71, 70<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Age-&#173;related macular degeneration (AMD)</p>
			<p class="em-only_endmatter-idx2">adult-&#173;onset foveomacular vitelliform dystrophy versus, 272, 273<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">aging as cause of, 61</p>
			<p class="em-only_endmatter-idx2">blindness caused by, 61</p>
			<p class="em-only_endmatter-idx2">Bruch membrane calcification in, 19</p>
			<p class="em-only_endmatter-idx2">cataract surgery effects on, 71</p>
			<p class="em-only_endmatter-idx2">central blindness progression of, 86</p>
			<p class="em-only_endmatter-idx2">central serous chorioretinopathy versus, 67, 76, 79</p>
			<p class="em-only_endmatter-idx2">choroidal neovascularization progression of, 64</p>
			<p class="em-only_endmatter-idx2">cigarette smoking and, 62</p>
			<p class="em-only_endmatter-idx2">exudative, 79</p>
			<p class="em-only_endmatter-idx2">ge&#173;ne&#173;tics of, 62–63</p>
			<p class="em-only_endmatter-idx2">ge&#173;ne&#173;tic testing for, 63</p>
			<p class="em-only_endmatter-idx2">low vision therapies and rehabilitation, 86</p>
			<p class="em-only_endmatter-idx2">management of, 68–71, 79–86, 81<span class="italic">f,</span> 82<span class="italic">t,</span> 84<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">neovascular (“wet”)</p>
			<p class="em-only_endmatter-idx3">aflibercept for, 82–83</p>
			<p class="em-only_endmatter-idx3">Amsler grid testing of, 71</p>
			<p class="em-only_endmatter-idx3">antiangiogenic therapies for, 79–80</p>
			<p class="em-only_endmatter-idx3">bevacizumab for, 83–85, 84<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">choroidal neovascularization associated with, 71–79. <span class="italic">See also</span> Choroidal neovascularization</p>
			<p class="em-only_endmatter-idx3">combination treatment for, 85</p>
			<p class="em-only_endmatter-idx3">differential diagnosis of, 76, 79</p>
			<p class="em-only_endmatter-idx3">intravitreal injections, 85</p>
			<p class="em-only_endmatter-idx3">&#173;laser photocoagulation for, 79</p>
			<p class="em-only_endmatter-idx3">low vision therapies for, 86</p>
			<p class="em-only_endmatter-idx3">macular translocation surgery for, 85</p>
			<p class="em-only_endmatter-idx3">management of, 79–86, 81<span class="italic">f,</span> 82<span class="italic">t,</span> 84<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">pegaptanib for, 80</p>
			<p class="em-only_endmatter-idx3">photodynamic therapy for, 79</p>
			<p class="em-only_endmatter-idx3">polypoidal choroidal vasculopathy, 75</p>
			<p class="em-only_endmatter-idx3">prevalence of, 61</p>
			<p class="em-only_endmatter-idx3">ranibizumab for, 80–82, 82<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">signs and symptoms of, 71</p>
			<p class="em-only_endmatter-idx3">submacular hemorrhage in, 85, 385</p>
			<p class="em-only_endmatter-idx3">surgical treatment for, 85–86</p>
			<p class="em-only_endmatter-idx3">treatment effect modifiers, 85</p>
			<p class="em-only_endmatter-idx3">verteporfin for, 79</p>
			<p class="em-only_endmatter-idx2">nonneovascular (“dry”)</p>
			<p class="em-only_endmatter-idx3">Amsler grid testing for, 68–69</p>
			<p class="em-only_endmatter-idx3">differential diagnosis of, 67–68</p>
			<p class="em-only_endmatter-idx3">disproven treatment approaches for, 71</p>
			<p class="em-only_endmatter-idx3">drusen associated with. <span class="italic">See</span> Drusen</p>
			<p class="em-only_endmatter-idx3">education regarding, 68</p>
			<p class="em-only_endmatter-idx3">focal atrophy in, 66</p>
			<p class="em-only_endmatter-idx3">follow-up for, 68</p>
			<p class="em-only_endmatter-idx3">geographic atrophy in, 64, 66, 67<span class="italic">f,</span> 68</p>
			<p class="em-only_endmatter-idx3">hydrochloroquine toxicity versus, 68</p>
			<p class="em-only_endmatter-idx3">hyperacuity testing for, 69</p>
			<p class="em-only_endmatter-idx3">lifestyle changes for, 71</p>
			<p class="em-only_endmatter-idx3">management of, 68–71</p>
			<p class="em-only_endmatter-idx3">micronutrients for, 69–71</p>
			<p class="em-only_endmatter-idx3">preferential hyperacuity perimetry for, 69</p>
			<p class="em-only_endmatter-idx3">prevalence of, 61</p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal pigment epithelium abnormalities in, <br />66–67</p>
			<p class="em-only_endmatter-idx3">shape-&#173;discrimination hyperacuity for, 69</p>
			<p class="em-only_endmatter-idx2">nonsubfoveal, 69</p>
			<p class="em-only_endmatter-idx2">pharmacogenomic testing for, 63</p>
			<p class="em-only_endmatter-idx2">prevalence of, 61</p>
			<p class="em-only_endmatter-idx2">race and, 62</p>
			<p class="em-only_endmatter-idx2">risk &#173;factors for, 62, 70<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">susceptibility genes for, 63</p>
			<p class="em-only_endmatter-idx1">Aggressive posterior retinopathy of prematurity, <br />177, 178<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">AIDS. <span class="italic">See also</span> HIV</p>
			<p class="em-only_endmatter-idx2">cytomegalovirus retinitis associated with, 235–236</p>
			<p class="em-only_endmatter-idx2">progressive outer ret&#173;i&#173;nal necrosis syndrome associated with, 236–237, 237<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">AIM. <span class="italic">See</span> Acute idiopathic maculopathy</p>
			<p class="em-only_endmatter-idx1">Alagille syndrome, 282<span class="italic">t,</span> 285</p>
			<p class="em-only_endmatter-idx1">Albinism, 288</p>
			<p class="em-only_endmatter-idx1">Albinoidism, 288</p>
			<p class="em-only_endmatter-idx1">Alkyl nitrites, 300, 300<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1"><span class="italic">Alphavirus,</span> 247</p>
			<p class="em-only_endmatter-idx1">Alstr<span class="accent">ö</span>m syndrome, 285</p>
			<p class="em-only_endmatter-idx1">Aluminum, in intraocular foreign body, 362</p>
			<p class="em-only_endmatter-idx1">Amacrine cells</p>
			<p class="em-only_endmatter-idx2">description of, 15</p>
			<p class="em-only_endmatter-idx2">illustration of, 15<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Amalric triangles, 198</p>
			<p class="em-only_endmatter-idx1">AMD. <span class="italic">See</span> Age-&#173;related macular degeneration</p>
			<p class="em-only_endmatter-idx1">Amelogenesis imperfecta, 286</p>
			<p class="em-only_endmatter-idx1">Amikacin, 300</p>
			<p class="em-only_endmatter-idx1">Amino acid disorders, 293</p>
			<p class="em-only_endmatter-idx1">Aminoglycosides, 300</p>
			<p class="em-only_endmatter-idx1">AMN. <span class="italic">See</span> Acute macular neuroretinopathy</p>
			<p class="em-only_endmatter-idx1">Amphotericin B, for fungal endophthalmitis, 239</p>
			<p class="em-only_endmatter-idx1">Amsler grid testing, in age-&#173;related macular degeneration, 68–69, 71</p>
			<p class="em-only_endmatter-idx1">Amyloidosis, 348, 349<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">ANCHOR study, 80–81</p>
			<p class="em-only_endmatter-idx1"><span class="italic">Ancylostoma caninum,</span> 246</p>
			<p class="em-only_endmatter-idx1">Anemia, diabetic retinopathy and, 98</p>
			<p class="em-only_endmatter-idx1">Anesthesia</p>
			<p class="em-only_endmatter-idx2">for intravitreal injections, 403</p>
			<p class="em-only_endmatter-idx2">for photocoagulation, 375</p>
			<p class="em-only_endmatter-idx1">Aneurysmal telangiectasia, 161</p>
			<p class="em-only_endmatter-idx1">Aneurysms, ret&#173;i&#173;nal arterial, 147–148, 148<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Angiogenesis</p>
			<p class="em-only_endmatter-idx2">activators of, 80</p>
			<p class="em-only_endmatter-idx2">definition of, 79</p>
			<p class="em-only_endmatter-idx2">endothelial cells in, 79</p>
			<p class="em-only_endmatter-idx2">inhibitors of, 80</p>
			<p class="em-only_endmatter-idx1">Angiography</p>
			<p class="em-only_endmatter-idx2">dye injection in, 24</p>
			<p class="em-only_endmatter-idx2">fluorescein. <span class="italic">See</span> Fluorescein angiography (FA)</p>
			<p class="em-only_endmatter-idx2">indocyanine green. <span class="italic">See</span> Indocyanine green angiography (IGA)</p>
			<p class="em-only_endmatter-idx2">optical coherence tomographic</p>
			<p class="em-only_endmatter-idx3">artifacts in, 29, 30<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">choroidal circulation abnormalities, 198</p>
			<p class="em-only_endmatter-idx3">choroidal neovascularization on, 75–76, 76<span class="italic">–&#173;</span>78<span class="italic">f,</span> 192</p>
			<p class="em-only_endmatter-idx3">depth resolution using, 29</p>
			<p class="em-only_endmatter-idx3">diabetic retinopathy on, 93, 94<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">fluorescein angiography versus, 29</p>
			<p class="em-only_endmatter-idx3">macular telangiectasia type 2 on, 163, 164<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">motion artifacts in, 29</p>
			<p class="em-only_endmatter-idx3">projection artifacts in, 29, 30<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">pseudoxanthoma elasticum on, 199<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal capillary layers on, 16</p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal disease evaluations using, 28–29</p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal vasculature on, 29, 30<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">severity of, 93, 94<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">scanning &#173;laser ophthalmoscopy versus, 24</p>
			<p class="em-only_endmatter-idx1">Angioid streaks</p>
			<p class="em-only_endmatter-idx2">choroidal neovascularization caused by, 87–89, 89<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">definition of, 87</p>
			<p class="em-only_endmatter-idx2">description of, 19</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography of, 87, 89<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">pseudoxanthoma elasticum and, 87, 89<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">safety glasses for patients with, 88</p>
			<p class="em-only_endmatter-idx2">in sickle cell disease, 154</p>
			<p class="em-only_endmatter-idx2">visual disturbances caused by, 88</p>
			<p class="em-only_endmatter-idx1">Angiokeratoma corporis diffusum. <span class="italic">See</span> Fabry disease</p>
			<p class="em-only_endmatter-idx1">Angiomas, ret&#173;i&#173;nal, 168</p>
			<p class="em-only_endmatter-idx1">Angle-&#173;closure glaucoma, in retinopathy of <br />prematurity, 181. <span class="italic">See also</span> Glaucoma</p>
			<p class="em-only_endmatter-idx1">Annular gap, 7</p>
			<p class="em-only_endmatter-idx1">Anomaloscope, 54</p>
			<p class="em-only_endmatter-idx1">Anomalous trichromatism, 249</p>
			<p class="em-only_endmatter-idx1">Anterior capsular phimosis, 116</p>
			<p class="em-only_endmatter-idx1">Anterior chamber</p>
			<p class="em-only_endmatter-idx2">paracentesis of, for central ret&#173;i&#173;nal artery occlusion, 146</p>
			<p class="em-only_endmatter-idx2">ultrasound biomicroscopy of, 40</p>
			<p class="em-only_endmatter-idx1">Anterior chamber &#173;angle neovascularization, in diabetes mellitus, 107</p>
			<p class="em-only_endmatter-idx1">Anterior cortical gel, 7</p>
			<p class="em-only_endmatter-idx1">Anterior hyaloid, 8<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Anterior per&#173;sis&#173;tent fetal vasculature, 341–342</p>
			<p class="em-only_endmatter-idx1">Anterior segment</p>
			<p class="em-only_endmatter-idx2">blunt trauma to, 353</p>
			<p class="em-only_endmatter-idx2">neovascularization in, in central ret&#173;i&#173;nal vein occlusion, 125</p>
			<p class="em-only_endmatter-idx2">surgery of</p>
			<p class="em-only_endmatter-idx3">cystoid macular edema &#173;after, 393, 394<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">endophthalmitis &#173;after. <span class="italic">See</span> Endophthalmitis, postoperative</p>
			<p class="em-only_endmatter-idx3">posteriorly dislocated intraocular lenses &#173;after, 393</p>
			<p class="em-only_endmatter-idx3">suprachoroidal hemorrhage &#173;after, 394–395, 395<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">vitrectomy for posterior segment complications of, 388–396</p>
			<p class="em-only_endmatter-idx1">Anterior vitreous, patellar fossa of, 7</p>
			<p class="em-only_endmatter-idx1">Antiangiogenic therapies</p>
			<p class="em-only_endmatter-idx2">complications of, 85</p>
			<p class="em-only_endmatter-idx2">neovascular age-&#173;related macular degeneration treated with, 79–80</p>
			<p class="em-only_endmatter-idx1">Antibiotics, for toxoplasmic retinochoroiditis, 243</p>
			<p class="em-only_endmatter-idx1">Anticoagulants, 346</p>
			<p class="em-only_endmatter-idx1">Antioxidants, for age-&#173;related macular degeneration, 69</p>
			<p class="em-only_endmatter-idx1">Anti-&#173;VEGF therapy</p>
			<p class="em-only_endmatter-idx2">adverse effects of, 113</p>
			<p class="em-only_endmatter-idx2">bevacizumab, 83–85, 84<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal artery occlusion treated with, 146</p>
			<p class="em-only_endmatter-idx2">choroidal neovascularization treated with, 87–88, 212, 355</p>
			<p class="em-only_endmatter-idx2">clinical &#173;trials of, 81</p>
			<p class="em-only_endmatter-idx2">Coats disease treated with, 161</p>
			<p class="em-only_endmatter-idx2">complications of, 104</p>
			<p class="em-only_endmatter-idx2">diabetic macular edema treated with, 101, 110–113, 112<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">diabetic retinopathy treated with</p>
			<p class="em-only_endmatter-idx3">description of, 101–102</p>
			<p class="em-only_endmatter-idx3">nonproliferative, 101–102</p>
			<p class="em-only_endmatter-idx3">proliferative, 103–104, 386</p>
			<p class="em-only_endmatter-idx2">follow-up &#173;after, 134</p>
			<p class="em-only_endmatter-idx2">intravitreal injections, 404</p>
			<p class="em-only_endmatter-idx2">low vision and, 86</p>
			<p class="em-only_endmatter-idx2">myopic choroidal neovascularization treated with, 212</p>
			<p class="em-only_endmatter-idx2">neovascular age-&#173;related macular degeneration treated with, 80–81</p>
			<p class="em-only_endmatter-idx2">nonproliferative diabetic retinopathy treated with, 101–102</p>
			<p class="em-only_endmatter-idx2">pathologic myopia treated with, 89</p>
			<p class="em-only_endmatter-idx2">polypoidal choroidal vasculopathy treated with, 76</p>
			<p class="em-only_endmatter-idx2">proliferative diabetic retinopathy treated with, 103–104</p>
			<p class="em-only_endmatter-idx2">radiation retinopathy treated with, 171</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal arterial macroaneurysms treated with, 148</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal vein occlusion treated with, 126</p>
			<p class="em-only_endmatter-idx2">retinopathy of prematurity treated with, 186–187</p>
			<p class="em-only_endmatter-idx2">subret&#173;i&#173;nal neovascularization treated with, 164</p>
			<p class="em-only_endmatter-idx1">Antiviral therapy</p>
			<p class="em-only_endmatter-idx2">acute ret&#173;i&#173;nal necrosis treated with, 236</p>
			<p class="em-only_endmatter-idx2">progressive outer ret&#173;i&#173;nal necrosis syndrome treated with, 236</p>
			<p class="em-only_endmatter-idx1"><span class="italic">APC</span> gene, 286</p>
			<p class="em-only_endmatter-idx1">Aphakia, ret&#173;i&#173;nal detachment risks, 319</p>
			<p class="em-only_endmatter-idx1">APMPPE. <span class="italic">See</span> Acute posterior multifocal placoid pigment epitheliopathy</p>
			<p class="em-only_endmatter-idx1">Appositional suprachoroidal hemorrhage, 394–395</p>
			<p class="em-only_endmatter-idx1">ARB. <span class="italic">See</span> Autosomal recessive bestrophinopathy</p>
			<p class="em-only_endmatter-idx1">Arden index/ratio, 50</p>
			<p class="em-only_endmatter-idx1">Area centralis, 9, 9<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Area of Martegiani, 7, 8<span class="italic">f,</span> 307</p>
			<p class="em-only_endmatter-idx1">AREDS. <span class="italic">See</span> Age-&#173;Related Eye Disease Study</p>
			<p class="em-only_endmatter-idx1">Argus II Ret&#173;i&#173;nal Prosthesis System, 264</p>
			<p class="em-only_endmatter-idx1">Argyria, 306</p>
			<p class="em-only_endmatter-idx1">Argyrosis, ocular, 306</p>
			<p class="em-only_endmatter-idx1"><span class="italic">ARMS2</span> gene, 63</p>
			<p class="em-only_endmatter-idx1">ARN. <span class="italic">See</span> Acute retinal necrosis </p>
			<p class="em-only_endmatter-idx1">Arrestin, 253</p>
			<p class="em-only_endmatter-idx1">Arterial macroaneurysms, ret&#173;i&#173;nal, 147–148, 148<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Arteriohepatic dysplasia, 282<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Arteriosclerotic retinopathy, 122</p>
			<p class="em-only_endmatter-idx1">Arthro-&#173;ophthalmopathy, 282<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Artifacts</p>
			<p class="em-only_endmatter-idx2">in optical coherence tomography angiography, 29, 30<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">projection, 29, 30<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ascorbate, vitreous levels of, 9</p>
			<p class="em-only_endmatter-idx1"><span class="italic">Aspergillus</span> fungal endophthalmitis, 239</p>
			<p class="em-only_endmatter-idx1">Aspirin, diabetic retinopathy and, 100</p>
			<p class="em-only_endmatter-idx1">ASPPC. <span class="italic">See</span> Acute syphilitic posterior placoid chorioretinitis</p>
			<p class="em-only_endmatter-idx1">Asteroid hyalosis, 346<span class="italic">f,</span> 346–347</p>
			<p class="em-only_endmatter-idx1">Asymptomatic ret&#173;i&#173;nal breaks, 318</p>
			<p class="em-only_endmatter-idx1"><span class="italic">ATOH7</span> gene, 341</p>
			<p class="em-only_endmatter-idx1">Atrophic ret&#173;i&#173;nal holes</p>
			<p class="em-only_endmatter-idx2">definition of, 315</p>
			<p class="em-only_endmatter-idx2">lattice degeneration with, 310, 311<span class="italic">f,</span> 316<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal detachment secondary to, 310</p>
			<p class="em-only_endmatter-idx1">Atrophy</p>
			<p class="em-only_endmatter-idx2">chorioret&#173;i&#173;nal</p>
			<p class="em-only_endmatter-idx3">genes and loci associated with, 256<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">in pathologic myopia, 214<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">choroid, age-&#173;related, 200, 212</p>
			<p class="em-only_endmatter-idx2">geographic</p>
			<p class="em-only_endmatter-idx3">in Best vitelliform dystrophy, 271</p>
			<p class="em-only_endmatter-idx3">description of, 64, 66, 67<span class="italic">f,</span> 68</p>
			<p class="em-only_endmatter-idx3">in drusenoid ret&#173;i&#173;nal pigment epithelium detachment, 272</p>
			<p class="em-only_endmatter-idx2">gyrate, 268–269, 269<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">macula, 265, 265<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium, 106<span class="italic">f,</span> 294<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Atrophy creep, 89</p>
			<p class="em-only_endmatter-idx1">Autofluorescence</p>
			<p class="em-only_endmatter-idx2">central serous chorioretinopathy findings, 192<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">enhanced depth imaging optical coherence tomography and, 39</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography, 35</p>
			<p class="em-only_endmatter-idx2">retinitis pigmentosa findings, 261</p>
			<p class="em-only_endmatter-idx2">serpiginous choroidopathy findings, 223<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Autoimmune retinopathy, 286</p>
			<p class="em-only_endmatter-idx1">Autosomal recessive bestrophinopathy (ARB)</p>
			<p class="em-only_endmatter-idx2">description of, 271</p>
			<p class="em-only_endmatter-idx2">electro-&#173;oculography of, 51</p>
			<p class="em-only_endmatter-idx1">a-&#173;waves</p>
			<p class="em-only_endmatter-idx2">electroretinography, 46, 251</p>
			<p class="em-only_endmatter-idx2">in rod–&#173;cone dystrophies, 261</p>
			<p class="em-only_endmatter-idx1">Axial resolution, of contact B-&#173;scan ultrasonography, 39</p>
			<p class="em-only_endmatter-idx1">Azathioprine, for Beh<span class="accent">ç</span>et disease, 230</p>
			<p class="em-only_endmatter-idx1">AZOOR. <span class="italic">See</span> Acute zonal occult outer retinopathy</p>
			<p class="em-only_endmatter-idx-alpha"><span class="italic">Bacillus cereus</span> endophthalmitis, 363</p>
			<p class="em-only_endmatter-idx1">Bacterial endophthalmitis, endogenous, 237–239, <br />238<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Bardet-&#173;Biedl syndrome</p>
			<p class="em-only_endmatter-idx2">clinical features of, 282<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">genes and loci associated with, 256<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">renal abnormalities associated with, 285</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal degeneration associated with, 281, 284, <br />284<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1"><span class="italic">Bartonella henselae,</span> 243<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Basilar laminar deposits</p>
			<p class="em-only_endmatter-idx2">age-&#173;related changes in, 61</p>
			<p class="em-only_endmatter-idx2">definition of, 64</p>
			<p class="em-only_endmatter-idx2">illustration of, 62<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Basilar linear deposits</p>
			<p class="em-only_endmatter-idx2">definition of, 64</p>
			<p class="em-only_endmatter-idx2">illustration of, 62<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Batten disease, 283<span class="italic">t,</span> 290<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1"><span class="italic">Baylisascaris procyonis,</span> 246</p>
			<p class="em-only_endmatter-idx1">BDUMP. <span class="italic">See</span> Bilateral diffuse uveal melanocytic proliferation</p>
			<p class="em-only_endmatter-idx1">BEAT-ROP Cooperative Group study, 186–187</p>
			<p class="em-only_endmatter-idx1">Beh<span class="accent">ç</span>et disease, 230, 230<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Berger space, 7, 8<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Bergmeister papilla, 341</p>
			<p class="em-only_endmatter-idx1">Best disease</p>
			<p class="em-only_endmatter-idx2">characteristics of, 271, 272<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">definition of, 51</p>
			<p class="em-only_endmatter-idx2">electro-&#173;oculography of, 51, 271</p>
			<p class="em-only_endmatter-idx1"><span class="italic">BEST1</span> gene, 271</p>
			<p class="em-only_endmatter-idx1">Bestrophin, 50</p>
			<p class="em-only_endmatter-idx1">Best vitelliform dystrophy, 271, 272<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Bevacizumab</p>
			<p class="em-only_endmatter-idx2">adverse effects of, 85</p>
			<p class="em-only_endmatter-idx2">branch ret&#173;i&#173;nal vein occlusion treated with, 135</p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal vein occlusion treated with, 135</p>
			<p class="em-only_endmatter-idx2">choroidal neovascularization treated with, 73<span class="italic">f,</span> 213<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">diabetic macular edema treated with, 113</p>
			<p class="em-only_endmatter-idx2">endophthalmitis caused by, 404</p>
			<p class="em-only_endmatter-idx2">neovascular age-&#173;related macular degeneration treated with, 83–85, 84<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">off-&#173;label uses of, 85</p>
			<p class="em-only_endmatter-idx2">ranibizumab and, comparison between, 83, 84<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal vein occlusion treated with, 135</p>
			<p class="em-only_endmatter-idx2">retinopathy of prematurity treated with, 186–187</p>
			<p class="em-only_endmatter-idx1">Bietti crystalline dystrophy, 258, 269, 282<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Bilateral diffuse uveal melanocytic proliferation (BDUMP), 204–205, 205<span class="italic">f,</span> 287</p>
			<p class="em-only_endmatter-idx1">Binocular indirect ophthalmoscopes/ophthalmoscopy</p>
			<p class="em-only_endmatter-idx2">disadvantages of, 22</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal disease evaluations using, 21–22</p>
			<p class="em-only_endmatter-idx1">Bipolar cells</p>
			<p class="em-only_endmatter-idx2">ganglion cells and, 13</p>
			<p class="em-only_endmatter-idx2">illustration of, 15<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">midget, 13</p>
			<p class="em-only_endmatter-idx1">Birdshot chorioretinopathy, 49</p>
			<p class="em-only_endmatter-idx1">Birdshot uveitis</p>
			<p class="em-only_endmatter-idx2">characteristics of, 220<span class="italic">t,</span> 224–225, 225<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">uveal lymphoma and, 234</p>
			<p class="em-only_endmatter-idx1">Bis-&#173;retinoids, 31</p>
			<p class="em-only_endmatter-idx1">Bleb-&#173;associated endophthalmitis, 390–391, 391<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Blebitis, 390–391</p>
			<p class="em-only_endmatter-idx1">Blind loop syndrome, 290</p>
			<p class="em-only_endmatter-idx1">Blindness</p>
			<p class="em-only_endmatter-idx2">central, age-&#173;related macular degeneration progression to, 86</p>
			<p class="em-only_endmatter-idx2">methanol toxicity as cause of, 301</p>
			<p class="em-only_endmatter-idx2">night. <span class="italic">See</span> Night blindness</p>
			<p class="em-only_endmatter-idx2">retinopathy of prematurity as cause of, 182</p>
			<p class="em-only_endmatter-idx1">Bloch-&#173;Sulzberger syndrome, 283<span class="italic">t,</span> 286</p>
			<p class="em-only_endmatter-idx1">Blocked fluorescence, in fluorescein angiography, 35</p>
			<p class="em-only_endmatter-idx1">Blood–&#173;brain barrier, 16</p>
			<p class="em-only_endmatter-idx1">Blood–&#173;ocular barrier, fluorescein passage affected by, 33</p>
			<p class="em-only_endmatter-idx1">Blood–&#173;retina barrier</p>
			<p class="em-only_endmatter-idx2">fluorescein passage affected by, 33</p>
			<p class="em-only_endmatter-idx2">hyperglycemia-&#173;induced breakdown of, 108</p>
			<p class="em-only_endmatter-idx1">Blue-&#173;cone monochromatism</p>
			<p class="em-only_endmatter-idx2">description of, 250, 250<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">electroretinography findings in, 46, 47<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Blue–yellow color deficiency, 54</p>
			<p class="em-only_endmatter-idx1">Blunt trauma, 315, 353–358, 354<span class="italic">–&#173;</span>357<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Bone marrow derived stem cells, hyalocytes from, 7</p>
			<p class="em-only_endmatter-idx1"><span class="italic">Borrelia burgdorferi,</span> 245</p>
			<p class="em-only_endmatter-idx1">Bradyopsia, electroretinography findings in, 49</p>
			<p class="em-only_endmatter-idx1">Branch ret&#173;i&#173;nal artery occlusion (BRAO)</p>
			<p class="em-only_endmatter-idx2">emboli that cause, 141, 142<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">hypertensive retinopathy and, 122</p>
			<p class="em-only_endmatter-idx2">imaging of, 141<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">management of, 142</p>
			<p class="em-only_endmatter-idx2">multiple, 152<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">in nonproliferative sickle cell retinopathy, 152<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal infarction caused by, 141</p>
			<p class="em-only_endmatter-idx2">in Susac syndrome, 156</p>
			<p class="em-only_endmatter-idx1">Branch ret&#173;i&#173;nal vein occlusion (BRVO)</p>
			<p class="em-only_endmatter-idx2">aflibercept for, 135</p>
			<p class="em-only_endmatter-idx2">at arteriovenous crossing, 126</p>
			<p class="em-only_endmatter-idx2">bevacizumab for, 135</p>
			<p class="em-only_endmatter-idx2">clinical findings of, 125–127, 126<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">corticosteroids for, 137–138</p>
			<p class="em-only_endmatter-idx2">diabetes mellitus and, 128</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography of, 129<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">glaucoma as risk &#173;factor for, 125</p>
			<p class="em-only_endmatter-idx2">hypertensive retinopathy and, 122</p>
			<p class="em-only_endmatter-idx2">intraret&#173;i&#173;nal hemorrhages associated with, 125, 126<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">macular &#173;laser surgery for, 128</p>
			<p class="em-only_endmatter-idx2">neovascularization in, 125, 128, 129<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">pars plana vitrectomy for, 130</p>
			<p class="em-only_endmatter-idx2">pharmacologic management of, 135–138</p>
			<p class="em-only_endmatter-idx2">prognosis for, 128</p>
			<p class="em-only_endmatter-idx2">ranibizumab for, 135</p>
			<p class="em-only_endmatter-idx2">risk &#173;factors for, 127–128</p>
			<p class="em-only_endmatter-idx2">scatter photocoagulation for, 128–130</p>
			<p class="em-only_endmatter-idx2">spontaneous resolution of, 125</p>
			<p class="em-only_endmatter-idx2">surgical management of, 128–130</p>
			<p class="em-only_endmatter-idx2">treatment of, 128–130</p>
			<p class="em-only_endmatter-idx2">triamcinolone for, 137</p>
			<p class="em-only_endmatter-idx2">vision loss caused by, 128</p>
			<p class="em-only_endmatter-idx1">BRAO. <span class="italic">See</span> Branch retinal artery occlusion</p>
			<p class="em-only_endmatter-idx1">Bruch membrane</p>
			<p class="em-only_endmatter-idx2">anatomy of, 210–211</p>
			<p class="em-only_endmatter-idx2">argyrosis effects on, 306</p>
			<p class="em-only_endmatter-idx2">basilar laminar deposits effect on, 62<span class="italic">f,</span> 64</p>
			<p class="em-only_endmatter-idx2">choroidal neovascularization &#173;after damage to, 355, 355<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">degeneration of, 19, 71</p>
			<p class="em-only_endmatter-idx2">disorders that affect, 89</p>
			<p class="em-only_endmatter-idx2">embryologic development of, 210</p>
			<p class="em-only_endmatter-idx2">histology of, 18<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">layers of, 18<span class="italic">f,</span> 19</p>
			<p class="em-only_endmatter-idx2">ocular expansion effects on, 211</p>
			<p class="em-only_endmatter-idx2">outer lamella of, 211</p>
			<p class="em-only_endmatter-idx2">photocoagulation-&#173;related rupture of, 378</p>
			<p class="em-only_endmatter-idx2">remodeling of, 210</p>
			<p class="em-only_endmatter-idx2">rupture of, 378</p>
			<p class="em-only_endmatter-idx2">supertraction crescent, 210</p>
			<p class="em-only_endmatter-idx2">tears in, 354</p>
			<p class="em-only_endmatter-idx2">type 1 choroidal neovascularization in, 72<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">BRVO. <span class="italic">See</span> Branch retinal vein occlusion</p>
			<p class="em-only_endmatter-idx1">B-&#173;scan optical coherence tomography</p>
			<p class="em-only_endmatter-idx2">definition of, 26</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium subret&#173;i&#173;nal fluid on, 77<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">volume rendering versus, 27</p>
			<p class="em-only_endmatter-idx1">B-&#173;scan ultrasonography, intraocular foreign body evaluations using, 352. <span class="italic">See also</span> Contact B-scan ultrasonography</p>
			<p class="em-only_endmatter-idx1">Bullous retinoschisis, 326</p>
			<p class="em-only_endmatter-idx1">Bull’s-&#173;eye maculopathy</p>
			<p class="em-only_endmatter-idx2">chloroquine toxicity as cause of, 295, 296<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">clofazimine as cause of, 298</p>
			<p class="em-only_endmatter-idx2">in neuronal ceroid lipofuscinoses, 289</p>
			<p class="em-only_endmatter-idx1">Bull’s-&#173;eye pattern</p>
			<p class="em-only_endmatter-idx2">in acute idiopathic maculopathy, 229</p>
			<p class="em-only_endmatter-idx2">in Bardet-&#173;Biedl syndrome, 284</p>
			<p class="em-only_endmatter-idx2">in Lyme disease, 245</p>
			<p class="em-only_endmatter-idx2">in macular atrophy, 265</p>
			<p class="em-only_endmatter-idx2">in Stargardt disease, 270</p>
			<p class="em-only_endmatter-idx1">Bull’s-&#173;eye rash, 245, 265<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Bupropion, 306</p>
			<p class="em-only_endmatter-idx1">Butterfly-&#173;type pattern dystrophy, 276, 276<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">b-&#173;waves, 42–44, 43<span class="italic">f</span>, 46, 47<span class="italic">f</span>, 50, 261</p>
			<p class="em-only_endmatter-idx-alpha">Calcific drusen, 66</p>
			<p class="em-only_endmatter-idx1">Canals, in vitreous, 7</p>
			<p class="em-only_endmatter-idx1">Cancer-&#173;associated retinopathy (CAR), 286, 287<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1"><span class="italic">Candida</span> endophthalmitis, 239–240, 240<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Canthaxanthine, 303</p>
			<p class="em-only_endmatter-idx1">Capillary plexus</p>
			<p class="em-only_endmatter-idx2">deep, 16</p>
			<p class="em-only_endmatter-idx2">intermediate, 16</p>
			<p class="em-only_endmatter-idx1">CAR. <span class="italic">See</span> Cancer-&#173;associated retinopathy</p>
			<p class="em-only_endmatter-idx1">Carbogen, for central ret&#173;i&#173;nal artery occlusion, 146</p>
			<p class="em-only_endmatter-idx1">Carbonic anhydrase inhibitors, in sickle cell patients, <br />154–155</p>
			<p class="em-only_endmatter-idx1">Carotid-&#173;cavernous fistulas, 198</p>
			<p class="em-only_endmatter-idx1">Carotid occlusive disease</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal hemorrhages in, 138</p>
			<p class="em-only_endmatter-idx2">retinopathy of, 138</p>
			<p class="em-only_endmatter-idx1">Cataract, nuclear sclerotic, 402, 402<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cataractous lens, B-&#173;scan ultrasonography of, 40<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Cataract surgery</p>
			<p class="em-only_endmatter-idx2">age-&#173;related macular degeneration progression affected by, 71</p>
			<p class="em-only_endmatter-idx2">cystoid macular edema &#173;after, 157, 159, 260</p>
			<p class="em-only_endmatter-idx2">photic retinopathy &#173;after, 368</p>
			<p class="em-only_endmatter-idx2">posterior capsular opacification &#173;after, 260</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal detachment &#173;after, 319</p>
			<p class="em-only_endmatter-idx2">vitreous abnormalities secondary to, 349</p>
			<p class="em-only_endmatter-idx2">vitreous loss during, 349</p>
			<p class="em-only_endmatter-idx2">wound management in, 349</p>
			<p class="em-only_endmatter-idx1">Cat-&#173;scratch disease, 242–243, 243<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">CATT clinical trial, 83, 84<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cavernous hemangioma, ret&#173;i&#173;nal, 168, 169<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">CD4<span class="symbol">+</span> T cells, in cytomegalovirus retinitis, 235</p>
			<p class="em-only_endmatter-idx1">Ceftazidime, for postoperative endophthalmitis, 389</p>
			<p class="em-only_endmatter-idx1">Cellophane maculopathy, 335</p>
			<p class="em-only_endmatter-idx1">Center-&#173;involved diabetic macular edema</p>
			<p class="em-only_endmatter-idx2">description of, 92</p>
			<p class="em-only_endmatter-idx2">imaging of, 109, 110<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Central areolar choroidal dystrophy, 277</p>
			<p class="em-only_endmatter-idx1">Central blindness, age-&#173;related macular degeneration progression to, 86</p>
			<p class="em-only_endmatter-idx1">Central macular atrophic lesions, 266</p>
			<p class="em-only_endmatter-idx1">Central ner&#173;vous system</p>
			<p class="em-only_endmatter-idx2">Beh<span class="accent">ç</span>et disease involvement of, 230</p>
			<p class="em-only_endmatter-idx2">incontinentia pigmenti involvement of, 286</p>
			<p class="em-only_endmatter-idx2">metabolic abnormalities of</p>
			<p class="em-only_endmatter-idx3">abetalipoproteinemia, 289–290</p>
			<p class="em-only_endmatter-idx3">lysosomal, 291–292, 292<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">mucopolysaccharidoses, 290–291</p>
			<p class="em-only_endmatter-idx3">neuronoid ceroid lipofuscinoses, 289, 290<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">peroxisomal disorders, 290</p>
			<p class="em-only_endmatter-idx3">Refsum disease, 290</p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal degeneration caused by, 288–292</p>
			<p class="em-only_endmatter-idx3">vitamin A deficiency, 289–290</p>
			<p class="em-only_endmatter-idx2">primary vitreoret&#173;i&#173;nal lymphoma involvement of, 234</p>
			<p class="em-only_endmatter-idx1">Central ret&#173;i&#173;nal artery</p>
			<p class="em-only_endmatter-idx2">anatomy of, 16</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal inner layers supplied by, 140</p>
			<p class="em-only_endmatter-idx1">Central ret&#173;i&#173;nal artery occlusion (CRAO)</p>
			<p class="em-only_endmatter-idx2">anti-&#173;VEGF therapy for, 146</p>
			<p class="em-only_endmatter-idx2">&#173;causes of, 144</p>
			<p class="em-only_endmatter-idx2">ciliary artery occlusion with, 144, 145<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">electroretinography findings in, 50</p>
			<p class="em-only_endmatter-idx2">emboli as cause of, 144</p>
			<p class="em-only_endmatter-idx2">&#173;giant cell arteritis as cause of, 145</p>
			<p class="em-only_endmatter-idx2">illustration of, 16<span class="italic">f,</span> 144<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">iris neovascularization in, 146</p>
			<p class="em-only_endmatter-idx2">management of, 146</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal infarction caused by, 143</p>
			<p class="em-only_endmatter-idx2">spectral-&#173;domain optical coherence tomography <br />of, 144<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">symptoms and signs of, 143</p>
			<p class="em-only_endmatter-idx2">vision loss caused by, 143–144</p>
			<p class="em-only_endmatter-idx1">Central ret&#173;i&#173;nal vein occlusion (CRVO)</p>
			<p class="em-only_endmatter-idx2">aflibercept for, 135</p>
			<p class="em-only_endmatter-idx2">age and, 133</p>
			<p class="em-only_endmatter-idx2">bevacizumab for, 135</p>
			<p class="em-only_endmatter-idx2">&#173;causes of, 133–134</p>
			<p class="em-only_endmatter-idx2">chronic changes caused by, 127<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">cilioret&#173;i&#173;nal artery occlusion caused by, 143</p>
			<p class="em-only_endmatter-idx2">clinical findings of, 127<span class="italic">f,</span> 130</p>
			<p class="em-only_endmatter-idx2">complications of, 135</p>
			<p class="em-only_endmatter-idx2">corticosteroids for, 137–138</p>
			<p class="em-only_endmatter-idx2">cystoid macular edema caused by, 136<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">differential diagnosis of, 134</p>
			<p class="em-only_endmatter-idx2">diuretic and, 134</p>
			<p class="em-only_endmatter-idx2">electroretinography findings in, 50</p>
			<p class="em-only_endmatter-idx2">evaluation of, 134–135</p>
			<p class="em-only_endmatter-idx2">follow-up for, 134</p>
			<p class="em-only_endmatter-idx2">hypercoagulable conditions presenting with, 134</p>
			<p class="em-only_endmatter-idx2">hypertensive retinopathy and, 122</p>
			<p class="em-only_endmatter-idx2">hyperviscosity retinopathy versus, 134</p>
			<p class="em-only_endmatter-idx2">intraocular pressure in, 133</p>
			<p class="em-only_endmatter-idx2">iris neovascularization in, 133, 135</p>
			<p class="em-only_endmatter-idx2">ischemic, 132<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">macular &#173;laser surgery for, 135</p>
			<p class="em-only_endmatter-idx2">management of, 134–135</p>
			<p class="em-only_endmatter-idx2">neovascularization in, 125</p>
			<p class="em-only_endmatter-idx2">nonischemic, 130, 131<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">ocular ischemic syndrome versus, 134</p>
			<p class="em-only_endmatter-idx2">open-&#173;angle glaucoma in, 133</p>
			<p class="em-only_endmatter-idx2">oral contraceptives and, 134</p>
			<p class="em-only_endmatter-idx2">panret&#173;i&#173;nal photocoagulation for, 135</p>
			<p class="em-only_endmatter-idx2">pars plana vitrectomy for, 135</p>
			<p class="em-only_endmatter-idx2">pharmacologic management of, 135–138</p>
			<p class="em-only_endmatter-idx2">progression of, follow-up for, 134</p>
			<p class="em-only_endmatter-idx2">ranibizumab for, 135</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal microvascular changes in, 125, 127<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">risk &#173;factors for, 133–134</p>
			<p class="em-only_endmatter-idx2">spontaneous resolution of, 125</p>
			<p class="em-only_endmatter-idx2">treatment of, 135</p>
			<p class="em-only_endmatter-idx2">vision loss caused by, 130</p>
			<p class="em-only_endmatter-idx2">vitreous hemorrhage secondary to, 135</p>
			<p class="em-only_endmatter-idx1">Central scotomas, 86, 265</p>
			<p class="em-only_endmatter-idx1">Central serous chorioretinopathy (CSC)</p>
			<p class="em-only_endmatter-idx2">age and, 189</p>
			<p class="em-only_endmatter-idx2">age-&#173;related macular degeneration versus, 67, 76, 79</p>
			<p class="em-only_endmatter-idx2">autofluorescence abnormalities in, 192<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">choroidal thickening in, 191</p>
			<p class="em-only_endmatter-idx2">corticosteroids as cause of, 300</p>
			<p class="em-only_endmatter-idx2">demographics of, 189–191, 190<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">differential diagnosis of, 193–194</p>
			<p class="em-only_endmatter-idx2">discovery of, 189</p>
			<p class="em-only_endmatter-idx2">enhanced depth imaging optical coherence tomography findings, 67, 191, 193<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">fluorescein angiography findings in, 190, 191<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">fundus autofluorescence of, 32</p>
			<p class="em-only_endmatter-idx2">historical descriptions of, 189</p>
			<p class="em-only_endmatter-idx2">imaging of, 190–192, 191<span class="italic">–&#173;</span>193<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">indocyanine green angiography of, 38, 192, 194<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">neovascularization associated with, 194</p>
			<p class="em-only_endmatter-idx2">nonneovascular age-&#173;related macular degeneration versus, 67, 76</p>
			<p class="em-only_endmatter-idx2">optical coherence tomography of, 32</p>
			<p class="em-only_endmatter-idx2">photodynamic therapy for, 194</p>
			<p class="em-only_endmatter-idx2">polypoidal choroidal vasculopathy versus, 193</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal detachment caused by, 189, 191</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium pigmentation in, 190, 190<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">sildenafil as cause of, 299</p>
			<p class="em-only_endmatter-idx2">stress and, 191</p>
			<p class="em-only_endmatter-idx2">symptoms and signs of, 189–190</p>
			<p class="em-only_endmatter-idx2">systemic conditions associated with, 191</p>
			<p class="em-only_endmatter-idx2">systemic corticosteroids as risk &#173;factor for, 191</p>
			<p class="em-only_endmatter-idx2">treatment of, 194</p>
			<p class="em-only_endmatter-idx2">visual acuity in, 190</p>
			<p class="em-only_endmatter-idx2">white dots with, 191, 191<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Central vitreous, 7</p>
			<p class="em-only_endmatter-idx1">Ceramide trihexoside, 291</p>
			<p class="em-only_endmatter-idx1">Ce&#173;re&#173;bral vasculitis, 222</p>
			<p class="em-only_endmatter-idx1">C<span class="CharOverride-1">3</span>F<span class="CharOverride-1">8</span>. <span class="italic">See</span> Perfluoropropane</p>
			<p class="em-only_endmatter-idx1"><span class="italic">CFH</span> gene, 63</p>
			<p class="em-only_endmatter-idx1">Chalcosis, 362</p>
			<p class="em-only_endmatter-idx1">Charcot-&#173;Marie-&#173;Tooth disease, 282<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Charles Bonnet syndrome, 86</p>
			<p class="em-only_endmatter-idx1">Ch<span class="accent">é</span>diak-&#173;Higashi syndrome, 288</p>
			<p class="em-only_endmatter-idx1">Chemotherapy</p>
			<p class="em-only_endmatter-idx2">MEK inhibitors, 299</p>
			<p class="em-only_endmatter-idx2">primary vitreoret&#173;i&#173;nal lymphoma treated with, 234</p>
			<p class="em-only_endmatter-idx1">Cherry-&#173;red spot</p>
			<p class="em-only_endmatter-idx2">in central ret&#173;i&#173;nal artery occlusion, 143</p>
			<p class="em-only_endmatter-idx2">in commotio ret&#173;i&#173;nae, 353</p>
			<p class="em-only_endmatter-idx2">ophthalmic artery occlusion and, 146</p>
			<p class="em-only_endmatter-idx2">in Tay-&#173;Sachs disease, 291, 292<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Chikungunya virus retinitis, 247</p>
			<p class="em-only_endmatter-idx1">&#173;Children. <span class="italic">See also</span> Infants</p>
			<p class="em-only_endmatter-idx2">Coats disease in, 159</p>
			<p class="em-only_endmatter-idx2">congenital toxoplasmosis in, 243</p>
			<p class="em-only_endmatter-idx2">electroretinography applications in, 50</p>
			<p class="em-only_endmatter-idx2">trauma in, 316–317, 365–366, 366<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">visual evoked potentials application in, 53</p>
			<p class="em-only_endmatter-idx1">Chloroquine</p>
			<p class="em-only_endmatter-idx2">bull’s-&#173;eye maculopathy caused by, 295, 296<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">indications for, 295</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium abnormalities caused by, 295–297, 296<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Chlorpromazine, 297</p>
			<p class="em-only_endmatter-idx1"><span class="italic">CHM</span> gene, 268</p>
			<p class="em-only_endmatter-idx1">Cholesterolosis, 348</p>
			<p class="em-only_endmatter-idx1">Choriocapillaris</p>
			<p class="em-only_endmatter-idx2">age-&#173;related changes in, 61</p>
			<p class="em-only_endmatter-idx2">anatomy of, 17, 19, 20<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">atrophy of, in choroideremia, 258</p>
			<p class="em-only_endmatter-idx2">blood flow abnormalities in, 198</p>
			<p class="em-only_endmatter-idx2">ghost vessels in, 198</p>
			<p class="em-only_endmatter-idx2">hypertensive choroidopathy findings, 123</p>
			<p class="em-only_endmatter-idx2">optical coherence tomography angiography of, 30<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">in pseudoxanthoma elasticum, 199<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">in type 1 choroidal neovascularization, 71</p>
			<p class="em-only_endmatter-idx1">Chorioret&#173;i&#173;nal atrophy</p>
			<p class="em-only_endmatter-idx2">genes and loci associated with, 256<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">in pathologic myopia, 214<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Chorioret&#173;i&#173;nal disruption, traumatic, 357<span class="italic">f,</span> 357–358</p>
			<p class="em-only_endmatter-idx1">Chorioret&#173;i&#173;nal edema, 379</p>
			<p class="em-only_endmatter-idx1">Chorioret&#173;i&#173;nal folds, 200–201, 201<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Chorioret&#173;i&#173;nal scars</p>
			<p class="em-only_endmatter-idx2">in congenital toxoplasmosis, 243</p>
			<p class="em-only_endmatter-idx2">in ocular histoplasmosis syndrome, 87</p>
			<p class="em-only_endmatter-idx1">Chorioretinitis</p>
			<p class="em-only_endmatter-idx2">acute syphilitic posterior placoid, 241</p>
			<p class="em-only_endmatter-idx2">focal, 238, 238<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">in neuroretinitis, 242</p>
			<p class="em-only_endmatter-idx2">syphilitic, 241–242, 242<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">vitiliginous. <span class="italic">See</span> Birdshot uveitis</p>
			<p class="em-only_endmatter-idx2">West Nile virus, 246, 247<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">Zika virus, 247</p>
			<p class="em-only_endmatter-idx1">Chorioretinopathy</p>
			<p class="em-only_endmatter-idx2">birdshot, 49</p>
			<p class="em-only_endmatter-idx2">central serous</p>
			<p class="em-only_endmatter-idx3">age and, 189</p>
			<p class="em-only_endmatter-idx3">age-&#173;related macular degeneration versus, 67, 76, 79</p>
			<p class="em-only_endmatter-idx3">autofluorescence abnormalities in, 192<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">choroidal thickening in, 191</p>
			<p class="em-only_endmatter-idx3">corticosteroids as cause of, 300</p>
			<p class="em-only_endmatter-idx3">demographics of, 189–191, 190<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">differential diagnosis of, 193–194</p>
			<p class="em-only_endmatter-idx3">discovery of, 189</p>
			<p class="em-only_endmatter-idx3">enhanced depth imaging optical coherence tomography findings, 67, 191, 193<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">fluorescein angiography findings in, 190, 191<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">fundus autofluorescence of, 32</p>
			<p class="em-only_endmatter-idx3">historical descriptions of, 189</p>
			<p class="em-only_endmatter-idx3">imaging of, 190–192, 191<span class="italic">–&#173;</span>193<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">indocyanine green angiography of, 38, 192, 194<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">neovascularization associated with, 194</p>
			<p class="em-only_endmatter-idx3">nonneovascular age-&#173;related macular degeneration versus, 67, 76</p>
			<p class="em-only_endmatter-idx3">optical coherence tomography of, 32</p>
			<p class="em-only_endmatter-idx3">photodynamic therapy for, 194</p>
			<p class="em-only_endmatter-idx3">polypoidal choroidal vasculopathy versus, 193</p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal detachment caused by, 189, 191</p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal pigment epithelium pigmentation in, 190, 190<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">sildenafil as cause of, 299</p>
			<p class="em-only_endmatter-idx3">stress and, 191</p>
			<p class="em-only_endmatter-idx3">symptoms and signs of, 189–190</p>
			<p class="em-only_endmatter-idx3">systemic conditions associated with, 191</p>
			<p class="em-only_endmatter-idx3">systemic corticosteroids as risk &#173;factor for, 191</p>
			<p class="em-only_endmatter-idx3">treatment of, 194</p>
			<p class="em-only_endmatter-idx3">visual acuity in, 190</p>
			<p class="em-only_endmatter-idx3">white dots with, 191, 191<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Choroid</p>
			<p class="em-only_endmatter-idx2">age-&#173;related atrophy of, 200, 212</p>
			<p class="em-only_endmatter-idx2">anatomy of, 19–20, 20<span class="italic">f,</span> 193<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">arterial supply to, 194, 195<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">autoimmune conditions of</p>
			<p class="em-only_endmatter-idx3">Beh<span class="accent">ç</span>et disease, 230, 230<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">inflammatory vasculitis, 230–231</p>
			<p class="em-only_endmatter-idx3">intermediate uveitis, 231–232</p>
			<p class="em-only_endmatter-idx3">intraocular lymphoma, 233–234, 234<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">lupus vasculitis, 230–231, 231<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">overview of, 229</p>
			<p class="em-only_endmatter-idx3">sympathetic ophthalmia, 233</p>
			<p class="em-only_endmatter-idx3">Vogt-&#173;Koyanagi-&#173;Harada disease, 232<span class="italic">f,</span> 232–233</p>
			<p class="em-only_endmatter-idx2">bilateral diffuse uveal melanocytic proliferation effects on, 204</p>
			<p class="em-only_endmatter-idx2">blood circulation in, 19–20, 20<span class="italic">f,</span> 194, 195<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">blood flow abnormalities in, 198</p>
			<p class="em-only_endmatter-idx2">capillary arrangement in, 19</p>
			<p class="em-only_endmatter-idx2">in choroidal neovascularization, 36, 37<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">detachment of, 379, 379<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">enhanced depth imaging optical coherence tomography of, 25, 193<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">filling defects in, 198</p>
			<p class="em-only_endmatter-idx2">folds in, 200–201, 201<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">functions of, 212</p>
			<p class="em-only_endmatter-idx2">Haller layer, 19</p>
			<p class="em-only_endmatter-idx2">as heat sink, 20</p>
			<p class="em-only_endmatter-idx2">inflammation of</p>
			<p class="em-only_endmatter-idx3">infectious &#173;causes, 235–247</p>
			<p class="em-only_endmatter-idx3">noninfectious &#173;causes, 219–234</p>
			<p class="em-only_endmatter-idx3">white dot syndromes as cause of. <span class="italic">See</span> White dot syndromes</p>
			<p class="em-only_endmatter-idx2">inner structure of, 193<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">in pathologic myopia, 212–216, 214<span class="italic">–&#173;</span>215<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">retinal metabolic needs supplied by, 20</p>
			<p class="em-only_endmatter-idx2">rupture of, 88, 354–355, 354<span class="italic">–&#173;</span>356<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">Sattler layer, 19</p>
			<p class="em-only_endmatter-idx2">subfoveal thickness of, 19</p>
			<p class="em-only_endmatter-idx2">thickness of</p>
			<p class="em-only_endmatter-idx3">description of, 19</p>
			<p class="em-only_endmatter-idx3">mea&#173;sure&#173;ment of, 212</p>
			<p class="em-only_endmatter-idx3">subfoveal, 212, 214<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">thinning of, 214</p>
			<p class="em-only_endmatter-idx2">trauma-&#173;related rupture of, 354–355, 354<span class="italic">–&#173;</span>356<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">venous pressure increases in, 198</p>
			<p class="em-only_endmatter-idx2">vortex veins in, 19</p>
			<p class="em-only_endmatter-idx1">Choroidal detachment, 379, 379<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Choroidal diseases</p>
			<p class="em-only_endmatter-idx2">bilateral diffuse uveal melanocytic proliferation, 204–205, 205<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">central serous chorioretinopathy. <span class="italic">See</span> Central serous chorioretinopathy (CSC)</p>
			<p class="em-only_endmatter-idx2">hemangiomas, 202<span class="italic">f,</span> 202–203</p>
			<p class="em-only_endmatter-idx2">nonarteritic, 195–196, 197<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">perfusion abnormalities, 194, 195<span class="italic">–&#173;</span>197<span class="italic">f,</span> <br />199<span class="italic">–&#173;</span>200<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">uveal effusion syndrome, 203, 204<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Choroidal dystrophies</p>
			<p class="em-only_endmatter-idx2">Bietti crystalline dystrophy, 258, 269, 282<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">central areolar, 277</p>
			<p class="em-only_endmatter-idx2">choroidemia, 267–268, 268<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">classification of, 255</p>
			<p class="em-only_endmatter-idx2">gyrate atrophy, 268–269, 269<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Choroidal effusions</p>
			<p class="em-only_endmatter-idx2">bupropion as cause of, 306</p>
			<p class="em-only_endmatter-idx2">contact B-&#173;scan ultrasonography of, 39<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Choroidal granuloma, 241<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Choroidal neovascularization (CNV)</p>
			<p class="em-only_endmatter-idx2">in acute posterior multifocal placoid pigment epitheliopathy, 222</p>
			<p class="em-only_endmatter-idx2">age-&#173;related macular degeneration progression to, 64</p>
			<p class="em-only_endmatter-idx2">anatomical classification of, 71–75</p>
			<p class="em-only_endmatter-idx2">angioid streaks as cause of, 87–89, 89<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">anti-&#173;VEGF therapy for, 87–88, 212, 355</p>
			<p class="em-only_endmatter-idx2">bevacizumab for, 73<span class="italic">f,</span> 213<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">&#173;after Bruch membrane damage, 355, 355<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">classic, 72, 73<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">conditions associated with, 90<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">fluorescein angiography of, 36, 37<span class="italic">f,</span> 72–73, 73<span class="italic">–&#173;</span>74<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">green &#173;laser for, 373</p>
			<p class="em-only_endmatter-idx2">idiopathic, 89–90</p>
			<p class="em-only_endmatter-idx2">indocyanine green angiography of, 73</p>
			<p class="em-only_endmatter-idx2">&#173;laser photocoagulation for, 376</p>
			<p class="em-only_endmatter-idx2">late leakage from an undetermined source, 72</p>
			<p class="em-only_endmatter-idx2">miscellaneous &#173;causes of, 89–90</p>
			<p class="em-only_endmatter-idx2">multifocal choroiditis in, 226, 226<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">occult, 72–73</p>
			<p class="em-only_endmatter-idx2">ocular histoplasmosis syndrome as cause of, <br />86–87, 88<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">optical coherence tomographic angiography of, 75–76, 76<span class="italic">–&#173;</span>78<span class="italic">f,</span> 192</p>
			<p class="em-only_endmatter-idx2">optical coherence tomography of, 192, 194</p>
			<p class="em-only_endmatter-idx2">in pathologic myopia, 89, 211<span class="italic">f,</span> 211–212</p>
			<p class="em-only_endmatter-idx2">photocoagulation for, 376</p>
			<p class="em-only_endmatter-idx2">photodynamic therapy for, 212, 213<span class="italic">f,</span> 380</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium tears in, 31</p>
			<p class="em-only_endmatter-idx2">scar tissue versus, 73</p>
			<p class="em-only_endmatter-idx2">signs and symptoms of, 71</p>
			<p class="em-only_endmatter-idx2">spectral-&#173;domain optical coherence tomography of, 73–75, 75<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">subfoveal, 355, 380</p>
			<p class="em-only_endmatter-idx2">subret&#173;i&#173;nal hemorrhages versus, 211</p>
			<p class="em-only_endmatter-idx2">susceptibility genes for, 63</p>
			<p class="em-only_endmatter-idx2">type 1, 71–72, 72<span class="italic">f,</span> 76<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">type 2, 72, 75, 77<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">type 3, 72–73, 75, 78<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">vascular endothelial growth &#173;factor concentrations in, 80</p>
			<p class="em-only_endmatter-idx2">vitelliform exudative macular detachment <br />versus, 272</p>
			<p class="em-only_endmatter-idx2">vitreous hemorrhage secondary to, 231<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Choroidal nevi, scanning &#173;laser ophthalmoscopy of, 24</p>
			<p class="em-only_endmatter-idx1">Choroideremia, 267–268, 268<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">choriocapillaris atrophy in, 258</p>
			<p class="em-only_endmatter-idx2">electroretinography findings in, 50</p>
			<p class="em-only_endmatter-idx1">Choroiditis</p>
			<p class="em-only_endmatter-idx2">birdshot uveitis on, 225, 225<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">multifocal, 220<span class="italic">t,</span> 225–226, 226<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Choroidopathy, hypertension, 123, 123<span class="italic">–&#173;</span>124<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Chronic progressive external ophthalmoplegia (CPEO), 293–294</p>
			<p class="em-only_endmatter-idx1">Cicatricial ret&#173;i&#173;nal detachment, 286</p>
			<p class="em-only_endmatter-idx1">Cigarette smoking, age-&#173;related macular degeneration risks, 62</p>
			<p class="em-only_endmatter-idx1">Ciliary artery occlusion, 144, 145<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ciliary body, 40</p>
			<p class="em-only_endmatter-idx1">Cilioret&#173;i&#173;nal artery</p>
			<p class="em-only_endmatter-idx2">anatomy of, 16, 16<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">occlusion of, 143</p>
			<p class="em-only_endmatter-idx1">Circle of Zinn-&#173;Haller, 217</p>
			<p class="em-only_endmatter-idx1">Circulation</p>
			<p class="em-only_endmatter-idx2">choroid, 19–20</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal, 16<span class="italic">f,</span> 16–17</p>
			<p class="em-only_endmatter-idx1">11-&#173;<span class="italic">cis-</span>&#173;retinaldehyde, 17</p>
			<p class="em-only_endmatter-idx1">11-&#173;<span class="italic">cis-&#173;</span>retinol dehydrogenase, 252</p>
			<p class="em-only_endmatter-idx1">Cisterns, in vitreous, 7</p>
			<p class="em-only_endmatter-idx1">Clindamycin, for toxoplasmic retinochoroiditis, 243</p>
			<p class="em-only_endmatter-idx1">Clinically significant diabetic macular edema (CSME), 92, 110, 114. <span class="italic">See also</span> Diabetic macular edema</p>
			<p class="em-only_endmatter-idx1">Clinically significant retinopathy of prematurity (CSROP), 184<span class="italic">t. See also</span> Retinopathy of prematurity</p>
			<p class="em-only_endmatter-idx1">Clofazimine, 298</p>
			<p class="em-only_endmatter-idx1">Cloquet canal</p>
			<p class="em-only_endmatter-idx2">anatomy of, 7, 8<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">formation of, 341</p>
			<p class="em-only_endmatter-idx1">CME. <span class="italic">See</span> Cystoid macular edema</p>
			<p class="em-only_endmatter-idx1">CMV. <span class="italic">See</span> Cytomegalovirus (CMV) retinitis</p>
			<p class="em-only_endmatter-idx1">CNV. <span class="italic">See</span> Choroidal neovascularization</p>
			<p class="em-only_endmatter-idx1">Coats disease, 159–161, 160<span class="italic">f,</span> 326</p>
			<p class="em-only_endmatter-idx1">Coats reaction, 260</p>
			<p class="em-only_endmatter-idx1">Cobblestone degeneration, 313, 314<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1"><span class="italic">COL2A1</span> gene, 343</p>
			<p class="em-only_endmatter-idx1">Collagen fibers, in vitreous, 7, 344</p>
			<p class="em-only_endmatter-idx1">Color vision</p>
			<p class="em-only_endmatter-idx2">abnormalities of</p>
			<p class="em-only_endmatter-idx3">achromatopsia, 250, 250<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">acquired, 249, 250<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">congenital, 249–251, 250<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">description of, 249</p>
			<p class="em-only_endmatter-idx3">drugs that cause, 304–305</p>
			<p class="em-only_endmatter-idx2">blue-&#173;yellow deficiency, 54</p>
			<p class="em-only_endmatter-idx2">description of, 54</p>
			<p class="em-only_endmatter-idx2">red-&#173;green deficiency, 54</p>
			<p class="em-only_endmatter-idx1">Color vision tests</p>
			<p class="em-only_endmatter-idx2">Farnsworth-&#173;Munsell 100-&#173;hue test, 55</p>
			<p class="em-only_endmatter-idx2">Farnsworth Panel D-15 test, 55<span class="italic">f,</span> 55–56</p>
			<p class="em-only_endmatter-idx2">Hardy-&#173;Rand-&#173;Rittler plates, 54</p>
			<p class="em-only_endmatter-idx2">Ishihara plates, 54, 55<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">panel tests, 55</p>
			<p class="em-only_endmatter-idx2">pseudoisochromatic plates, 54, 55<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Comma sign, 154</p>
			<p class="em-only_endmatter-idx1">Commotio ret&#173;i&#173;nae, 353, 354<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Computed tomography</p>
			<p class="em-only_endmatter-idx2">intraocular foreign body evaluations, 352</p>
			<p class="em-only_endmatter-idx2">uveal lymphoma evaluations, 234</p>
			<p class="em-only_endmatter-idx1">Cone(s)</p>
			<p class="em-only_endmatter-idx2">bipolar cells synapsing with, 13</p>
			<p class="em-only_endmatter-idx2">in fovea, 11</p>
			<p class="em-only_endmatter-idx2">inner segments of, 11–12, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">L, 54</p>
			<p class="em-only_endmatter-idx2">light-&#173;sensitive molecules in, 12</p>
			<p class="em-only_endmatter-idx2">M, 54</p>
			<p class="em-only_endmatter-idx2">outer segments of, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">photoreceptors in, 13</p>
			<p class="em-only_endmatter-idx2">S, 54</p>
			<p class="em-only_endmatter-idx2">schematic diagram of, 14<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">types of, 54</p>
			<p class="em-only_endmatter-idx1">Cone dystrophies</p>
			<p class="em-only_endmatter-idx2">bull’s-&#173;eye pattern associated with, 265, 265<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">description of, 264–265</p>
			<p class="em-only_endmatter-idx2">electroretinography findings in, 46, 47<span class="italic">f,</span> 265</p>
			<p class="em-only_endmatter-idx2">genes and loci associated with, 256<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">with supernormal rod ERG, 49</p>
			<p class="em-only_endmatter-idx1">Cone–&#173;rod dystrophies</p>
			<p class="em-only_endmatter-idx2">genes and loci associated with, 256<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">Jalili syndrome, 286</p>
			<p class="em-only_endmatter-idx2">retinitis punctata albescens, 258, 258<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Confluent drusen, 65</p>
			<p class="em-only_endmatter-idx1">Confocal scanning &#173;laser ophthalmoscopy (SLO), for ret&#173;i&#173;nal disease evaluations, 24</p>
			<p class="em-only_endmatter-idx1">Congenital stationary night blindness (CSNB)</p>
			<p class="em-only_endmatter-idx2">Duchenne muscular dystrophy and, 285</p>
			<p class="em-only_endmatter-idx2">electroretinography findings in, 46, 47<span class="italic">f,</span> 251, 252<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">genes and loci associated with, 256<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">retinitis pigmentosa versus, 251</p>
			<p class="em-only_endmatter-idx2">subtypes of, 251</p>
			<p class="em-only_endmatter-idx2">X-&#173;linked, 252</p>
			<p class="em-only_endmatter-idx1">Congenital toxoplasmosis, 243</p>
			<p class="em-only_endmatter-idx1">Conjunctival filtering blebs, endophthalmitis associated with, 390–391, 391<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Contact B-&#173;scan ultrasonography, 39, 39<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Contact lenses</p>
			<p class="em-only_endmatter-idx2">fundus on, 22</p>
			<p class="em-only_endmatter-idx2">in photocoagulation delivery, 375</p>
			<p class="em-only_endmatter-idx1">Contraceptives (oral), central ret&#173;i&#173;nal vein occlusion risks, 134</p>
			<p class="em-only_endmatter-idx1">Contrast sensitivity, 56–57, 57<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Contrecoup, 315</p>
			<p class="em-only_endmatter-idx1">Copper, 362</p>
			<p class="em-only_endmatter-idx1">Corneal lacerations, 359</p>
			<p class="em-only_endmatter-idx1">Corneal verticillata, 295</p>
			<p class="em-only_endmatter-idx1">Corticosteroids</p>
			<p class="em-only_endmatter-idx2">acute posterior multifocal placoid pigment epitheliopathy treated with, 222</p>
			<p class="em-only_endmatter-idx2">acute ret&#173;i&#173;nal necrosis treated with, 236</p>
			<p class="em-only_endmatter-idx2">branch ret&#173;i&#173;nal vein occlusion treated with, 137–138</p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal vein occlusion treated with, 137–138</p>
			<p class="em-only_endmatter-idx2">central serous chorioretinopathy caused by, 300</p>
			<p class="em-only_endmatter-idx2">cystoid macular edema treated with, 159, 393</p>
			<p class="em-only_endmatter-idx2">cytomegalovirus retinitis and, 236</p>
			<p class="em-only_endmatter-idx2">diabetic macular edema treated with, 113–114</p>
			<p class="em-only_endmatter-idx2">&#173;giant cell arteritis treated with, 145</p>
			<p class="em-only_endmatter-idx2">progressive outer ret&#173;i&#173;nal necrosis syndrome treated with, 237</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal vein occlusion treated with, 137–138</p>
			<p class="em-only_endmatter-idx2">toxoplasmic retinochoroiditis treated with, 244</p>
			<p class="em-only_endmatter-idx1">Cotton-&#173;wool spots</p>
			<p class="em-only_endmatter-idx2">cytomegalovirus retinitis and, 235</p>
			<p class="em-only_endmatter-idx2">in diabetic retinopathy, 140–141</p>
			<p class="em-only_endmatter-idx2">in hypertensive retinopathy, 122, 122<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">in Purtscher retinopathy, 171</p>
			<p class="em-only_endmatter-idx2">in systemic lupus erythematosus, 230</p>
			<p class="em-only_endmatter-idx1">Coup, 315</p>
			<p class="em-only_endmatter-idx1">CPEO. <span class="italic">See</span> Chronic progressive external ophthalmoplegia</p>
			<p class="em-only_endmatter-idx1">CRAO. <span class="italic">See</span> Central ret&#173;i&#173;nal artery occlusion</p>
			<p class="em-only_endmatter-idx1">CRAVE study, 135</p>
			<p class="em-only_endmatter-idx1"><span class="italic">CRB1</span> mutations, 258</p>
			<p class="em-only_endmatter-idx1">CRVO. <span class="italic">See</span> Central ret&#173;i&#173;nal vein occlusion</p>
			<p class="em-only_endmatter-idx1">Cryoablation, for retinopathy of prematurity, 185–186</p>
			<p class="em-only_endmatter-idx1">Cryopexy</p>
			<p class="em-only_endmatter-idx2">transconjunctival, 398</p>
			<p class="em-only_endmatter-idx2">transscleral, 398</p>
			<p class="em-only_endmatter-idx1">Cryotherapy</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal cavernous hemangioma treated with, 168</p>
			<p class="em-only_endmatter-idx2">von Hippel–&#173;Lindau syndrome treated with, 167</p>
			<p class="em-only_endmatter-idx1">Crystalline retinopathy</p>
			<p class="em-only_endmatter-idx2">cause of, 302–304, 303<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">drugs that cause, 302–304</p>
			<p class="em-only_endmatter-idx2">tamoxifen as cause of, 303, 304<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">West African, 303–304, 305<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">CSC. <span class="italic">See</span> Central serous chorioretinopathy</p>
			<p class="em-only_endmatter-idx1">C-&#173;scan, 26</p>
			<p class="em-only_endmatter-idx1">CSME. <span class="italic">See</span> Clinically significant diabetic macular edema</p>
			<p class="em-only_endmatter-idx1">CSNB. <span class="italic">See</span> Congenital stationary night blindness</p>
			<p class="em-only_endmatter-idx1">CSROP. <span class="italic">See</span> Clinically significant retinopathy of prematurity</p>
			<p class="em-only_endmatter-idx1"><span class="italic">Culex</span> mosquitoes, 246</p>
			<p class="em-only_endmatter-idx1">Cuticular drusen, 274, 275<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Cyclosporine, for Beh<span class="accent">ç</span>et disease, 230</p>
			<p class="em-only_endmatter-idx1"><span class="italic">CYP4V2,</span> 257<span class="italic">t</span>, 258, 269</p>
			<p class="em-only_endmatter-idx1">Cysteamine, 293</p>
			<p class="em-only_endmatter-idx1">Cystinosis, 293</p>
			<p class="em-only_endmatter-idx1">Cystoid macular edema (CME)</p>
			<p class="em-only_endmatter-idx2">birdshot uveitis in, 224</p>
			<p class="em-only_endmatter-idx2">cataract surgery as cause of, 157, 159, 260</p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal vein occlusion as cause of, 136<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">characteristics of, 156–157</p>
			<p class="em-only_endmatter-idx2">corticosteroids for, 159, 393</p>
			<p class="em-only_endmatter-idx2">in cytomegalovirus retinitis, 235</p>
			<p class="em-only_endmatter-idx2">differential diagnosis of, 157</p>
			<p class="em-only_endmatter-idx2">drugs that cause, 301</p>
			<p class="em-only_endmatter-idx2">edema sources in, 156–157</p>
			<p class="em-only_endmatter-idx2">etiologies of, 157</p>
			<p class="em-only_endmatter-idx2">fingolimod as cause of, 302</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography of, 36<span class="italic">f,</span> 157</p>
			<p class="em-only_endmatter-idx2">incidence of, 157, 159</p>
			<p class="em-only_endmatter-idx2">in Irvine-&#173;Gass syndrome, 157</p>
			<p class="em-only_endmatter-idx2">nicotinic acid as cause of, 301</p>
			<p class="em-only_endmatter-idx2">optical coherence tomography of, 132<span class="italic">f,</span> 157, 158<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">petaloid, 157</p>
			<p class="em-only_endmatter-idx2">predisposing &#173;factors for, 157, 159</p>
			<p class="em-only_endmatter-idx2">pseudophakic</p>
			<p class="em-only_endmatter-idx3">definition of, 157</p>
			<p class="em-only_endmatter-idx3">imaging of, 394<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">optical coherence tomography of, 158<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">pars plana vitrectomy for, 394<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">in ret&#173;i&#173;nal dystrophies, 260, 260<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal vein occlusion as cause of, 135. <span class="italic">See also</span> Ret&#173;i&#173;nal vein occlusion (RVO)</p>
			<p class="em-only_endmatter-idx2">retinitis pigmentosa and, 260</p>
			<p class="em-only_endmatter-idx2">spontaneous resolution of, 159</p>
			<p class="em-only_endmatter-idx2">subret&#173;i&#173;nal diseases that cause, 157</p>
			<p class="em-only_endmatter-idx2">taxanes as cause of, 301</p>
			<p class="em-only_endmatter-idx2">treatment of, 159</p>
			<p class="em-only_endmatter-idx2">vision loss caused by, 225</p>
			<p class="em-only_endmatter-idx2">vitrectomy for, 159, 393, 394<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Cytomegalovirus (CMV) retinitis, 235–236, 238<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx-alpha">Dark adaptation</p>
			<p class="em-only_endmatter-idx2">in electro-&#173;oculography, 50</p>
			<p class="em-only_endmatter-idx2">in full-&#173;field (Ganzfield) electroretinography, 42</p>
			<p class="em-only_endmatter-idx2">in Oguchi disease, 253</p>
			<p class="em-only_endmatter-idx1">Dark adaptometry, 57–58</p>
			<p class="em-only_endmatter-idx1">DCCT. <span class="italic">See</span> Diabetes Control and Complications<br />Trial</p>
			<p class="em-only_endmatter-idx1">Deep capillary plexus, 16</p>
			<p class="em-only_endmatter-idx1">Deferoxamine, 298–299</p>
			<p class="em-only_endmatter-idx1">Dehiscences, in lamina cribrosa, 218, 218<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Demarcation lines</p>
			<p class="em-only_endmatter-idx2">pigmented, in rhegmatogenous ret&#173;i&#173;nal detachment, 324</p>
			<p class="em-only_endmatter-idx2">in retinoschisis, 328</p>
			<p class="em-only_endmatter-idx1">Demyelinating optic neuritis, visual evoked potentials in, 52</p>
			<p class="em-only_endmatter-idx1">Dental diseases, ret&#173;i&#173;nal degeneration associated <br />with, 286</p>
			<p class="em-only_endmatter-idx1">Dentate pro&#173;cesses</p>
			<p class="em-only_endmatter-idx2">definition of, 10</p>
			<p class="em-only_endmatter-idx2">illustration of, 11<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Dermatologic diseases, ret&#173;i&#173;nal degeneration associated with, 286</p>
			<p class="em-only_endmatter-idx1">Descemet membrane, chalcosis findings in, 362</p>
			<p class="em-only_endmatter-idx1">Deutan red-&#173;green color deficiency, 54</p>
			<p class="em-only_endmatter-idx1">Deuteranomalous dichromatism, 250<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Deuteranomalous trichromatism, 250<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Dexamethasone implant</p>
			<p class="em-only_endmatter-idx2">complications of, 404</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal vein occlusion treated with, 137</p>
			<p class="em-only_endmatter-idx1">DHA. <span class="italic">See</span> Docosahexaenoic acid</p>
			<p class="em-only_endmatter-idx1">Diabetes Control and Complications Trial (DCCT), 96</p>
			<p class="em-only_endmatter-idx1">Diabetes mellitus</p>
			<p class="em-only_endmatter-idx2">asteroid hyalosis and, 346</p>
			<p class="em-only_endmatter-idx2">cataract surgery in, 116, 117<span class="italic">–&#173;</span>120<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">Diabetes Control and Complications Trial, 96</p>
			<p class="em-only_endmatter-idx2">insulin-&#173;dependent, 91</p>
			<p class="em-only_endmatter-idx2">non–&#173;insulin-&#173;dependent, 91</p>
			<p class="em-only_endmatter-idx2">ophthalmic examinations for, 93–94, 95<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal vein occlusion risks, 128</p>
			<p class="em-only_endmatter-idx2">type 1, 91</p>
			<p class="em-only_endmatter-idx2">type 2, 91</p>
			<p class="em-only_endmatter-idx2">United Kingdom Prospective Diabetes Study, 96–97</p>
			<p class="em-only_endmatter-idx1">Diabetic macular edema (DME)</p>
			<p class="em-only_endmatter-idx2">cataract surgery effects on, 116</p>
			<p class="em-only_endmatter-idx2">center-&#173;involved, 92, 109, 110<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">classification of, 109–110, 110<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">clinically significant (CSME), 92, 110, 114</p>
			<p class="em-only_endmatter-idx2">contrast sensitivity issues in, 56</p>
			<p class="em-only_endmatter-idx2">definition of, 92</p>
			<p class="em-only_endmatter-idx2">focal, 110</p>
			<p class="em-only_endmatter-idx2">mechanism of, 108, 109<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">non–&#173;center-&#173;involved, 109, 111<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">optical coherence tomography of, 111<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">spectral-&#173;domain optical coherence tomography of, 109<span class="italic">f,</span> 125</p>
			<p class="em-only_endmatter-idx2">treatment of</p>
			<p class="em-only_endmatter-idx3">aflibercept, 113</p>
			<p class="em-only_endmatter-idx3">anti-&#173;VEGF therapy, 101, 110–113</p>
			<p class="em-only_endmatter-idx3">bevacizumab, 113</p>
			<p class="em-only_endmatter-idx3">corticosteroids, 113–114</p>
			<p class="em-only_endmatter-idx3">Diabetic Retinopathy Clinical Research Network findings, 112<span class="italic">f,</span> 113</p>
			<p class="em-only_endmatter-idx3">intravitreal ste&#173;roids, 101</p>
			<p class="em-only_endmatter-idx3">&#173;laser surgery, 114–115, 376</p>
			<p class="em-only_endmatter-idx3">overview of, 110–111</p>
			<p class="em-only_endmatter-idx3">pars plana vitrectomy, 115</p>
			<p class="em-only_endmatter-idx3">ranibizumab, 111–112, 112<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">surgery, 114–115, 388</p>
			<p class="em-only_endmatter-idx3">vitrectomy, 388</p>
			<p class="em-only_endmatter-idx2">vision loss caused by, 94</p>
			<p class="em-only_endmatter-idx1">Diabetic nephropathy, 98</p>
			<p class="em-only_endmatter-idx1">Diabetic retinopathy</p>
			<p class="em-only_endmatter-idx2">anemia and, 98</p>
			<p class="em-only_endmatter-idx2">aspirin and, 100</p>
			<p class="em-only_endmatter-idx2">cotton-&#173;wool spots associated with, 140–141</p>
			<p class="em-only_endmatter-idx2">description of, 91</p>
			<p class="em-only_endmatter-idx2">diabetic nephropathy associated with, 98</p>
			<p class="em-only_endmatter-idx2">epidemiology of, 92–93</p>
			<p class="em-only_endmatter-idx2">4:2:1 rule for, 99</p>
			<p class="em-only_endmatter-idx2">glycemic control for, 96–98</p>
			<p class="em-only_endmatter-idx2">hemoglobin A<span class="CharOverride-1">1c</span> levels in, 96, 98</p>
			<p class="em-only_endmatter-idx2">medical management of, 96–98</p>
			<p class="em-only_endmatter-idx2">nonproliferative (NPDR)</p>
			<p class="em-only_endmatter-idx3">anti-&#173;VEGF therapy for, 101–102</p>
			<p class="em-only_endmatter-idx3">clinical findings in, 99</p>
			<p class="em-only_endmatter-idx3">definition of, 91</p>
			<p class="em-only_endmatter-idx3">intraret&#173;i&#173;nal hemorrhages associated with, 100<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">intraret&#173;i&#173;nal microvascular abnormalities in, <br />100<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">microaneurysms associated with, 100<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">optical coherence tomography angiography of, 94<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">panret&#173;i&#173;nal photocoagulation for, 101</p>
			<p class="em-only_endmatter-idx3">posterior vitreous detachment creation for, 102</p>
			<p class="em-only_endmatter-idx3">progression of, to proliferative diabetic <br />retinopathy, 101</p>
			<p class="em-only_endmatter-idx3">ranibizumab for, 102</p>
			<p class="em-only_endmatter-idx3">scatter photocoagulation for, 116</p>
			<p class="em-only_endmatter-idx3">severity of, 95<span class="italic">t,</span> 99</p>
			<p class="em-only_endmatter-idx3">treatment of, 101–102</p>
			<p class="em-only_endmatter-idx3">venous beading associated with, 100<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">vision loss in, 101</p>
			<p class="em-only_endmatter-idx2">ophthalmic examinations for, 93–94, 95<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">pathogenesis of, 93</p>
			<p class="em-only_endmatter-idx2">pregnancy-&#173;related progression of, 93–94</p>
			<p class="em-only_endmatter-idx2">progression of</p>
			<p class="em-only_endmatter-idx3">fenofibrate effects on, 102</p>
			<p class="em-only_endmatter-idx3">hypertension as risk &#173;factor for, 98</p>
			<p class="em-only_endmatter-idx3">pregnancy-&#173;related, 93–94</p>
			<p class="em-only_endmatter-idx2">proliferative (PDR)</p>
			<p class="em-only_endmatter-idx3">anti-&#173;VEGF therapy for, 103–104, 386</p>
			<p class="em-only_endmatter-idx3">complications of, 103–108</p>
			<p class="em-only_endmatter-idx3">definition of, 91–92</p>
			<p class="em-only_endmatter-idx3">extraret&#173;i&#173;nal fibrovascular proliferation associated with, 102</p>
			<p class="em-only_endmatter-idx3">high-&#173;risk characteristics of, 103</p>
			<p class="em-only_endmatter-idx3">&#173;laser surgery for, 104–107</p>
			<p class="em-only_endmatter-idx3">management of, 103–108</p>
			<p class="em-only_endmatter-idx3">neovascular proliferation associated with, 102</p>
			<p class="em-only_endmatter-idx3">neovascularization in, 151</p>
			<p class="em-only_endmatter-idx3">nonproliferative diabetic retinopathy progression to, 101</p>
			<p class="em-only_endmatter-idx3">nonsurgical management of, 103–104</p>
			<p class="em-only_endmatter-idx3">optical coherence tomography angiography of, 94<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">panret&#173;i&#173;nal photocoagulation for, 104, 106, 106<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">photocoagulation for, 94</p>
			<p class="em-only_endmatter-idx3">in pregnancy, 94</p>
			<p class="em-only_endmatter-idx3">proangiogenic &#173;factors in, 102</p>
			<p class="em-only_endmatter-idx3">proliferative sickle cell retinopathy versus, 151</p>
			<p class="em-only_endmatter-idx3">ranibizumab for, 104</p>
			<p class="em-only_endmatter-idx3">scatter photocoagulation for, 116</p>
			<p class="em-only_endmatter-idx3">severe carotid artery occlusive disease associated with, 98</p>
			<p class="em-only_endmatter-idx3">severity of, 95<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">stages of, 102</p>
			<p class="em-only_endmatter-idx3">ste&#173;roids for, 103–104</p>
			<p class="em-only_endmatter-idx3">surgical management of, 104–107</p>
			<p class="em-only_endmatter-idx3">tractional ret&#173;i&#173;nal detachment caused by, 103, 108, 387–388</p>
			<p class="em-only_endmatter-idx3">vitreous hemorrhage caused by, 103, 103<span class="italic">f,</span> 107–108, 386–387</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal capillary nonperfusion associated with, 101</p>
			<p class="em-only_endmatter-idx2">severity of, 95<span class="italic">t,</span> 101</p>
			<p class="em-only_endmatter-idx2">studies of</p>
			<p class="em-only_endmatter-idx3">Diabetes Control and Complications Trial, 96</p>
			<p class="em-only_endmatter-idx3">Early Treatment Diabetic Retinopathy Study, 99–101</p>
			<p class="em-only_endmatter-idx3">United Kingdom Prospective Diabetes Study, 96–97</p>
			<p class="em-only_endmatter-idx2">systemic medical management of, 96–98</p>
			<p class="em-only_endmatter-idx2">terminology associated with, 91–92</p>
			<p class="em-only_endmatter-idx2">vision loss from</p>
			<p class="em-only_endmatter-idx3">abnormalities associated with, 98</p>
			<p class="em-only_endmatter-idx3">lipid levels and, 98</p>
			<p class="em-only_endmatter-idx3">mechanisms of, 101</p>
			<p class="em-only_endmatter-idx1">Diabetic Retinopathy Clinical Research Network</p>
			<p class="em-only_endmatter-idx2">cataract surgery in diabetes mellitus studies, 116, 117<span class="italic">–&#173;</span>120<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">diabetic macular edema treatment, 112<span class="italic">f,</span> 113</p>
			<p class="em-only_endmatter-idx1">Diabetic Retinopathy Study (DRS), 104–105</p>
			<p class="em-only_endmatter-idx1">Dichromacy, 250</p>
			<p class="em-only_endmatter-idx1">Dideoxyinosine, 299</p>
			<p class="em-only_endmatter-idx1">Diet, retinopathy of prematurity and, 184–185</p>
			<p class="em-only_endmatter-idx1">Diffuse macular edema, 110, 111<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Diffuse unilateral subacute neuroretinitis (DUSN), 246</p>
			<p class="em-only_endmatter-idx1">Digitalis, 305</p>
			<p class="em-only_endmatter-idx1">Digital resolution, of scanning &#173;laser ophthalmoscopy, 24</p>
			<p class="em-only_endmatter-idx1">Direct ophthalmoscope/ophthalmoscopy. <span class="italic">See also</span> Ophthalmoscopy</p>
			<p class="em-only_endmatter-idx2">limitations of, 21</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal disease evaluations using, 21</p>
			<p class="em-only_endmatter-idx1">Disseminated intravascular coagulation, 196</p>
			<p class="em-only_endmatter-idx1">Diuretics, 134</p>
			<p class="em-only_endmatter-idx1">DME. <span class="italic">See</span> Diabetic macular edema</p>
			<p class="em-only_endmatter-idx1">Docetaxel, 301</p>
			<p class="em-only_endmatter-idx1">Docosahexaenoic acid (DHA), 70</p>
			<p class="em-only_endmatter-idx1">Doxycycline, for cat-&#173;scratch disease, 242–243</p>
			<p class="em-only_endmatter-idx1">Doyne honeycomb dystrophy, 275</p>
			<p class="em-only_endmatter-idx1">DRS. <span class="italic">See</span> Diabetic Retinopathy Study</p>
			<p class="em-only_endmatter-idx1">Drugs. <span class="italic">See also specific drug</span></p>
			<p class="em-only_endmatter-idx2">color-&#173;vision abnormalities caused by, 304–305</p>
			<p class="em-only_endmatter-idx2">crystalline retinopathy caused by, 302–304, 304<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">ganglion cell toxicity caused by, 301</p>
			<p class="em-only_endmatter-idx2">hyaloidal separation effects on, 85</p>
			<p class="em-only_endmatter-idx2">macular edema caused by, 301–302, 302<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">microvasculopathy caused by, 300–301</p>
			<p class="em-only_endmatter-idx2">occlusive retinopathy caused by, 300–301</p>
			<p class="em-only_endmatter-idx2">ocular toxicities caused by, 305–306</p>
			<p class="em-only_endmatter-idx2">optic nerve toxicity caused by, 301</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal toxicity caused by</p>
			<p class="em-only_endmatter-idx3">alkyl nitrites, 300, 300<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">chloroquine derivatives, 295–297, 296<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">clofazimine, 298</p>
			<p class="em-only_endmatter-idx3">deferoxamine, 298–299</p>
			<p class="em-only_endmatter-idx3">dideoxyinosine, 299</p>
			<p class="em-only_endmatter-idx3">hydroxychloroquine, 295–297, 296<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">MEK inhibitors, 299, 299<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">nucleoside reverse transcriptase inhibitors, 299</p>
			<p class="em-only_endmatter-idx3">phenothiazines, 297–298, 298<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">scleral delivery of, 20</p>
			<p class="em-only_endmatter-idx2">toxicity caused by, ret&#173;i&#173;nal signs of, 68</p>
			<p class="em-only_endmatter-idx1">Drusen</p>
			<p class="em-only_endmatter-idx2">bound&#173;aries of, 65</p>
			<p class="em-only_endmatter-idx2">calcific, 66</p>
			<p class="em-only_endmatter-idx2">categorization of, 64–65</p>
			<p class="em-only_endmatter-idx2">confluent, 65</p>
			<p class="em-only_endmatter-idx2">cuticular, 274, 275<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">definition of, 63</p>
			<p class="em-only_endmatter-idx2">early-&#173;onset, 273, 274<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">fluorescein angiography of, 65</p>
			<p class="em-only_endmatter-idx2">fundus camera imaging of, 23, 23<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">geographic atrophy and, 66</p>
			<p class="em-only_endmatter-idx2">hard, 65</p>
			<p class="em-only_endmatter-idx2">histologic appearance of, 63, 64<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">large colloid, 274</p>
			<p class="em-only_endmatter-idx2">optical coherence tomography of, 65–66</p>
			<p class="em-only_endmatter-idx2">photoreceptors affected by, 64</p>
			<p class="em-only_endmatter-idx2">pigment epithelial detachment associated with, 64</p>
			<p class="em-only_endmatter-idx2">refractile, 23<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">soft, 65, 68, 75, 200<span class="italic">f,</span> 272</p>
			<p class="em-only_endmatter-idx2">spectral-&#173;domain optical coherence tomography <br />of, 64<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">subret&#173;i&#173;nal deposits, 200</p>
			<p class="em-only_endmatter-idx1">Drusenoid pigment epithelial detachment, 64, 272, 274<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">“Dry” age-&#173;related macular degeneration. <span class="italic">See</span> Nonneovascular (“dry”) age-&#173;related macular degeneration</p>
			<p class="em-only_endmatter-idx1">Duchenne muscular dystrophy, 285</p>
			<p class="em-only_endmatter-idx1">Dural arteriovenous malformations, 198, 199<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">DUSN. <span class="italic">See</span> Diffuse unilateral subacute neuroretinitis</p>
			<p class="em-only_endmatter-idx1">Dyschromatopsia, 249, 265</p>
			<p class="em-only_endmatter-idx1">Dystrophic lipidization, 66</p>
			<p class="em-only_endmatter-idx1">Dystrophies</p>
			<p class="em-only_endmatter-idx2">adult-&#173;onset foveomacular vitelliform, 272, 276</p>
			<p class="em-only_endmatter-idx2">butterfly-&#173;type pattern, 276, 276<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">choroidal</p>
			<p class="em-only_endmatter-idx3">Bietti crystalline dystrophy, 258, 269, 282<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">central areolar, 277</p>
			<p class="em-only_endmatter-idx3">choroideremia, 267–268, 268<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">classification of, 255</p>
			<p class="em-only_endmatter-idx3">gyrate atrophy, 268–269, 269<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">cone</p>
			<p class="em-only_endmatter-idx3">bull’s-&#173;eye pattern associated with, 265, 265<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">description of, 264–265</p>
			<p class="em-only_endmatter-idx3">electroretinography findings in, 46, 47<span class="italic">f,</span> 265</p>
			<p class="em-only_endmatter-idx3">genes and loci associated with, 256<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">with supernormal rod ERG, 49</p>
			<p class="em-only_endmatter-idx2">cone–&#173;rod</p>
			<p class="em-only_endmatter-idx3">genes and loci associated with, 256<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">Jalili syndrome, 286</p>
			<p class="em-only_endmatter-idx3">retinitis punctata albescens, 258, 258<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">macular</p>
			<p class="em-only_endmatter-idx3">adult-&#173;onset vitelliform lesions, 272, 273<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">aty&#173;pi&#173;cal, 277</p>
			<p class="em-only_endmatter-idx3">Best disease, 271, 272<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">early-&#173;onset “drusenoid,” 273–276, 274<span class="italic">–&#173;</span>275<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">electroretinography findings in, 46, 47<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">North Carolina, 277, 278<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">occult, 277</p>
			<p class="em-only_endmatter-idx3">pattern dystrophies, 276<span class="italic">f,</span> 276–277</p>
			<p class="em-only_endmatter-idx3">Sorsby, 275<span class="italic">f,</span> 275–276</p>
			<p class="em-only_endmatter-idx3">Stargardt disease. <span class="italic">See</span> Macular dystrophies</p>
			<p class="em-only_endmatter-idx2">panret&#173;i&#173;nal</p>
			<p class="em-only_endmatter-idx3">clinical findings of, 261, 263<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">Coats reaction associated with, 260</p>
			<p class="em-only_endmatter-idx3">nonsyndromic, 258–259</p>
			<p class="em-only_endmatter-idx3">syndromic, 259</p>
			<p class="em-only_endmatter-idx2">pattern, 67, 272, 276<span class="italic">f,</span> 276–277</p>
			<p class="em-only_endmatter-idx2">rod–&#173;cone. <span class="italic">See also</span> Retinitis pigmentosa</p>
			<p class="em-only_endmatter-idx3">in Bardet-&#173;Biedl syndrome, 284</p>
			<p class="em-only_endmatter-idx3">characteristics of, 261–264, 262<span class="italic">–&#173;</span>264<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">conventional testing of, 261</p>
			<p class="em-only_endmatter-idx3">electroretinography evaluations, 46, 47<span class="italic">f,</span> 261</p>
			<p class="em-only_endmatter-idx3">imaging of, 262<span class="italic">–&#173;</span>264<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">macula-&#173;spared, 46, 47<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Dystrophin, 285</p>
			<p class="em-only_endmatter-idx-alpha">Eales disease, 156, 241</p>
			<p class="em-only_endmatter-idx1">Early macular telangiectasia, 277</p>
			<p class="em-only_endmatter-idx1">Early-&#173;onset “drusenoid” macular dystrophies, 273–276, 274<span class="italic">–&#173;</span>275<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Early Treatment Diabetic Retinopathy Study (ETDRS), 99–101, 110</p>
			<p class="em-only_endmatter-idx1">Early Treatment of Retinopathy of Prematurity (ETROP), 179, 185</p>
			<p class="em-only_endmatter-idx1">Ebola virus (EBOV) panuveitis, 247</p>
			<p class="em-only_endmatter-idx1">Echography, for vitreous hemorrhage, 347</p>
			<p class="em-only_endmatter-idx1">Eclampsia, 196</p>
			<p class="em-only_endmatter-idx1">Eclipse retinopathy. <span class="italic">See</span> Solar retinopathy</p>
			<p class="em-only_endmatter-idx1">EDI-OCT. <span class="italic">See</span> Enhanced depth imaging optical coherence tomography</p>
			<p class="em-only_endmatter-idx1"><span class="italic">EFEMP1</span> gene, 275</p>
			<p class="em-only_endmatter-idx1">Eicosapentaenoic acid (EPA), 70</p>
			<p class="em-only_endmatter-idx1">Electrical injuries, 357</p>
			<p class="em-only_endmatter-idx1">Electro-&#173;oculography/electro-&#173;oculogram (EOG)</p>
			<p class="em-only_endmatter-idx2">acute zonal occult outer retinopathy evaluations, 51</p>
			<p class="em-only_endmatter-idx2">autosomal recessive bestrophinopathy <br />evaluations, 51</p>
			<p class="em-only_endmatter-idx2">Best disease evaluations, 51, 271</p>
			<p class="em-only_endmatter-idx2">bestrophin mutation evaluations, 51</p>
			<p class="em-only_endmatter-idx2">illustration of, 52<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">purpose of, 50</p>
			<p class="em-only_endmatter-idx2">technique of, 50</p>
			<p class="em-only_endmatter-idx2">vitelliform macular dystrophy evaluations, 51</p>
			<p class="em-only_endmatter-idx1">Electrophysiologic testing</p>
			<p class="em-only_endmatter-idx2">International Society for Clinical Electrophysiology of Vision standards for, 41</p>
			<p class="em-only_endmatter-idx2">purpose of, 41</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal, 41–42</p>
			<p class="em-only_endmatter-idx1">Electroretinography (ERG)</p>
			<p class="em-only_endmatter-idx2"><span class="italic">ABCA4</span> retinopathy findings, 48<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">achromatopsia, 250</p>
			<p class="em-only_endmatter-idx2">acute zonal occult outer retinopathy findings, 227</p>
			<p class="em-only_endmatter-idx2">a-&#173;waves, 46, 251, 261</p>
			<p class="em-only_endmatter-idx2">Best disease findings, 271</p>
			<p class="em-only_endmatter-idx2">birdshot chorioretinopathy findings, 49</p>
			<p class="em-only_endmatter-idx2">bradyopsia findings, 49</p>
			<p class="em-only_endmatter-idx2">b-waves, 42–44, 43<span class="italic">f</span>, 46, 47<span class="italic">f</span>, 50, 261</p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal artery occlusion findings, 50</p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal vein occlusion findings, 50</p>
			<p class="em-only_endmatter-idx2">in &#173;children, 50</p>
			<p class="em-only_endmatter-idx2">choroideremia findings, 50</p>
			<p class="em-only_endmatter-idx2">clinical considerations for, 46, 49–50</p>
			<p class="em-only_endmatter-idx2">cone dystrophies</p>
			<p class="em-only_endmatter-idx3">findings associated with, 46, 47<span class="italic">f,</span> 265</p>
			<p class="em-only_endmatter-idx3">with supernormal rod ERG findings, 49</p>
			<p class="em-only_endmatter-idx2">cone–&#173;rod dystrophy phenotype in, 44</p>
			<p class="em-only_endmatter-idx2">congenital stationary night blindness findings, 46, 47<span class="italic">f,</span> 251, 252<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">dark adaptometry and, 58</p>
			<p class="em-only_endmatter-idx2">drugs that cause abnormalities in, 304–305</p>
			<p class="em-only_endmatter-idx2">electrodes used in, 42</p>
			<p class="em-only_endmatter-idx2">enhanced S-&#173;cone disease/syndrome findings, 49, 266, 267<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">full-&#173;field (Ganzfield). <span class="italic">See</span> Full-&#173;field (Ganzfield) electroretinography</p>
			<p class="em-only_endmatter-idx2">functions of, 42</p>
			<p class="em-only_endmatter-idx2">fundus albipunctatus findings, 252</p>
			<p class="em-only_endmatter-idx2">hydrochloroquine toxicity findings, 45, 49<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">inherent noise in, 44</p>
			<p class="em-only_endmatter-idx2">Leber congenital amaurosis findings, 266</p>
			<p class="em-only_endmatter-idx2">macular dystrophy findings, 44, 46, 47<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">melanoma-&#173;associated retinopathy findings, 286</p>
			<p class="em-only_endmatter-idx2">multifocal, 45, 48<span class="italic">–&#173;</span>49<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">multiple evanescent white dot syndrome on, <br />224</p>
			<p class="em-only_endmatter-idx2">in newborn, 44</p>
			<p class="em-only_endmatter-idx2">night blindness findings, 46</p>
			<p class="em-only_endmatter-idx2">ocular ischemic syndrome findings, 138, 139<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">pattern, 45–46, 46<span class="italic">–&#173;</span>49<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">peak-&#173;time shift in, 44</p>
			<p class="em-only_endmatter-idx2">photophobia findings, 46</p>
			<p class="em-only_endmatter-idx2">rod monochromatism findings, 250</p>
			<p class="em-only_endmatter-idx2">S-&#173;cone monochromatism findings, 250</p>
			<p class="em-only_endmatter-idx2">siderosis bulbi findings, 362</p>
			<p class="em-only_endmatter-idx2">vigabatrin-&#173;related abnormalities of, 305</p>
			<p class="em-only_endmatter-idx2">X-&#173;linked retinitis pigmentosa findings, 50</p>
			<p class="em-only_endmatter-idx1">Elevated intraocular pressure</p>
			<p class="em-only_endmatter-idx2">in central ret&#173;i&#173;nal artery occlusion, 146</p>
			<p class="em-only_endmatter-idx2">in central ret&#173;i&#173;nal vein occlusion, 133</p>
			<p class="em-only_endmatter-idx2">&#173;after intravitreal injection of anti-&#173;VEGF drugs, <br />404</p>
			<p class="em-only_endmatter-idx1">ELISA. <span class="italic">See</span> Enzyme-&#173;linked immunosorbent assay</p>
			<p class="em-only_endmatter-idx1">Ellipsoid, 12</p>
			<p class="em-only_endmatter-idx1">Ellipsoidal mirror, scanning &#173;laser ophthalmoscopy use of, 24</p>
			<p class="em-only_endmatter-idx1">ELM. <span class="italic">See</span> External limiting membrane</p>
			<p class="em-only_endmatter-idx1">Elschnig spots, 123, 123<span class="italic">f,</span> 196</p>
			<p class="em-only_endmatter-idx1">Embolism, ret&#173;i&#173;nal vasculitis versus, 156</p>
			<p class="em-only_endmatter-idx1">Endogenous bacterial endophthalmitis, 237–239, <br />238<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Endophthalmitis</p>
			<p class="em-only_endmatter-idx2"><span class="italic">Bacillus cereus,</span> 363</p>
			<p class="em-only_endmatter-idx2">bevacizumab and, 85</p>
			<p class="em-only_endmatter-idx2">bleb-&#173;associated, 390–391, 391f</p>
			<p class="em-only_endmatter-idx2">endogenous</p>
			<p class="em-only_endmatter-idx3">bacterial, 237–239, 238<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">fungal, 239–240, 240<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">exogenous fungal, 239–240</p>
			<p class="em-only_endmatter-idx2">fungal, 239, 239f</p>
			<p class="em-only_endmatter-idx2">&#173;after intravitreal injections, 404</p>
			<p class="em-only_endmatter-idx2">postoperative</p>
			<p class="em-only_endmatter-idx3">acute-&#173;onset, 388–390, 390<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">bleb-&#173;associated, 390–391, 391<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">chronic (delayed-&#173;onset), 390, 391<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">posttraumatic, 362–363</p>
			<p class="em-only_endmatter-idx2"><span class="italic">Streptococcus viridans</span> as cause of, 404</p>
			<p class="em-only_endmatter-idx2">yeast, 239–240, 240<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Endophthalmitis Vitrectomy Study (EVS), 389–390</p>
			<p class="em-only_endmatter-idx1">Endothelial cells, in angiogenesis, 79</p>
			<p class="em-only_endmatter-idx1">En face scan</p>
			<p class="em-only_endmatter-idx2">definition of, 26</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal disease evaluations, 26, 29</p>
			<p class="em-only_endmatter-idx1">Enhanced depth imaging optical coherence tomography (EDI-OCT)</p>
			<p class="em-only_endmatter-idx2">autofluorescence imaging and, 39</p>
			<p class="em-only_endmatter-idx2">central serous chorioretinopathy findings, 67, 191, 193<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">choroidal layer on, 79, 193<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">choroidal-&#173;scleral interface on, 66</p>
			<p class="em-only_endmatter-idx2">description of, 25</p>
			<p class="em-only_endmatter-idx2">pachychoroid on, 76</p>
			<p class="em-only_endmatter-idx1">Enhanced S-&#173;cone disease (ESCD), 266, 267<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Enhanced S-&#173;cone syndrome, 49</p>
			<p class="em-only_endmatter-idx1">Enucleation, for penetrating ocular injury, 233</p>
			<p class="em-only_endmatter-idx1">Enzyme-&#173;linked immunosorbent assay (ELISA)</p>
			<p class="em-only_endmatter-idx2">in Lyme disease, 246</p>
			<p class="em-only_endmatter-idx2">in toxocariasis, 245</p>
			<p class="em-only_endmatter-idx1">EOG. <span class="italic">See</span> Electro-&#173;oculography/electro-&#173;oculogram</p>
			<p class="em-only_endmatter-idx1">EPA. <span class="italic">See</span> Eicosapentaenoic acid</p>
			<p class="em-only_endmatter-idx1">Epiret&#173;i&#173;nal membranes (ERMs)</p>
			<p class="em-only_endmatter-idx2">asymptomatic, 336</p>
			<p class="em-only_endmatter-idx2">&#173;causes of, 332</p>
			<p class="em-only_endmatter-idx2">contracture of, 335</p>
			<p class="em-only_endmatter-idx2">definition of, 332</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography findings, 335</p>
			<p class="em-only_endmatter-idx2">incidence of, 333</p>
			<p class="em-only_endmatter-idx2">optical coherence tomography of, 335, 383<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">prevalence of, 333</p>
			<p class="em-only_endmatter-idx2">“pseudohole” appearance with, 334</p>
			<p class="em-only_endmatter-idx2">scanning &#173;laser ophthalmoscopy of, 334<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">secondary, 333</p>
			<p class="em-only_endmatter-idx2">signs and symptoms of, 334<span class="italic">–&#173;</span>335<span class="italic">f,</span> 334–336</p>
			<p class="em-only_endmatter-idx2">spectral-&#173;domain optical coherence tomography of, 335<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">treatment of, 336, 382, 383<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">vitrectomy for, 382, 383<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">vitreomacular traction syndrome versus, 382–383</p>
			<p class="em-only_endmatter-idx1">Equatorial ret&#173;ina, 9–10</p>
			<p class="em-only_endmatter-idx1">ERG. <span class="italic">See</span> Electroretinography</p>
			<p class="em-only_endmatter-idx1">Ergot alkaloids, 300</p>
			<p class="em-only_endmatter-idx1">ERMs. <span class="italic">See</span> Epiret&#173;i&#173;nal membranes</p>
			<p class="em-only_endmatter-idx1">Erythema migrans, 245</p>
			<p class="em-only_endmatter-idx1">ESCD. <span class="italic">See</span> Enhanced S-&#173;cone disease</p>
			<p class="em-only_endmatter-idx1"><span class="italic">Escherichia coli,</span> urinary tract infections caused by, 238</p>
			<p class="em-only_endmatter-idx1">ETDRS. <span class="italic">See</span> Early Treatment Diabetic Retinopathy Study</p>
			<p class="em-only_endmatter-idx1">Ethylene glycol, 303</p>
			<p class="em-only_endmatter-idx1">ETROP. <span class="italic">See</span> Early Treatment of Retinopathy of Prematurity</p>
			<p class="em-only_endmatter-idx1">Evisceration, for penetrating ocular injury, 233</p>
			<p class="em-only_endmatter-idx1"><span class="italic">EVR1</span> gene, 346<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1"><span class="italic">EVR2</span> gene, 346<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1"><span class="italic">EVR3</span> gene, 346<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1"><span class="italic">EVR4</span> gene, 346<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1"><span class="italic">EVR5</span> gene, 346<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">EVS. <span class="italic">See</span> Endophthalmitis Vitrectomy Study</p>
			<p class="em-only_endmatter-idx1">External limiting membrane (ELM)</p>
			<p class="em-only_endmatter-idx2">anatomy of, 15</p>
			<p class="em-only_endmatter-idx2">histology of, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Extra-&#173;areal periphery, 9</p>
			<p class="em-only_endmatter-idx1">Extracranial to intracranial bypass surgery, for ocular ischemic syndrome, 140</p>
			<p class="em-only_endmatter-idx1">Exudates</p>
			<p class="em-only_endmatter-idx2">hard, 122, 160</p>
			<p class="em-only_endmatter-idx2">macular, 124<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">soft, 122</p>
			<p class="em-only_endmatter-idx1">Exudative ret&#173;i&#173;nal detachment</p>
			<p class="em-only_endmatter-idx2">&#173;causes of, 320</p>
			<p class="em-only_endmatter-idx2">diagnostic features of, 321<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">in familial exudative vitreoretinopathy, 343</p>
			<p class="em-only_endmatter-idx2">imaging of, 325<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">management of, 325–326</p>
			<p class="em-only_endmatter-idx2">photocoagulation as cause of, 379</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal surface in, 326</p>
			<p class="em-only_endmatter-idx2">subret&#173;i&#173;nal fluid findings in, 326</p>
			<p class="em-only_endmatter-idx1">Eye movement tracking, optical coherence tomography with, 27</p>
			<p class="em-only_endmatter-idx-alpha">FA. <span class="italic">See</span> Fluorescein angiography</p>
			<p class="em-only_endmatter-idx1">Fabry disease, 291–292</p>
			<p class="em-only_endmatter-idx1">Familial adenomatous polyposis (FAP), 285–286</p>
			<p class="em-only_endmatter-idx1">Familial cerebello ret&#173;i&#173;nal angiomatosis. <span class="italic">See</span> von <br />Hippel–&#173;Lindau (VHL) syndrome</p>
			<p class="em-only_endmatter-idx1">Familial exudative vitreoretinopathy (FEVR), 343–344, 345<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Familial juvenile nephronophthisis, 285</p>
			<p class="em-only_endmatter-idx1">FAP. <span class="italic">See</span> Familial adenomatous polyposis </p>
			<p class="em-only_endmatter-idx1">Farnsworth-&#173;Munsell 100-&#173;hue test, 55</p>
			<p class="em-only_endmatter-idx1">Farnsworth Panel D-15 test, 55<span class="italic">f,</span> 55–56</p>
			<p class="em-only_endmatter-idx1">Fat emboli/embolism, 141, 173</p>
			<p class="em-only_endmatter-idx1">FAZ. <span class="italic">See</span> Foveal avascular zone</p>
			<p class="em-only_endmatter-idx1">Fellow eye</p>
			<p class="em-only_endmatter-idx2">macular hole risks, 339</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal detachment in, 319</p>
			<p class="em-only_endmatter-idx1">Fenofibrate, diabetic retinopathy progression affected by, 102</p>
			<p class="em-only_endmatter-idx1">FEVR. <span class="italic">See</span> Familial exudative vitreoretinopathy</p>
			<p class="em-only_endmatter-idx1">Fibronectin, 7</p>
			<p class="em-only_endmatter-idx1">Fibrovascular pigment epithelial detachment, 72–73</p>
			<p class="em-only_endmatter-idx1">Fingolimod, 301</p>
			<p class="em-only_endmatter-idx1">FIPTs. <span class="italic">See</span> Focal intraret&#173;i&#173;nal periarteriolar transudates</p>
			<p class="em-only_endmatter-idx1">Flap tears, of ret&#173;ina, 315, 318–319</p>
			<p class="em-only_endmatter-idx1"><span class="italic">Flaviviridae,</span> 247</p>
			<p class="em-only_endmatter-idx1">Floaters</p>
			<p class="em-only_endmatter-idx2">description of, 344</p>
			<p class="em-only_endmatter-idx2">in posterior vitreous detachment, 308–309</p>
			<p class="em-only_endmatter-idx2">in rhegmatogenous ret&#173;i&#173;nal detachment, 320</p>
			<p class="em-only_endmatter-idx2">in toxocariasis, 244</p>
			<p class="em-only_endmatter-idx2">in toxoplasmic retinochoroiditis, 243</p>
			<p class="em-only_endmatter-idx2">vitrectomy for, 386</p>
			<p class="em-only_endmatter-idx1">Fluconazole, for yeast endophthalmitis, 240</p>
			<p class="em-only_endmatter-idx1">Fluorescein</p>
			<p class="em-only_endmatter-idx2">characteristics of, 33</p>
			<p class="em-only_endmatter-idx2">leakage of, 35</p>
			<p class="em-only_endmatter-idx2">pooling of, 35, 36<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Fluorescein angiography (FA)</p>
			<p class="em-only_endmatter-idx2">acute idiopathic maculopathy on, 228</p>
			<p class="em-only_endmatter-idx2">acute posterior multifocal placoid pigment epitheliopathy on, 221<span class="italic">f,</span> 222</p>
			<p class="em-only_endmatter-idx2">acute zonal occult outer retinopathy on, 227</p>
			<p class="em-only_endmatter-idx2">adult-&#173;onset vitelliform maculopathy on, 68</p>
			<p class="em-only_endmatter-idx2">adverse effects of, 36</p>
			<p class="em-only_endmatter-idx2">angioid streaks on, 87, 89<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">asteroid hyalosis on, 347</p>
			<p class="em-only_endmatter-idx2">autofluorescence, 35</p>
			<p class="em-only_endmatter-idx2">bilateral diffuse uveal melanocytic proliferation <br />on, 205<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">birdshot uveitis on, 224–225, 225<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">blocked fluorescence in, 35</p>
			<p class="em-only_endmatter-idx2">branch ret&#173;i&#173;nal artery occlusions on, 152<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal artery occlusion on, 144<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal vein occlusion on, 130, 131<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">central serous chorioretinopathy on, 190, 191<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">choroidal neovascularization on, 36, 37<span class="italic">f,</span> 72–73, 73<span class="italic">–&#173;</span>74<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">choroidemia on, 268</p>
			<p class="em-only_endmatter-idx2">Coats disease on, 160<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">cystoid macular edema on, 36<span class="italic">f,</span> 157</p>
			<p class="em-only_endmatter-idx2">drusen on, 65</p>
			<p class="em-only_endmatter-idx2">epiret&#173;i&#173;nal membranes on, 335</p>
			<p class="em-only_endmatter-idx2">familial exudative vitreoretinopathy on, 345<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">fluorescein dye used in, 33</p>
			<p class="em-only_endmatter-idx2">fovea in, 34</p>
			<p class="em-only_endmatter-idx2">foveal avascular zone in, 9</p>
			<p class="em-only_endmatter-idx2">fundus camera for, 23, 36</p>
			<p class="em-only_endmatter-idx2">hyperfluorescence in, 35</p>
			<p class="em-only_endmatter-idx2">hypertensive choroidopathy findings, 123, 124<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">illustration of, 34<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">ischemic central ret&#173;i&#173;nal vein occlusion on, 132<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">&#173;laser therapy for diabetic macular edema guided using, 115</p>
			<p class="em-only_endmatter-idx2">lupus vasculitis on, 231<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">macular telangiectasia type 2 on, 163, 163<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">multiple evanescent white dot syndrome on, 223–224</p>
			<p class="em-only_endmatter-idx2">nonischemic central ret&#173;i&#173;nal vein occlusion on, <br />130, 131<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">ocular ischemic syndrome findings, 138, 139<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">optical coherence tomography angiography versus, 29</p>
			<p class="em-only_endmatter-idx2">in pregnancy, 36</p>
			<p class="em-only_endmatter-idx2">prepapillary vascular loops on, 341</p>
			<p class="em-only_endmatter-idx2">radiation retinopathy on, 170, 170<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">recirculation phase of, 34</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal cavernous hemangioma on, 169<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal disease evaluations using, 33–38, 34<span class="italic">f,</span> 36<span class="italic">–&#173;</span>37<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">retinal pigment epithelium cells on, 34</p>
			<p class="em-only_endmatter-idx2">skin yellowing caused by, 36</p>
			<p class="em-only_endmatter-idx2">Stargardt disease on, 269–270, 270<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">technique for, 33–34, 34<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">uveal effusion syndrome on, 204<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">vascular filling defects in, 35</p>
			<p class="em-only_endmatter-idx2">vitreoret&#173;i&#173;nal traction syndrome on, 337</p>
			<p class="em-only_endmatter-idx2">Vogt-&#173;Koyanagi-&#173;Harada disease findings, 232</p>
			<p class="em-only_endmatter-idx2">wide-&#173;angle, 36, 37<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Fluo&#173;rescent treponemal antibody absorption (FTA-&#173;ABS) test, 241</p>
			<p class="em-only_endmatter-idx1">Fluorophores, in fundus autofluorescence, 29</p>
			<p class="em-only_endmatter-idx1">Focal chorioretinitis, 238, 238<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Focal intraret&#173;i&#173;nal periarteriolar transudates (FIPTs), 121–122, 122<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Focal macular edema, 110, 111<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Footplates of M<span class="accent">ü</span>ller cells, 15, 15<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Foreign bodies, intraocular</p>
			<p class="em-only_endmatter-idx2">aluminum, 362</p>
			<p class="em-only_endmatter-idx2">chalcosis secondary to, 362</p>
			<p class="em-only_endmatter-idx2">composition of, 362</p>
			<p class="em-only_endmatter-idx2">copper, 362</p>
			<p class="em-only_endmatter-idx2">evaluation of, 351</p>
			<p class="em-only_endmatter-idx2">imaging of, 352–353, 360, 361<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">iron, 362</p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 353</p>
			<p class="em-only_endmatter-idx2">migration of, 362</p>
			<p class="em-only_endmatter-idx2">ocular reaction to, 362</p>
			<p class="em-only_endmatter-idx2">plain-&#173;film x-&#173;ray studies of, 352–353</p>
			<p class="em-only_endmatter-idx2">retained, 362</p>
			<p class="em-only_endmatter-idx2">siderosis bulbi secondary to, 362, 363<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">surgical removal of, 360–362</p>
			<p class="em-only_endmatter-idx2">zinc as, 362</p>
			<p class="em-only_endmatter-idx1">Form-&#173;deprivation errors, 216</p>
			<p class="em-only_endmatter-idx1">Foscarnet</p>
			<p class="em-only_endmatter-idx2">acute ret&#173;i&#173;nal necrosis treated with, 236</p>
			<p class="em-only_endmatter-idx2">cytomegalovirus retinitis treated with, 235, 238<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">progressive outer ret&#173;i&#173;nal necrosis syndrome treated with, 236</p>
			<p class="em-only_endmatter-idx1">4:2:1 rule, for diabetic retinopathy, 99</p>
			<p class="em-only_endmatter-idx1">Fovea</p>
			<p class="em-only_endmatter-idx2">anatomy of, 9, 9<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">characteristics of, 10<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">cones in, 11</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography of, 34</p>
			<p class="em-only_endmatter-idx2">inner cellular layers in, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">photocoagulation-&#173;related burns of, 378</p>
			<p class="em-only_endmatter-idx1">Fovea centralis, 9, 9<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Foveal avascular zone (FAZ)</p>
			<p class="em-only_endmatter-idx2">definition of, 9</p>
			<p class="em-only_endmatter-idx2">optical coherence tomography angiography of, 77<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Foveal center, rods in, 11</p>
			<p class="em-only_endmatter-idx1">Foveola</p>
			<p class="em-only_endmatter-idx2">anatomy of, 9, 9<span class="italic">f,</span> 11</p>
			<p class="em-only_endmatter-idx2">characteristics of, 10<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Foveomacular retinitis. <span class="italic">See</span> Solar retinopathy</p>
			<p class="em-only_endmatter-idx1">FTA-&#173;ABS. <span class="italic">See</span> Fluo&#173;rescent treponemal antibody absorption (FTA-&#173;ABS) test</p>
			<p class="em-only_endmatter-idx1">Full-&#173;field (Ganzfield) electroretinography</p>
			<p class="em-only_endmatter-idx2"><span class="italic">ABCA4</span> retinopathy findings, 48<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">cone dystrophies, 265</p>
			<p class="em-only_endmatter-idx2">cone–&#173;rod dystrophies, 265</p>
			<p class="em-only_endmatter-idx2">description of, 42–45, 43<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">mixed rod-&#173;cone, 43</p>
			<p class="em-only_endmatter-idx2">normal response in, 43<span class="italic">f,</span> 44</p>
			<p class="em-only_endmatter-idx2">photopic flicker, 44</p>
			<p class="em-only_endmatter-idx2">photopic single-&#173;flash, 44</p>
			<p class="em-only_endmatter-idx2">quinine toxicity on, 302<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">rod-&#173;specific, 42</p>
			<p class="em-only_endmatter-idx1">Fundus</p>
			<p class="em-only_endmatter-idx2">arteriolar narrowing of, 261</p>
			<p class="em-only_endmatter-idx2">autofluorescence imaging of, 23<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">color photo&#173;graph of, 23, 23<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">retinitis pigmentosa findings, 261, 262<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">“sunset glow” appearance of, 232<span class="italic">f,</span> 232–233</p>
			<p class="em-only_endmatter-idx1">Fundus albipunctatus, 252, 253<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Fundus autofluorescence</p>
			<p class="em-only_endmatter-idx2">definition of, 29</p>
			<p class="em-only_endmatter-idx2">fluorophores, 29</p>
			<p class="em-only_endmatter-idx2">hyperspectral, 33</p>
			<p class="em-only_endmatter-idx2">near-&#173;infrared, 32–33</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal disease evaluations, 29, 31–33</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium tears on, 31, 32<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">Stargardt disease on, 270</p>
			<p class="em-only_endmatter-idx1">Fundus camera</p>
			<p class="em-only_endmatter-idx2">disadvantages of, 23</p>
			<p class="em-only_endmatter-idx2">flash illumination used by, 23</p>
			<p class="em-only_endmatter-idx2">for fluorescein angiography, 23, 36</p>
			<p class="em-only_endmatter-idx2">for indocyanine green angiography, 23</p>
			<p class="em-only_endmatter-idx2">operating princi&#173;ples of, 22–23</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal disease evaluations using, 22–23, 23<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Fundus flavimaculatus, 269</p>
			<p class="em-only_endmatter-idx2">description of, 44</p>
			<p class="em-only_endmatter-idx2">electroretinography findings in, 48<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Fundus photography</p>
			<p class="em-only_endmatter-idx2">exudative ret&#173;i&#173;nal detachment on, 325<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">lattice degeneration on, 310<span class="italic">–&#173;</span>311<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">retinopathy of prematurity screening uses of, 184</p>
			<p class="em-only_endmatter-idx1">Fundus pulverlentus, 276–277</p>
			<p class="em-only_endmatter-idx1">Fungal endophthalmitis, 239, 239<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Fungemia, 239</p>
			<p class="em-only_endmatter-idx1"><span class="italic">Fusarium</span> endophthalmitis, 239</p>
			<p class="em-only_endmatter-idx-alpha">Ganciclovir</p>
			<p class="em-only_endmatter-idx2">acute ret&#173;i&#173;nal necrosis treated with, 236</p>
			<p class="em-only_endmatter-idx2">cytomegalovirus retinitis treated with, 235, 238<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">progressive outer ret&#173;i&#173;nal necrosis syndrome treated with, 236</p>
			<p class="em-only_endmatter-idx1">Ganglion cell(s)</p>
			<p class="em-only_endmatter-idx2">bipolar cells and, 13</p>
			<p class="em-only_endmatter-idx2">drug toxicity affecting, 301</p>
			<p class="em-only_endmatter-idx1">Ganglion cell layer (GCL)</p>
			<p class="em-only_endmatter-idx2">anatomy of, 15</p>
			<p class="em-only_endmatter-idx2">histology of, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">quinine effects on, 301</p>
			<p class="em-only_endmatter-idx2">superficial vascular plexus in, 16</p>
			<p class="em-only_endmatter-idx1">Ganzfeld bowl, 42</p>
			<p class="em-only_endmatter-idx1">Ganzfeld ERG. <span class="italic">See</span> Full-field (Ganzfeld) electroretinography</p>
			<p class="em-only_endmatter-idx1">Gardner syndrome. <span class="italic">See</span> Familial adenomatous polyposis (FAP)</p>
			<p class="em-only_endmatter-idx1">Gastrointestinal diseases, ret&#173;i&#173;nal degeneration associated with, 285–286</p>
			<p class="em-only_endmatter-idx1">Gaucher disease, 291</p>
			<p class="em-only_endmatter-idx1">GCA. <span class="italic">See</span> &#173;Giant cell arteritis </p>
			<p class="em-only_endmatter-idx1">GCL. <span class="italic">See</span> Ganglion cell layer</p>
			<p class="em-only_endmatter-idx1">General anesthesia, 50</p>
			<p class="em-only_endmatter-idx1">Gene therapy</p>
			<p class="em-only_endmatter-idx2">for choroidemia, 268</p>
			<p class="em-only_endmatter-idx2">for Leber congenital amaurosis, 266</p>
			<p class="em-only_endmatter-idx2">for ret&#173;i&#173;nal dystrophies, 260, 266</p>
			<p class="em-only_endmatter-idx1">Ge&#173;ne&#173;tic heterogeneity, 255</p>
			<p class="em-only_endmatter-idx1">Ge&#173;ne&#173;tic testing, for age-&#173;related macular <br />degeneration, 63</p>
			<p class="em-only_endmatter-idx1">Gentamicin, 300</p>
			<p class="em-only_endmatter-idx1">Geographic atrophy, of ret&#173;i&#173;nal pigment epithelium</p>
			<p class="em-only_endmatter-idx2">in Best vitelliform dystrophy, 271</p>
			<p class="em-only_endmatter-idx2">description of, 64, 66, 67<span class="italic">f,</span> 68</p>
			<p class="em-only_endmatter-idx2">in drusenoid ret&#173;i&#173;nal pigment epithelium detachment, 272</p>
			<p class="em-only_endmatter-idx1">Ghost cell glaucoma, 347</p>
			<p class="em-only_endmatter-idx1">&#173;Giant cell arteritis (GCA)</p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal artery occlusion caused by, 145</p>
			<p class="em-only_endmatter-idx2">description of, 195</p>
			<p class="em-only_endmatter-idx2">indocyanine green angiography of, 196<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">&#173;Giant tears, of ret&#173;ina, 315</p>
			<p class="em-only_endmatter-idx1">Glaucoma</p>
			<p class="em-only_endmatter-idx2">angle-&#173;closure, in retinopathy of prematurity, 181</p>
			<p class="em-only_endmatter-idx2">ghost cell, 347</p>
			<p class="em-only_endmatter-idx2">nerve damage caused by, 328</p>
			<p class="em-only_endmatter-idx2">open-&#173;angle</p>
			<p class="em-only_endmatter-idx3">in central ret&#173;i&#173;nal vein occlusion, 133</p>
			<p class="em-only_endmatter-idx3">vitrectomy as risk &#173;factor for, 402</p>
			<p class="em-only_endmatter-idx2">in pathologic myopia, 218, 218<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">pupillary-&#173;block, in retinopathy of prematurity, 181</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal vein occlusion risks secondary to, 125</p>
			<p class="em-only_endmatter-idx1">Globe injuries</p>
			<p class="em-only_endmatter-idx2">lacerating injuries, 358</p>
			<p class="em-only_endmatter-idx2">needle perforation/penetration of, 358, 395<span class="italic">f,</span> <br />395–396</p>
			<p class="em-only_endmatter-idx2">penetrating, 358</p>
			<p class="em-only_endmatter-idx2">perforating, 358</p>
			<p class="em-only_endmatter-idx2">primary repair of, 359</p>
			<p class="em-only_endmatter-idx2">scleral rupture, 352, 358</p>
			<p class="em-only_endmatter-idx2">surgical management of, 359–360</p>
			<p class="em-only_endmatter-idx2">vitrectomy for, 359–360</p>
			<p class="em-only_endmatter-idx2">wound closure of, 359</p>
			<p class="em-only_endmatter-idx1">Glycemic control, for diabetic retinopathy, 96–98</p>
			<p class="em-only_endmatter-idx1">GM<span class="CharOverride-1">2</span> gangliosidosis type I, 291</p>
			<p class="em-only_endmatter-idx1">Goldmann-&#173;Favre syndrome. <span class="italic">See</span> Enhanced S-&#173;cone disease (ESCD)</p>
			<p class="em-only_endmatter-idx1">Goldmann-&#173;Weekers (G-&#173;W) adaptometer, 57–58</p>
			<p class="em-only_endmatter-idx1">Granulomas</p>
			<p class="em-only_endmatter-idx2">choroidal, 241<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">posterior pole, 245</p>
			<p class="em-only_endmatter-idx2">in toxocariasis, 244, 245<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Granulomatosis with polyangiitis, 195, 196<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Green &#173;laser, 373</p>
			<p class="em-only_endmatter-idx1"><span class="italic">GRK1</span> gene, 253</p>
			<p class="em-only_endmatter-idx1">Gr<span class="accent">ö</span>nblad-&#173;Strandberg syndrome, 87</p>
			<p class="em-only_endmatter-idx1">“Guttering,” 79</p>
			<p class="em-only_endmatter-idx1">Gyrate atrophy, 268–269, 269<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx-alpha"><span class="italic">Haemophilus</span> spp, bleb-&#173;associated endophthalmitis caused by, 391</p>
			<p class="em-only_endmatter-idx1">Haller layer, 19</p>
			<p class="em-only_endmatter-idx1">Handheld laser-&#173;pointer injury, 369</p>
			<p class="em-only_endmatter-idx1">HARBOR study, 82</p>
			<p class="em-only_endmatter-idx1">Hard drusen, 65</p>
			<p class="em-only_endmatter-idx1">Hard exudates, 122, 160</p>
			<p class="em-only_endmatter-idx1">Hardy-&#173;Rand-&#173;Rittler plates, for color vision testing, 54</p>
			<p class="em-only_endmatter-idx1">Hearing loss</p>
			<p class="em-only_endmatter-idx2">pigmentary retinopathy and, 284</p>
			<p class="em-only_endmatter-idx2">retinitis pigmentosa and, 284</p>
			<p class="em-only_endmatter-idx1">Helicoid peripapillary choroidopathy. <span class="italic">See</span> Serpiginous choroidopathy</p>
			<p class="em-only_endmatter-idx1">HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome, 197<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Hemangioblastomas, in von Hippel–&#173;Lindau syndrome, 165–166, 166<span class="italic">f,</span> 168</p>
			<p class="em-only_endmatter-idx1">Hemangiomas</p>
			<p class="em-only_endmatter-idx2">cavernous, 168, 169<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">choroidal, 202<span class="italic">f,</span> 202–203</p>
			<p class="em-only_endmatter-idx1">Hemeralopia, 264</p>
			<p class="em-only_endmatter-idx1">Hemiret&#173;i&#173;nal vein occlusion (HRVO), 130, 133<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Hemoglobin, 373, 374<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Hemoglobin A<span class="CharOverride-1">1c</span>, diabetic retinopathy and, 96, 98</p>
			<p class="em-only_endmatter-idx1">Hemoglobin S, 149</p>
			<p class="em-only_endmatter-idx1">Hemorrhage</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal</p>
			<p class="em-only_endmatter-idx3">in abusive head trauma, 366, 366<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">in carotid occlusive disease, 138</p>
			<p class="em-only_endmatter-idx2">salmon-&#173;patch, 150, 150<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">submacular</p>
			<p class="em-only_endmatter-idx3">in neovascular age-&#173;related macular degeneration, 85, 385</p>
			<p class="em-only_endmatter-idx3">posttraumatic, 354<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">vitrectomy for, 385, 386<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">subret&#173;i&#173;nal</p>
			<p class="em-only_endmatter-idx3">choroidal neovascularization versus, 211</p>
			<p class="em-only_endmatter-idx3">in polypoidal choroidal vasculopathy, 76</p>
			<p class="em-only_endmatter-idx2">suprachoroidal, 394–395, 395<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">vitreous</p>
			<p class="em-only_endmatter-idx3">in central ret&#173;i&#173;nal vein occlusion, 135</p>
			<p class="em-only_endmatter-idx3">echography for, 347</p>
			<p class="em-only_endmatter-idx3">peripheral neovascularization, 232</p>
			<p class="em-only_endmatter-idx3">photocoagulation as cause of, 379</p>
			<p class="em-only_endmatter-idx3">in polypoidal choroidal vasculopathy, 75</p>
			<p class="em-only_endmatter-idx3">posterior vitreous detachment and, 309</p>
			<p class="em-only_endmatter-idx3">in proliferative diabetic retinopathy, 103, 103<span class="italic">f,</span> 107–108</p>
			<p class="em-only_endmatter-idx3">trauma-&#173;related, 357</p>
			<p class="em-only_endmatter-idx3">treatment of, 309</p>
			<p class="em-only_endmatter-idx3">in Valsalva retinopathy, 171</p>
			<p class="em-only_endmatter-idx3">vision loss caused by, 346</p>
			<p class="em-only_endmatter-idx1">Hemorrhagic occlusive ret&#173;i&#173;nal vasculitis (HORV), 300–301</p>
			<p class="em-only_endmatter-idx1">Henle fiber layer (HFL)</p>
			<p class="em-only_endmatter-idx2">definition of, 9</p>
			<p class="em-only_endmatter-idx2">histology of, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">myopia macular schisis of, 209</p>
			<p class="em-only_endmatter-idx1">Hereditary dystrophies</p>
			<p class="em-only_endmatter-idx2">choroidal</p>
			<p class="em-only_endmatter-idx3">Bietti crystalline dystrophy, 258, 269, 282<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">choroidemia, 267–268, 268<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">classification of, 255</p>
			<p class="em-only_endmatter-idx3">gyrate atrophy, 268–269, 269<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal</p>
			<p class="em-only_endmatter-idx3">bilateral symmetric involvement of, 258</p>
			<p class="em-only_endmatter-idx3">blindness concerns of patients with, 260</p>
			<p class="em-only_endmatter-idx3">cystoid macular edema in, 260, 260<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">diagnostic considerations for, 258–259</p>
			<p class="em-only_endmatter-idx3">enhanced S-&#173;cone disease, 266, 267<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">genes and loci associated with, 256<span class="italic">–&#173;</span>257<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">gene therapy for, 260, 266</p>
			<p class="em-only_endmatter-idx3">ge&#173;ne&#173;tic considerations for, 259</p>
			<p class="em-only_endmatter-idx3">inheritance patterns for, 259</p>
			<p class="em-only_endmatter-idx3">Leber congenital amaurosis, 265–266</p>
			<p class="em-only_endmatter-idx3">management of, 259–260, 260<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">molecular ge&#173;ne&#173;tic testing for, 259</p>
			<p class="em-only_endmatter-idx3">rod–&#173;cone dystrophies, 261–264, 262<span class="italic">–&#173;</span>264<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">stem cell therapy for, 260</p>
			<p class="em-only_endmatter-idx1">Hereditary hyaloideoretinopathies with optically empty vitreous, 342–343, 343<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Hermansky-&#173;Pudlak syndrome, 288</p>
			<p class="em-only_endmatter-idx1">Herpes simplex virus (HSV), necrotizing retinitis caused by, 236–237, 236<span class="italic">–&#173;</span>237<span class="italic">f,</span> 238<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">HFL. <span class="italic">See</span> Henle fiber layer</p>
			<p class="em-only_endmatter-idx1">High myopia. <span class="italic">See</span> Pathologic myopia</p>
			<p class="em-only_endmatter-idx1">High-&#173;plus-&#173;power lenses, 375</p>
			<p class="em-only_endmatter-idx1">Histiocytic lymphoma. <span class="italic">See</span> Primary vitreoret&#173;i&#173;nal lymphoma</p>
			<p class="em-only_endmatter-idx1"><span class="italic">Histoplasma capsulatum,</span> 86–87</p>
			<p class="em-only_endmatter-idx1">Histoplasmosis, 86–87</p>
			<p class="em-only_endmatter-idx1">HIV. <span class="italic">See also</span> AIDS</p>
			<p class="em-only_endmatter-idx2">cytomegalovirus retinitis and, 235</p>
			<p class="em-only_endmatter-idx2">intraocular lymphoma risks, 234</p>
			<p class="em-only_endmatter-idx2">toxoplasmic retinochoroiditis and, 243</p>
			<p class="em-only_endmatter-idx1">Hives, fluorescein angiography as cause of, 36</p>
			<p class="em-only_endmatter-idx1">HLA-&#173;B5, 230</p>
			<p class="em-only_endmatter-idx1">Holes</p>
			<p class="em-only_endmatter-idx2">macular</p>
			<p class="em-only_endmatter-idx3">contusion injury as cause of, 315</p>
			<p class="em-only_endmatter-idx3">fellow-&#173;eye risk for development of, 339</p>
			<p class="em-only_endmatter-idx3">formation of, 339, 340<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">idiopathic</p>
			<p class="em-only_endmatter-idx4">description of, 337–339, 338<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx4">vitrectomy for, 384–385, 385<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">International Vitreomacular Traction Study Classification System for, 336<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">lamellar, 28<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">management of, 339–340</p>
			<p class="em-only_endmatter-idx3">optical coherence tomography of, 27<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">in pathologic myopia, 209</p>
			<p class="em-only_endmatter-idx3">posttraumatic, 355–357, 356<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">rhegmatogenous ret&#173;i&#173;nal detachment caused by, 330, 330<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">spontaneous resolution of, 340</p>
			<p class="em-only_endmatter-idx3">stage 0, 339</p>
			<p class="em-only_endmatter-idx3">stage 1, 339–340</p>
			<p class="em-only_endmatter-idx3">stage 2, 339</p>
			<p class="em-only_endmatter-idx3">stage 3, 339</p>
			<p class="em-only_endmatter-idx3">stage 4, 339</p>
			<p class="em-only_endmatter-idx3">surgical management of, 339–340</p>
			<p class="em-only_endmatter-idx2">outer-&#173;schisis-&#173;layer, 327, 327<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal</p>
			<p class="em-only_endmatter-idx3">atrophic</p>
			<p class="em-only_endmatter-idx4">definition of, 315</p>
			<p class="em-only_endmatter-idx4">lattice degeneration with, 310, 311<span class="italic">f,</span> 316<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx4">ret&#173;i&#173;nal detachment secondary to, 310</p>
			<p class="em-only_endmatter-idx3">description of, 378</p>
			<p class="em-only_endmatter-idx3">operculated, 315–316</p>
			<p class="em-only_endmatter-idx1">Hollenhorst plaques, 141, 142<span class="italic">f,</span> 144</p>
			<p class="em-only_endmatter-idx1">Homocystinuria, 282<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">HORIZON study, 81–82</p>
			<p class="em-only_endmatter-idx1">Horseshoe-&#173;shaped ret&#173;i&#173;nal tears, 316, 323<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">HORV. <span class="italic">See</span> Hemorrhagic occlusive ret&#173;i&#173;nal vasculitis</p>
			<p class="em-only_endmatter-idx1">HRVO. <span class="italic">See</span> Hemiret&#173;i&#173;nal vein occlusion</p>
			<p class="em-only_endmatter-idx1">HSV. <span class="italic">See</span> Herpes simplex virus</p>
			<p class="em-only_endmatter-idx1">Hunter syndrome, 283<span class="italic">t,</span> 291</p>
			<p class="em-only_endmatter-idx1">Hurler syndrome, 282<span class="italic">t,</span> 290</p>
			<p class="em-only_endmatter-idx1">Hyalocytes</p>
			<p class="em-only_endmatter-idx2">oxygen consumption by, 7</p>
			<p class="em-only_endmatter-idx2">in vitreous, 7</p>
			<p class="em-only_endmatter-idx1">Hyaloid artery, 340–341</p>
			<p class="em-only_endmatter-idx1">Hyaluronan, 331</p>
			<p class="em-only_endmatter-idx1">Hydroxychloroquine toxicity</p>
			<p class="em-only_endmatter-idx2">description of, 295–297</p>
			<p class="em-only_endmatter-idx2">multifocal electroretinography findings in, 45, 49<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">nonneovascular age-&#173;related macular degeneration versus, 68</p>
			<p class="em-only_endmatter-idx1">Hyperacuity testing, in age-&#173;related macular degeneration, 69</p>
			<p class="em-only_endmatter-idx1">Hyperautofluorescence, in chloroquine toxicity, 297</p>
			<p class="em-only_endmatter-idx1">Hyperfluorescence, in fluorescein angiography, 35</p>
			<p class="em-only_endmatter-idx1">Hyperglycemia, blood–&#173;retina barrier breakdown <br />caused by, 108</p>
			<p class="em-only_endmatter-idx1">Hyperhomocysteinemia, 134</p>
			<p class="em-only_endmatter-idx1">Hyperopia, 201</p>
			<p class="em-only_endmatter-idx1">Hypertension</p>
			<p class="em-only_endmatter-idx2">arteriosclerotic vascular disease and, 122</p>
			<p class="em-only_endmatter-idx2">asteroid hyalosis and, 346</p>
			<p class="em-only_endmatter-idx2">choroidopathy caused by, 123, 123<span class="italic">–&#173;</span>124<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">classification of, 121</p>
			<p class="em-only_endmatter-idx2">diabetic retinopathy progression associated with, 98</p>
			<p class="em-only_endmatter-idx2">focal intraret&#173;i&#173;nal periarteriolar transudates caused <br />by, 121–122, 122<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">malignant, 196</p>
			<p class="em-only_endmatter-idx2">optic neuropathy caused by, 123, 125</p>
			<p class="em-only_endmatter-idx2">prevalence of, 121</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal vascular diseases associated with, 121–125, 122<span class="italic">–&#173;</span>124<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">retinopathy caused by, 121–123, 122<span class="italic">f,</span> 124<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Hyperviscosity retinopathy, central ret&#173;i&#173;nal vein occlusion versus, 134</p>
			<p class="em-only_endmatter-idx1">Hyphema, traumatic, 154</p>
			<p class="em-only_endmatter-idx1">Hypoautofluorescence, in chloroquine toxicity, 297</p>
			<p class="em-only_endmatter-idx1">Hypopyon, 390</p>
			<p class="em-only_endmatter-idx1">Hypotony maculopathy, 201</p>
			<p class="em-only_endmatter-idx-alpha">Idiopathic macular holes</p>
			<p class="em-only_endmatter-idx2">description of, 337–339, 338<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">vitrectomy for, 384–385, 385<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Idiopathic ret&#173;i&#173;nal vasculitis, aneurysms, and neuroretinitis (IRVAN), 156</p>
			<p class="em-only_endmatter-idx1">IGA. <span class="italic">See</span> Indocyanine green angiography</p>
			<p class="em-only_endmatter-idx1">IGF-1. <span class="italic">See</span> Insulin growth factor-1</p>
			<p class="em-only_endmatter-idx1">Illumination, in indirect ophthalmoscope/ophthalmoscopy, 21</p>
			<p class="em-only_endmatter-idx1">ILM. <span class="italic">See</span> Internal limiting membrane</p>
			<p class="em-only_endmatter-idx1">Incontinentia pigmenti, 283<span class="italic">t,</span> 286</p>
			<p class="em-only_endmatter-idx1">Indirect ophthalmoscope/ophthalmoscopy</p>
			<p class="em-only_endmatter-idx2">illumination in, 21</p>
			<p class="em-only_endmatter-idx2">posterior vitreous detachment diagnosed using, <br />309, 331</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal disease evaluations using, 21–22</p>
			<p class="em-only_endmatter-idx1">Indocyanine green angiography (IGA)</p>
			<p class="em-only_endmatter-idx2">acute idiopathic maculopathy on, 228</p>
			<p class="em-only_endmatter-idx2">acute posterior multifocal placoid pigment epitheliopathy on, 222</p>
			<p class="em-only_endmatter-idx2">acute zonal occult outer retinopathy on, 227</p>
			<p class="em-only_endmatter-idx2">adverse effects of, 39</p>
			<p class="em-only_endmatter-idx2">applications of, 38–39</p>
			<p class="em-only_endmatter-idx2">central serous chorioretinopathy on, 38, 192, 194<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">choroidal hemangiomas on, 202<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">choroidal neovascularization on, 73</p>
			<p class="em-only_endmatter-idx2">definition of, 38</p>
			<p class="em-only_endmatter-idx2">fundus camera for, 23</p>
			<p class="em-only_endmatter-idx2">&#173;giant cell arteritis findings, 196<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">multiple evanescent white dot syndrome on, <br />223–224</p>
			<p class="em-only_endmatter-idx2">polypoidal choroidal vasculopathy on, 38, 38<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Infants. <span class="italic">See also</span> &#173;Children</p>
			<p class="em-only_endmatter-idx2">abusive head trauma in, 365–366, 366<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">congenital toxoplasmosis in, 243</p>
			<p class="em-only_endmatter-idx2">Leber congenital amaurosis in, 265–266</p>
			<p class="em-only_endmatter-idx2">neuronoid ceroid lipofuscinoses in, 289</p>
			<p class="em-only_endmatter-idx2">Refsum disease in, 290</p>
			<p class="em-only_endmatter-idx2">retinopathy of prematurity in, 175</p>
			<p class="em-only_endmatter-idx2">trauma in, 316–317, 365–366, 366<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">visual evoked potentials application in, 53</p>
			<p class="em-only_endmatter-idx1">Inferior staphyloma syndrome, 217, 217<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Inflammatory vasculitis, 230, 230<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Infrared &#173;laser, 374</p>
			<p class="em-only_endmatter-idx1">Inner nuclear layer (INL)</p>
			<p class="em-only_endmatter-idx2">histology of, 11, 12<span class="italic">f,</span> 15<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">paracentral acute &#173;middle maculopathy of, <br />143</p>
			<p class="em-only_endmatter-idx1">Inner-&#173;outer segment junction, 12</p>
			<p class="em-only_endmatter-idx1">Inner plexiform layer (IPL), 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Inner segments</p>
			<p class="em-only_endmatter-idx2">of cones, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">ellipsoid, 12</p>
			<p class="em-only_endmatter-idx2">of rods, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Insulin-&#173;dependent diabetes mellitus, 91</p>
			<p class="em-only_endmatter-idx1">Insulin growth factor-1 (IGF-1), retinopathy of prematurity screening and, 182</p>
			<p class="em-only_endmatter-idx1">Interferogram, 25</p>
			<p class="em-only_endmatter-idx1">Interferon alfa-2a, 300</p>
			<p class="em-only_endmatter-idx1">Intermediate capillary plexus, 16</p>
			<p class="em-only_endmatter-idx1">Intermediate uveitis, 231–232</p>
			<p class="em-only_endmatter-idx1">Internal limiting membrane (ILM)</p>
			<p class="em-only_endmatter-idx2">amacrine cells in, 15</p>
			<p class="em-only_endmatter-idx2">anatomy of, 15</p>
			<p class="em-only_endmatter-idx2">epiret&#173;i&#173;nal membranes, 332</p>
			<p class="em-only_endmatter-idx2">hemorrhagic detachment of, 171</p>
			<p class="em-only_endmatter-idx2">histology of, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">nonproliferative sickle cell retinopathy findings, 150</p>
			<p class="em-only_endmatter-idx2">peeling of, 209</p>
			<p class="em-only_endmatter-idx2">vitreous remnants on, 332</p>
			<p class="em-only_endmatter-idx1">International Federation for Clinical Neurophysiology electrophysiologic testing standards, 41</p>
			<p class="em-only_endmatter-idx1">International Society for Clinical Electrophysiology of Vision (ISCEV)</p>
			<p class="em-only_endmatter-idx2">electrophysiologic testing standards of, 41</p>
			<p class="em-only_endmatter-idx2">full-&#173;field electroretinography standards, 42, 43<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">International Vitreomacular Traction Study Classification System, 336<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Intraocular foreign bodies (IOFBs)</p>
			<p class="em-only_endmatter-idx2">aluminum, 362</p>
			<p class="em-only_endmatter-idx2">chalcosis secondary to, 362</p>
			<p class="em-only_endmatter-idx2">composition of, 362</p>
			<p class="em-only_endmatter-idx2">copper, 362</p>
			<p class="em-only_endmatter-idx2">evaluation of, 351</p>
			<p class="em-only_endmatter-idx2">imaging of, 352–353, 360, 361<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">iron, 362</p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 353</p>
			<p class="em-only_endmatter-idx2">migration of, 362</p>
			<p class="em-only_endmatter-idx2">ocular reaction to, 362</p>
			<p class="em-only_endmatter-idx2">plain-&#173;film x-&#173;ray studies of, 352–353</p>
			<p class="em-only_endmatter-idx2">retained, 362</p>
			<p class="em-only_endmatter-idx2">siderosis bulbi secondary to, 362, 363<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">surgical removal of, 360–362</p>
			<p class="em-only_endmatter-idx2">zinc as, 362</p>
			<p class="em-only_endmatter-idx1">Intraocular lenses (IOLs), posteriorly dislocated, 393</p>
			<p class="em-only_endmatter-idx1">Intraocular lymphoma, 233–234, 234<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Intraocular pressure (IOP)</p>
			<p class="em-only_endmatter-idx2">elevated</p>
			<p class="em-only_endmatter-idx3">in central ret&#173;i&#173;nal artery occlusion, 146</p>
			<p class="em-only_endmatter-idx3">in central ret&#173;i&#173;nal vein occlusion, 133</p>
			<p class="em-only_endmatter-idx3">&#173;after intravitreal injection of anti-&#173;VEGF drugs, 404</p>
			<p class="em-only_endmatter-idx2">in rhegmatogenous ret&#173;i&#173;nal detachment, 320</p>
			<p class="em-only_endmatter-idx2">scleral buckling effects on, 399</p>
			<p class="em-only_endmatter-idx2">in sickle cell retinopathy, 154</p>
			<p class="em-only_endmatter-idx2">in trauma patients, 352</p>
			<p class="em-only_endmatter-idx1">Intraret&#173;i&#173;nal hemorrhage</p>
			<p class="em-only_endmatter-idx2">in branch ret&#173;i&#173;nal vein occlusion, 125, 126<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">in nonproliferative diabetic retinopathy, 100<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">in systemic lupus erythematosus, 230–231</p>
			<p class="em-only_endmatter-idx1">Intraret&#173;i&#173;nal microvascular abnormalities (IRMAs), in nonproliferative diabetic retinopathy, 100<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Intrascleral fixation, 393</p>
			<p class="em-only_endmatter-idx1">Intravitreal injections</p>
			<p class="em-only_endmatter-idx2">anesthesia for, 403</p>
			<p class="em-only_endmatter-idx2">anti-&#173;VEGF drugs, 404</p>
			<p class="em-only_endmatter-idx2">aseptic technique for, 403–404</p>
			<p class="em-only_endmatter-idx2">complications of, 404</p>
			<p class="em-only_endmatter-idx2">corticosteroids</p>
			<p class="em-only_endmatter-idx3">diabetic macular edema treated with, 101</p>
			<p class="em-only_endmatter-idx3">proliferative diabetic retinopathy treated with, 104</p>
			<p class="em-only_endmatter-idx3">retinopathy of prematurity treated with, 187</p>
			<p class="em-only_endmatter-idx2">endophthalmitis &#173;after, 404</p>
			<p class="em-only_endmatter-idx2">indications for, 403</p>
			<p class="em-only_endmatter-idx2">prevalence of, 403</p>
			<p class="em-only_endmatter-idx2">technique for, 403, 403<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ionizing radiation, retinopathy caused by exposure to, 170<span class="italic">f,</span> 170–171</p>
			<p class="em-only_endmatter-idx1">IOFBs. <span class="italic">See</span> Intraocular foreign bodies.</p>
			<p class="em-only_endmatter-idx1">IOLs. <span class="italic">See</span> Intraocular lenses.</p>
			<p class="em-only_endmatter-idx1">IOP. <span class="italic">See</span> intraocular pressure</p>
			<p class="em-only_endmatter-idx1">IPL. <span class="italic">See</span> Inner plexiform layer</p>
			<p class="em-only_endmatter-idx1">Iris</p>
			<p class="em-only_endmatter-idx2">neovascularization of</p>
			<p class="em-only_endmatter-idx3">in branch ret&#173;i&#173;nal vein occlusion, 128–129, 129<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">in central ret&#173;i&#173;nal artery occlusion, 146</p>
			<p class="em-only_endmatter-idx3">in central ret&#173;i&#173;nal vein occlusion, 133, 135</p>
			<p class="em-only_endmatter-idx3">in diabetes mellitus, 107</p>
			<p class="em-only_endmatter-idx3">in radiation retinopathy, 170</p>
			<p class="em-only_endmatter-idx2">vitreous adhesions to, 159</p>
			<p class="em-only_endmatter-idx1">Iris fixation, 393</p>
			<p class="em-only_endmatter-idx1">IRMAs. <span class="italic">See</span> Intraretinal microvascular abnormalities</p>
			<p class="em-only_endmatter-idx1">IRVAN. <span class="italic">See</span> Idiopathic ret&#173;i&#173;nal vasculitis, aneurysms, <br />and neuroretinitis</p>
			<p class="em-only_endmatter-idx1">Irvine-&#173;Gass syndrome, 157, 349</p>
			<p class="em-only_endmatter-idx1">ISCEV. <span class="italic">See</span> International Society for Clinical Electrophysiology of Vision</p>
			<p class="em-only_endmatter-idx1">Ischemia</p>
			<p class="em-only_endmatter-idx2">choroidal, 196, 196<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">macular, 98, 101, 115</p>
			<p class="em-only_endmatter-idx2">ocular. <span class="italic">See</span> Ocular ischemic syndrome</p>
			<p class="em-only_endmatter-idx1">Ishihara plates, for color vision testing, 54, 55<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Isotretinoin, 305</p>
			<p class="em-only_endmatter-idx-alpha">Jalili syndrome, 286</p>
			<p class="em-only_endmatter-idx1">Joubert syndrome, 285</p>
			<p class="em-only_endmatter-idx1">Juxtafoveal telangiectasia, 161</p>
			<p class="em-only_endmatter-idx-alpha">Kayser-&#173;Fleischer ring, 362</p>
			<p class="em-only_endmatter-idx1">Kearns-&#173;Sayre syndrome, 283<span class="italic">t,</span> 294</p>
			<p class="em-only_endmatter-idx1">Keratitis, fungal, 239</p>
			<p class="em-only_endmatter-idx1"><span class="italic">Klebsiella pneumoniae</span> endophthalmitis, 238</p>
			<p class="em-only_endmatter-idx1">Kyrieleis plaques, 244<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx-alpha">Lacerations</p>
			<p class="em-only_endmatter-idx2">corneal, 359</p>
			<p class="em-only_endmatter-idx2">globe, 358</p>
			<p class="em-only_endmatter-idx2">scleral, 359</p>
			<p class="em-only_endmatter-idx1">Lacquer cracks, 211, 211<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lamellar macular hole, 28<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lamina cribrosa, dehiscences in, 218, 218<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Laminin, 7</p>
			<p class="em-only_endmatter-idx1">Lampalizumab, 71</p>
			<p class="em-only_endmatter-idx1">Large colloid drusen, 274</p>
			<p class="em-only_endmatter-idx1">&#173;Laser(s)</p>
			<p class="em-only_endmatter-idx2">green, 373</p>
			<p class="em-only_endmatter-idx2">infrared, 374</p>
			<p class="em-only_endmatter-idx2">photochemical effect caused by, 374</p>
			<p class="em-only_endmatter-idx2">photocoagulation using. <span class="italic">See</span> Photocoagulation</p>
			<p class="em-only_endmatter-idx2">red, 374</p>
			<p class="em-only_endmatter-idx2">transpupillary thermotherapy using, 380</p>
			<p class="em-only_endmatter-idx2">vaporization caused by, 374–375</p>
			<p class="em-only_endmatter-idx2">wavelength of, for photocoagulation, 373–375</p>
			<p class="em-only_endmatter-idx2">yellow, 374</p>
			<p class="em-only_endmatter-idx1">Laser-&#173;pointer injury, 369</p>
			<p class="em-only_endmatter-idx1">&#173;Laser retinopexy, 376–377</p>
			<p class="em-only_endmatter-idx1">&#173;Laser surgery</p>
			<p class="em-only_endmatter-idx2">adverse effects of, 114</p>
			<p class="em-only_endmatter-idx2">branch ret&#173;i&#173;nal vein occlusion treated with, 128</p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal vein occlusion treated with, 135</p>
			<p class="em-only_endmatter-idx2">diabetic macular edema treated with, 114–115</p>
			<p class="em-only_endmatter-idx2">proliferative diabetic retinopathy treated with, 104–107</p>
			<p class="em-only_endmatter-idx2">retinopathy of prematurity treated with, 185–186</p>
			<p class="em-only_endmatter-idx1">Lattice degeneration</p>
			<p class="em-only_endmatter-idx2">prophylactic treatment of, 319</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal detachment and, 309–311, 310<span class="italic">–&#173;</span>311<span class="italic">f,</span> 316<span class="italic">f,</span> 319</p>
			<p class="em-only_endmatter-idx1">LCA. <span class="italic">See</span> Leber congenital amaurosis</p>
			<p class="em-only_endmatter-idx1">L cone, 54</p>
			<p class="em-only_endmatter-idx1">LCPUFAs. <span class="italic">See</span> Long-chain polyunsaturated fatty acids</p>
			<p class="em-only_endmatter-idx1">Leakage, hyperfluorescence and, 35</p>
			<p class="em-only_endmatter-idx1">Leber congenital amaurosis (LCA)</p>
			<p class="em-only_endmatter-idx2">characteristics of, 265–266</p>
			<p class="em-only_endmatter-idx2">genes and loci associated with, 256<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal degeneration associated with, 281</p>
			<p class="em-only_endmatter-idx1">Leber stellate neuroretinitis, 242</p>
			<p class="em-only_endmatter-idx1">Lenses</p>
			<p class="em-only_endmatter-idx2">contact. <span class="italic">See</span> Contact lenses</p>
			<p class="em-only_endmatter-idx2">high-&#173;plus-&#173;power, 375</p>
			<p class="em-only_endmatter-idx2">for photocoagulation, 375, 376<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Leptochoroid, 19</p>
			<p class="em-only_endmatter-idx1">Leukocoria, 342</p>
			<p class="em-only_endmatter-idx1">Lifestyle changes, for age-&#173;related macular <br />degeneration, 71</p>
			<p class="em-only_endmatter-idx1">Ligament of Wieger, 7, 8<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Light adaptation</p>
			<p class="em-only_endmatter-idx2">in electro-&#173;oculography, 50</p>
			<p class="em-only_endmatter-idx2">in full-&#173;field (Ganzfield) electroretinography, 42</p>
			<p class="em-only_endmatter-idx1">Lightning injuries, 357</p>
			<p class="em-only_endmatter-idx1">Limiting membrane</p>
			<p class="em-only_endmatter-idx2">external</p>
			<p class="em-only_endmatter-idx3">anatomy of, 15</p>
			<p class="em-only_endmatter-idx3">histology of, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">internal</p>
			<p class="em-only_endmatter-idx3">amacrine cells in, 15</p>
			<p class="em-only_endmatter-idx3">anatomy of, 15</p>
			<p class="em-only_endmatter-idx3">epiret&#173;i&#173;nal membranes, 332</p>
			<p class="em-only_endmatter-idx3">hemorrhagic detachment of, 171</p>
			<p class="em-only_endmatter-idx3">histology of, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">nonproliferative sickle cell retinopathy findings, 150</p>
			<p class="em-only_endmatter-idx3">peeling of, 209</p>
			<p class="em-only_endmatter-idx3">vitreous remnants on, 332</p>
			<p class="em-only_endmatter-idx2">&#173;middle</p>
			<p class="em-only_endmatter-idx3">anatomy of, 15</p>
			<p class="em-only_endmatter-idx3">definition of, 16</p>
			<p class="em-only_endmatter-idx3">histology of, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lincoff rules, 320, 322<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lipofuscin</p>
			<p class="em-only_endmatter-idx2">in lysosomes, 31</p>
			<p class="em-only_endmatter-idx2">in ret&#173;i&#173;nal pigment epithelium, 32</p>
			<p class="em-only_endmatter-idx1">Liver abscesses, endogenous bacterial endophthalmitis and, 238</p>
			<p class="em-only_endmatter-idx1">Liver diseases, ret&#173;i&#173;nal degeneration associated with, 285</p>
			<p class="em-only_endmatter-idx1">Long-&#173;chain polyunsaturated fatty acids (LCPUFAs), 70</p>
			<p class="em-only_endmatter-idx1">Low-&#173;coherence light, in optical coherence <br />tomography, 25</p>
			<p class="em-only_endmatter-idx1">Low vision</p>
			<p class="em-only_endmatter-idx2">rehabilitation for, 86, 260</p>
			<p class="em-only_endmatter-idx2">therapies for, 86</p>
			<p class="em-only_endmatter-idx1"><span class="italic">LRP5</span> gene, 345<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lupus vasculitis, 230–231, 231<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lutein</p>
			<p class="em-only_endmatter-idx2">age-&#173;related macular degeneration managed with, 70<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">description of, 367</p>
			<p class="em-only_endmatter-idx1">Lyme disease, 245–246</p>
			<p class="em-only_endmatter-idx1">Lymphoma</p>
			<p class="em-only_endmatter-idx2">intraocular, 233–234, 234<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">primary vitreoret&#173;i&#173;nal, 233–234</p>
			<p class="em-only_endmatter-idx2">uveal, 234, 235<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lysosomal metabolic diseases, 291–292, 292<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lysosomes</p>
			<p class="em-only_endmatter-idx2">lipofuscin in, 31</p>
			<p class="em-only_endmatter-idx2">outer segment digestion by, 17</p>
			<p class="em-only_endmatter-idx-alpha">Macroaneurysms, ret&#173;i&#173;nal arterial, 147–148, 148<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Macula</p>
			<p class="em-only_endmatter-idx2">adaptive optics scanning &#173;laser ophthalmoscope of, 13<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">aminoglycoside effects on, 300</p>
			<p class="em-only_endmatter-idx2">anatomy of, 9</p>
			<p class="em-only_endmatter-idx2">atrophy of, 265, 265<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">characteristics of, 10<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">length of, 9</p>
			<p class="em-only_endmatter-idx2">photic lesions of, 369</p>
			<p class="em-only_endmatter-idx2">photocoagulation applications, 375–376</p>
			<p class="em-only_endmatter-idx2">puckering of, 335</p>
			<p class="em-only_endmatter-idx2">schisis of, 328</p>
			<p class="em-only_endmatter-idx2">superior, rods in, 12</p>
			<p class="em-only_endmatter-idx1">Macular colobomas, 266</p>
			<p class="em-only_endmatter-idx1">Macular degeneration</p>
			<p class="em-only_endmatter-idx2">age-&#173;related. <span class="italic">See</span> Age-&#173;related macular degeneration (AMD)</p>
			<p class="em-only_endmatter-idx2">exudative, 68</p>
			<p class="em-only_endmatter-idx2">genes and loci associated with, 256<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Macular detachment</p>
			<p class="em-only_endmatter-idx2">optic nerve pit with, 329<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">vitelliform exudative, 272, 274<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Macular dystrophies</p>
			<p class="em-only_endmatter-idx2">adult-&#173;onset vitelliform lesions, 272, 273<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">aty&#173;pi&#173;cal, 277</p>
			<p class="em-only_endmatter-idx2">Best disease, 271, 272<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">early-&#173;onset “drusenoid,” 273–276, 274<span class="italic">–&#173;</span>275<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">electroretinography findings in, 46, 47<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">North Carolina, 277, 278<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">occult, 277</p>
			<p class="em-only_endmatter-idx2">pattern dystrophies, 276<span class="italic">f,</span> 276–277</p>
			<p class="em-only_endmatter-idx2">Sorsby, 275<span class="italic">f,</span> 275–276</p>
			<p class="em-only_endmatter-idx2">Stargardt disease. <span class="italic">See</span> Stargardt disease</p>
			<p class="em-only_endmatter-idx1">Macular edema</p>
			<p class="em-only_endmatter-idx2">cystoid (CME)</p>
			<p class="em-only_endmatter-idx3">birdshot uveitis in, 224</p>
			<p class="em-only_endmatter-idx3">cataract surgery as cause of, 157, 159, 260</p>
			<p class="em-only_endmatter-idx3">central ret&#173;i&#173;nal vein occlusion as cause of, 136<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">characteristics of, 156–157</p>
			<p class="em-only_endmatter-idx3">corticosteroids for, 159, 393</p>
			<p class="em-only_endmatter-idx3">in cytomegalovirus retinitis, 235</p>
			<p class="em-only_endmatter-idx3">differential diagnosis of, 157</p>
			<p class="em-only_endmatter-idx3">drugs that cause, 301</p>
			<p class="em-only_endmatter-idx3">edema sources in, 156–157</p>
			<p class="em-only_endmatter-idx3">etiologies of, 157</p>
			<p class="em-only_endmatter-idx3">fingolimod as cause of, 302</p>
			<p class="em-only_endmatter-idx3">fluorescein angiography of, 36<span class="italic">f,</span> 157</p>
			<p class="em-only_endmatter-idx3">incidence of, 157, 159</p>
			<p class="em-only_endmatter-idx3">in Irvine-&#173;Gass syndrome, 157</p>
			<p class="em-only_endmatter-idx3">nicotinic acid as cause of, 301</p>
			<p class="em-only_endmatter-idx3">optical coherence tomography of, 132<span class="italic">f,</span> 157, <br />158<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">petaloid, 157</p>
			<p class="em-only_endmatter-idx3">predisposing &#173;factors for, 157, 159</p>
			<p class="em-only_endmatter-idx3">pseudophakic</p>
			<p class="em-only_endmatter-idx4">definition of, 157</p>
			<p class="em-only_endmatter-idx4">imaging of, 394<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx4">optical coherence tomography of, 158<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx4">pars plana vitrectomy for, 394<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">in ret&#173;i&#173;nal dystrophies, 260, 260<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal vein occlusion as cause of, 135. <span class="italic">See also</span> <br />Ret&#173;i&#173;nal vein occlusion (RVO)</p>
			<p class="em-only_endmatter-idx3">retinitis pigmentosa and, 260</p>
			<p class="em-only_endmatter-idx3">spontaneous resolution of, 159</p>
			<p class="em-only_endmatter-idx3">subret&#173;i&#173;nal diseases that cause, 157</p>
			<p class="em-only_endmatter-idx3">taxanes as cause of, 301</p>
			<p class="em-only_endmatter-idx3">treatment of, 159</p>
			<p class="em-only_endmatter-idx3">vision loss caused by, 225</p>
			<p class="em-only_endmatter-idx3">vitrectomy for, 159, 393, 394<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">diabetic (DME)</p>
			<p class="em-only_endmatter-idx3">cataract surgery effects on, 116</p>
			<p class="em-only_endmatter-idx3">center-&#173;involved, 92, 109, 110<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">classification of, 109–110, 110<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">clinically significant, 92, 110, 114</p>
			<p class="em-only_endmatter-idx3">contrast sensitivity issues in, 56</p>
			<p class="em-only_endmatter-idx3">definition of, 92</p>
			<p class="em-only_endmatter-idx3">focal, 110</p>
			<p class="em-only_endmatter-idx3">mechanism of, 108, 109<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">non–&#173;center-&#173;involved, 109, 111<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">optical coherence tomography of, 111<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">spectral-&#173;domain optical coherence tomography <br />of, 109<span class="italic">f,</span> 125</p>
			<p class="em-only_endmatter-idx3">treatment of</p>
			<p class="em-only_endmatter-idx4">aflibercept, 113</p>
			<p class="em-only_endmatter-idx4">anti-&#173;VEGF therapy, 101, 110–113</p>
			<p class="em-only_endmatter-idx4">bevacizumab, 113</p>
			<p class="em-only_endmatter-idx4">corticosteroids, 113–114</p>
			<p class="em-only_endmatter-idx4">Diabetic Retinopathy Clinical Research <br />Network findings, 112<span class="italic">f,</span> 113</p>
			<p class="em-only_endmatter-idx4">intravitreal ste&#173;roids, 101</p>
			<p class="em-only_endmatter-idx4">&#173;laser surgery, 114–115, 376</p>
			<p class="em-only_endmatter-idx4">overview of, 110–111</p>
			<p class="em-only_endmatter-idx4">pars plana vitrectomy, 115</p>
			<p class="em-only_endmatter-idx4">ranibizumab, 111–112, 112<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx4">surgery, 114–115, 388</p>
			<p class="em-only_endmatter-idx4">vitrectomy, 388</p>
			<p class="em-only_endmatter-idx3">vision loss caused by, 94</p>
			<p class="em-only_endmatter-idx2">diffuse, 110, 111<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">drugs that cause, 301–302, 302<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">Early Treatment Diabetic Retinopathy Study <br />findings for, 99–100</p>
			<p class="em-only_endmatter-idx2">focal, 110, 111<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">in gyrate atrophy, 268</p>
			<p class="em-only_endmatter-idx2">panret&#173;i&#173;nal photocoagulation effects on, 106, 379</p>
			<p class="em-only_endmatter-idx1">Macular exudates, 124<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Macular halo, 292<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Macular holes</p>
			<p class="em-only_endmatter-idx2">contusion injury as cause of, 315</p>
			<p class="em-only_endmatter-idx2">fellow-&#173;eye risk for development of, 339</p>
			<p class="em-only_endmatter-idx2">formation of, 339, 340<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">idiopathic</p>
			<p class="em-only_endmatter-idx3">description of, 337–339, 338<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">vitrectomy for, 384–385, 385<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">International Vitreomacular Traction Study Classification System for, 336<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">lamellar, 28<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">management of, 339–340</p>
			<p class="em-only_endmatter-idx2">optical coherence tomography of, 27<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">in pathologic myopia, 209</p>
			<p class="em-only_endmatter-idx2">posttraumatic, 355–357, 356<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">rhegmatogenous ret&#173;i&#173;nal detachment caused by, <br />330, 330<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">spontaneous resolution of, 340</p>
			<p class="em-only_endmatter-idx2">stage 0, 339</p>
			<p class="em-only_endmatter-idx2">stage 1, 339–340</p>
			<p class="em-only_endmatter-idx2">stage 2, 339</p>
			<p class="em-only_endmatter-idx2">stage 3, 339</p>
			<p class="em-only_endmatter-idx2">stage 4, 339</p>
			<p class="em-only_endmatter-idx2">surgical management of, 339–340</p>
			<p class="em-only_endmatter-idx1">Macular pits, 356</p>
			<p class="em-only_endmatter-idx1">Macular telangiectasia</p>
			<p class="em-only_endmatter-idx2">early, 277</p>
			<p class="em-only_endmatter-idx2">type 1, 161</p>
			<p class="em-only_endmatter-idx2">type 2, 161–164, 162<span class="italic">–&#173;</span>164<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">type 3, 164–165</p>
			<p class="em-only_endmatter-idx2">volume rendering of, 31</p>
			<p class="em-only_endmatter-idx1">Macular translocation surgery, 85</p>
			<p class="em-only_endmatter-idx1">Maculopathy</p>
			<p class="em-only_endmatter-idx2">acute exudative polymorphous vitelliform, 287</p>
			<p class="em-only_endmatter-idx2">acute idiopathic (AIM), 228–229</p>
			<p class="em-only_endmatter-idx2">adult-&#173;onset vitelliform</p>
			<p class="em-only_endmatter-idx3">fluorescein angiography of, 68</p>
			<p class="em-only_endmatter-idx3">spectral-&#173;domain optical coherence tomography <br />of, 67–68, 68<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">bull’s-&#173;eye</p>
			<p class="em-only_endmatter-idx3">chloroquine toxicity as cause of, 295, 296<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">clofazimine as cause of, 298</p>
			<p class="em-only_endmatter-idx3">in neuronal ceroid lipofuscinoses, 289</p>
			<p class="em-only_endmatter-idx2">cellophane, 335</p>
			<p class="em-only_endmatter-idx2">hypotony, 201</p>
			<p class="em-only_endmatter-idx2">optic pit, 328–329, 329<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">paracentral acute &#173;middle (PAMM), 143</p>
			<p class="em-only_endmatter-idx1">Magnetic resonance imaging (MRI)</p>
			<p class="em-only_endmatter-idx2">intraocular foreign body evaluations, 353</p>
			<p class="em-only_endmatter-idx2">primary vitreoret&#173;i&#173;nal lymphoma evaluations, 234</p>
			<p class="em-only_endmatter-idx1">Magnification, in indirect ophthalmoscope/ophthalmoscopy, 21</p>
			<p class="em-only_endmatter-idx1">Malattia Leventinese, 274–275</p>
			<p class="em-only_endmatter-idx1">Malignant hypertension, 196</p>
			<p class="em-only_endmatter-idx1">Mannosidosis, 282<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">MAR. <span class="italic">See</span> Melanoma-associated retinopathy</p>
			<p class="em-only_endmatter-idx1">MARINA study, 80–81</p>
			<p class="em-only_endmatter-idx1">Maternally inherited diabetes and deafness (MIDD), 283<span class="italic">t,</span> 294, 294<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">M cone, 54</p>
			<p class="em-only_endmatter-idx1">MEK inhibitors, 299, 299<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Melanin, 32–33, 367, 373, 374<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Melanolipofuscin, 33</p>
			<p class="em-only_endmatter-idx1">Melanolysosomes, 32</p>
			<p class="em-only_endmatter-idx1">Melanoma-&#173;associated retinopathy (MAR), 286</p>
			<p class="em-only_endmatter-idx1">MELAS. <span class="italic">See</span> Mitochondrial encephalopathy, lactic acidosis, strokelike episodes</p>
			<p class="em-only_endmatter-idx1">Meridional complex</p>
			<p class="em-only_endmatter-idx2">definition of, 10</p>
			<p class="em-only_endmatter-idx2">illustration of, 10<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Meridional folds</p>
			<p class="em-only_endmatter-idx2">definition of, 10, 312</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal detachment and, 312</p>
			<p class="em-only_endmatter-idx1">Methanol toxicity, 301</p>
			<p class="em-only_endmatter-idx1">Methotrexate, for primary vitreoret&#173;i&#173;nal lymphoma, 234</p>
			<p class="em-only_endmatter-idx1">Methoxyflurane, 303</p>
			<p class="em-only_endmatter-idx1">MEWDS. <span class="italic">See</span> Multiple evanescent white dot syndrome</p>
			<p class="em-only_endmatter-idx1">mfERG. <span class="italic">See</span> Multifocal electroretinography</p>
			<p class="em-only_endmatter-idx1">MHA-&#173;TP. <span class="italic">See</span> Microhemagglutination assay for <span class="italic">T pallidum</span> antibodies</p>
			<p class="em-only_endmatter-idx1">Microaneurysms, in nonproliferative diabetic retinopathy, 100<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Microelectromechanical systems, in swept-&#173;source optical coherence tomography, 25–26</p>
			<p class="em-only_endmatter-idx1">Microexplosions, 375</p>
			<p class="em-only_endmatter-idx1">Microhemagglutination assay for <span class="italic">T pallidum</span> antibodies (MHA-&#173;TP), 241</p>
			<p class="em-only_endmatter-idx1">Micronutrients, for age-&#173;related macular degeneration, 69–71</p>
			<p class="em-only_endmatter-idx1">MIDD. <span class="italic">See</span> Maternally inherited diabetes and deafness</p>
			<p class="em-only_endmatter-idx1">&#173;Middle limiting membrane (MLM)</p>
			<p class="em-only_endmatter-idx2">anatomy of, 15</p>
			<p class="em-only_endmatter-idx2">definition of, 16</p>
			<p class="em-only_endmatter-idx2">histology of, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Midget bipolar cell, 13</p>
			<p class="em-only_endmatter-idx1">“Milky Way” sign, in Vogt-&#173;Koyanagi-&#173;Harada disease, 232</p>
			<p class="em-only_endmatter-idx1">Mitochondrial disorders, 293–294</p>
			<p class="em-only_endmatter-idx1">Mitochondrial encephalopathy, lactic acidosis, strokelike episodes (MELAS), 283<span class="italic">t,</span> 294</p>
			<p class="em-only_endmatter-idx1">Mitochondrial myopathies, 293<span class="italic">f,</span> 293–294</p>
			<p class="em-only_endmatter-idx1">Mittendorf dot, 340</p>
			<p class="em-only_endmatter-idx1">Mizuo-&#173;Nakamura phenomenon, 253, 253<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">MLM. <span class="italic">See</span> &#173;Middle limiting membrane</p>
			<p class="em-only_endmatter-idx1">Monochromatism, 250<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Mosquito-&#173;borne diseases, 246–247</p>
			<p class="em-only_endmatter-idx1">Motion artifacts, in optical coherence tomography angiography, 29</p>
			<p class="em-only_endmatter-idx1">Motion contrast, 28</p>
			<p class="em-only_endmatter-idx1">MRI. <span class="italic">See</span> Magnetic resonance imaging</p>
			<p class="em-only_endmatter-idx1">Mucopolysaccharidoses, 282<span class="italic">–&#173;</span>283<span class="italic">t,</span> 290–291</p>
			<p class="em-only_endmatter-idx1">M<span class="accent">ü</span>ller cells</p>
			<p class="em-only_endmatter-idx2">defect of, 162</p>
			<p class="em-only_endmatter-idx2">footplates of, 15, 15<span class="italic">f,</span> 326</p>
			<p class="em-only_endmatter-idx2">outer extent of, 15</p>
			<p class="em-only_endmatter-idx2">retinoschisin and, 279</p>
			<p class="em-only_endmatter-idx1">Multi-&#173;Ethnic Study of Atherosclerosis (MESA), 62</p>
			<p class="em-only_endmatter-idx1">Multifocal choroiditis, 220<span class="italic">t,</span> 225–226, 226<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Multifocal electroretinography (mfERG), 45, 48<span class="italic">–&#173;</span>49<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Multiple evanescent white dot syndrome (MEWDS), 220<span class="italic">t,</span> 223–224, 224<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Multiple sclerosis</p>
			<p class="em-only_endmatter-idx2">intermediate uveitis associated with, 231</p>
			<p class="em-only_endmatter-idx2">optic nerve conduction delay in, 52</p>
			<p class="em-only_endmatter-idx1"><span class="italic">Mycobacterium tuberculosis,</span> 240</p>
			<p class="em-only_endmatter-idx1">Myoid, 12</p>
			<p class="em-only_endmatter-idx1">Myopia</p>
			<p class="em-only_endmatter-idx2">historical treatments for, 208</p>
			<p class="em-only_endmatter-idx2">pathologic</p>
			<p class="em-only_endmatter-idx3">chorioret&#173;i&#173;nal atrophy in, 214<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">choroidal neovascularization caused by, 89, 90<span class="italic">f,</span> 211<span class="italic">f,</span> 211–212</p>
			<p class="em-only_endmatter-idx3">choroid in, 212–216, 214<span class="italic">–&#173;</span>215<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">definition of, 207</p>
			<p class="em-only_endmatter-idx3">&#173;factors associated with, 207</p>
			<p class="em-only_endmatter-idx3">glaucoma in, 218, 218<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">global prevalence of, 207</p>
			<p class="em-only_endmatter-idx3">macular holes in, 209</p>
			<p class="em-only_endmatter-idx3">ocular expansion related to, 216</p>
			<p class="em-only_endmatter-idx3">optic nerve in, 217–218, 218<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">prevalence of, 207</p>
			<p class="em-only_endmatter-idx3">prevention of, 207–208</p>
			<p class="em-only_endmatter-idx3">ret&#173;ina in, 207–216, 209<span class="italic">–&#173;</span>215</p>
			<p class="em-only_endmatter-idx3">sclera in, 216–217, 217<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">swept-&#173;source optical coherence tomography of, 209<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">traction effects on ret&#173;i&#173;nal vessels in, 209</p>
			<p class="em-only_endmatter-idx2">topiramate as cause of, 305</p>
			<p class="em-only_endmatter-idx1">Myopic macular schisis, 209, 210<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Myotonic dystrophy, 282<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx-alpha">N95, 45</p>
			<p class="em-only_endmatter-idx1">NARP. <span class="italic">See</span> Neurogenic muscle weakness, ataxia, and retinitis pigmentosa</p>
			<p class="em-only_endmatter-idx1">Nausea and vomiting, fluorescein angiography as <br />cause of, 36</p>
			<p class="em-only_endmatter-idx1">NCLs. <span class="italic">See</span> Neuronal ceroid lipofuscinoses </p>
			<p class="em-only_endmatter-idx1">Nd:YAG &#173;laser</p>
			<p class="em-only_endmatter-idx2">cystoid macular edema treated with, 159</p>
			<p class="em-only_endmatter-idx2">mechanism of, 367</p>
			<p class="em-only_endmatter-idx2">ocular injury caused by, 367</p>
			<p class="em-only_endmatter-idx1">Near-&#173;infrared fundus autofluorescence, 32–33</p>
			<p class="em-only_endmatter-idx1">Near periphery, 9</p>
			<p class="em-only_endmatter-idx1">Necrotizing herpetic retinitis, 236–237, 236<span class="italic">–&#173;</span>237<span class="italic">f,</span> 238<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Necrotizing retinochoroiditis, 243</p>
			<p class="em-only_endmatter-idx1">Needle perforation/penetration injuries, of globe, 358, 395<span class="italic">f,</span> 395–396</p>
			<p class="em-only_endmatter-idx1">Neonatal adrenoleukodystrophy, 283<span class="italic">t,</span> 290, 291<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Neovascularization</p>
			<p class="em-only_endmatter-idx2">in branch ret&#173;i&#173;nal vein occlusion, 125, 128, 129<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">in central ret&#173;i&#173;nal vein occlusion, 125</p>
			<p class="em-only_endmatter-idx2">in central serous chorioretinopathy, 194</p>
			<p class="em-only_endmatter-idx2">choroidal. <span class="italic">See</span> Choroidal neovascularization</p>
			<p class="em-only_endmatter-idx2">iris</p>
			<p class="em-only_endmatter-idx3">in branch ret&#173;i&#173;nal vein occlusion, 128–129, 129<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">in central ret&#173;i&#173;nal artery occlusion, 146</p>
			<p class="em-only_endmatter-idx3">in central ret&#173;i&#173;nal vein occlusion, 133, 135</p>
			<p class="em-only_endmatter-idx3">in diabetes mellitus, 107</p>
			<p class="em-only_endmatter-idx3">in radiation retinopathy, 170</p>
			<p class="em-only_endmatter-idx2">optic nerve head, 128, 129<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">peripheral, 232</p>
			<p class="em-only_endmatter-idx2">peripheral ret&#173;i&#173;nal, 154<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">in proliferative sickle cell retinopathy, 151, 153<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">in retinopathy of prematurity, 180–181</p>
			<p class="em-only_endmatter-idx2">sea fan, 151, 153<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">subret&#173;i&#173;nal, 162</p>
			<p class="em-only_endmatter-idx1">Neovascular proliferation, in proliferative diabetic retinopathy, 102</p>
			<p class="em-only_endmatter-idx1">Neovascular (“wet”) age-&#173;related macular degeneration</p>
			<p class="em-only_endmatter-idx2">aflibercept for, 82–83</p>
			<p class="em-only_endmatter-idx2">Amsler grid testing of, 71</p>
			<p class="em-only_endmatter-idx2">antiangiogenic therapies for, 79–80</p>
			<p class="em-only_endmatter-idx2">bevacizumab for, 83–85, 84<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">choroidal neovascularization associated with, 71–79. <span class="italic">See also</span> Choroidal neovascularization</p>
			<p class="em-only_endmatter-idx2">combination treatment for, 85</p>
			<p class="em-only_endmatter-idx2">differential diagnosis of, 76, 79</p>
			<p class="em-only_endmatter-idx2">intravitreal injections, 85</p>
			<p class="em-only_endmatter-idx2">&#173;laser photocoagulation for, 79</p>
			<p class="em-only_endmatter-idx2">low vision therapies for, 86</p>
			<p class="em-only_endmatter-idx2">macular translocation surgery for, 85</p>
			<p class="em-only_endmatter-idx2">management of, 79–86, 81<span class="italic">f,</span> 82<span class="italic">t,</span> 84<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">pegaptanib for, 80</p>
			<p class="em-only_endmatter-idx2">photodynamic therapy for, 79</p>
			<p class="em-only_endmatter-idx2">polypoidal choroidal vasculopathy, 75</p>
			<p class="em-only_endmatter-idx2">prevalence of, 61</p>
			<p class="em-only_endmatter-idx2">ranibizumab for, 80–82, 82<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">signs and symptoms of, 71</p>
			<p class="em-only_endmatter-idx2">submacular hemorrhage in, 85, 385</p>
			<p class="em-only_endmatter-idx2">surgical treatment for, 85–86</p>
			<p class="em-only_endmatter-idx2">treatment effect modifiers, 85</p>
			<p class="em-only_endmatter-idx2">verteporfin for, 79</p>
			<p class="em-only_endmatter-idx1">Nerve fiber layer (NFL)</p>
			<p class="em-only_endmatter-idx2">anatomy of, 15</p>
			<p class="em-only_endmatter-idx2">cotton-&#173;wool spots, 122, 122<span class="italic">f,</span> 140, 140<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">histology of, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">infarction of, 140</p>
			<p class="em-only_endmatter-idx2">mea&#173;sure&#173;ment of, 26</p>
			<p class="em-only_endmatter-idx2">optical coherence tomography mea&#173;sure&#173;ment of, 218</p>
			<p class="em-only_endmatter-idx1">Nerve head sign of sickling, 154</p>
			<p class="em-only_endmatter-idx1">Neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP), 294</p>
			<p class="em-only_endmatter-idx1">Neuromuscular disorders, ret&#173;i&#173;nal degeneration associated with, 285</p>
			<p class="em-only_endmatter-idx1">Neuronal ceroid lipofuscinoses (NCLs), 283<span class="italic">t,</span> 289, 290<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">NFL. <span class="italic">See</span> Nerve fiber layer</p>
			<p class="em-only_endmatter-idx1">Nicotinic acid, 301</p>
			<p class="em-only_endmatter-idx1">Niemann-&#173;Pick disease, 291</p>
			<p class="em-only_endmatter-idx1">Night blindness</p>
			<p class="em-only_endmatter-idx2">in choroideremia, 267</p>
			<p class="em-only_endmatter-idx2">congenital stationary</p>
			<p class="em-only_endmatter-idx3">electroretinography findings in, 46, 47<span class="italic">f,</span> 251, 252<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">retinitis pigmentosa versus, 251</p>
			<p class="em-only_endmatter-idx3">subtypes of, 251</p>
			<p class="em-only_endmatter-idx2">dark adaptometry evaluations, 58</p>
			<p class="em-only_endmatter-idx2">electroretinography evaluations, 46</p>
			<p class="em-only_endmatter-idx2">fundus albipunctatus, 252, 253<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">in gyrate atrophy, 268</p>
			<p class="em-only_endmatter-idx1">Night vision abnormalities, 251–253, 251<span class="italic">–&#173;</span>253<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Nonarteritic anterior ischemic optic neuropathy, visual evoked potentials in, 52</p>
			<p class="em-only_endmatter-idx1">Non–&#173;center-&#173;involved diabetic macular edema, 109, <br />111<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Noncontact indirect biomicroscopy, 22</p>
			<p class="em-only_endmatter-idx1">Non–&#173;contact lens, indirect ophthalmoscopy using, 22</p>
			<p class="em-only_endmatter-idx1">Nonexudative macular degeneration, contrast sensitivity issues in, 56</p>
			<p class="em-only_endmatter-idx1">Non–Hodgkin lymphoma of the central ner&#173;vous system. <span class="italic">See</span> Primary vitreoret&#173;i&#173;nal lymphoma</p>
			<p class="em-only_endmatter-idx1">Non–&#173;insulin-&#173;dependent diabetes mellitus, 91</p>
			<p class="em-only_endmatter-idx1">Nonneovascular (“dry”) age-&#173;related macular degeneration</p>
			<p class="em-only_endmatter-idx2">Amsler grid testing for, 68–69</p>
			<p class="em-only_endmatter-idx2">differential diagnosis of, 67–68</p>
			<p class="em-only_endmatter-idx2">disproven treatment approaches for, 71</p>
			<p class="em-only_endmatter-idx2">drusen associated with. <span class="italic">See</span> Drusen</p>
			<p class="em-only_endmatter-idx2">education regarding, 68</p>
			<p class="em-only_endmatter-idx2">focal atrophy in, 66</p>
			<p class="em-only_endmatter-idx2">follow-up for, 68</p>
			<p class="em-only_endmatter-idx2">geographic atrophy in, 64, 66, 67<span class="italic">f,</span> 68</p>
			<p class="em-only_endmatter-idx2">hydrochloroquine toxicity versus, 68</p>
			<p class="em-only_endmatter-idx2">hyperacuity testing for, 69</p>
			<p class="em-only_endmatter-idx2">lifestyle changes for, 71</p>
			<p class="em-only_endmatter-idx2">management of, 68–71</p>
			<p class="em-only_endmatter-idx2">micronutrients for, 69–71</p>
			<p class="em-only_endmatter-idx2">preferential hyperacuity perimetry for, 69</p>
			<p class="em-only_endmatter-idx2">prevalence of, 61</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium abnormalities in, 66–67</p>
			<p class="em-only_endmatter-idx2">shape-&#173;discrimination hyperacuity for, 69</p>
			<p class="em-only_endmatter-idx1">Nonproliferative diabetic retinopathy (NPDR)</p>
			<p class="em-only_endmatter-idx2">anti-&#173;VEGF therapy for, 101–102</p>
			<p class="em-only_endmatter-idx2">clinical findings in, 99</p>
			<p class="em-only_endmatter-idx2">definition of, 91</p>
			<p class="em-only_endmatter-idx2">intraret&#173;i&#173;nal hemorrhages associated with, 100<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">intraret&#173;i&#173;nal microvascular abnormalities in, 100<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">microaneurysms associated with, 100<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">optical coherence tomography angiography of, 94<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">panret&#173;i&#173;nal photocoagulation for, 101</p>
			<p class="em-only_endmatter-idx2">posterior vitreous detachment creation for, 102</p>
			<p class="em-only_endmatter-idx2">progression of, to proliferative diabetic retinopathy, <br />101</p>
			<p class="em-only_endmatter-idx2">ranibizumab for, 102</p>
			<p class="em-only_endmatter-idx2">scatter photocoagulation for, 116</p>
			<p class="em-only_endmatter-idx2">severity of, 95<span class="italic">t,</span> 99</p>
			<p class="em-only_endmatter-idx2">treatment of, 101–102</p>
			<p class="em-only_endmatter-idx2">venous beading associated with, 100<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">vision loss in, 101</p>
			<p class="em-only_endmatter-idx1">Nonproliferative sickle cell retinopathy  (NPSR)</p>
			<p class="em-only_endmatter-idx2">branch ret&#173;i&#173;nal artery occlusions in, 152<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">characteristics of, 149–150</p>
			<p class="em-only_endmatter-idx2">imaging of, 150<span class="italic">–&#173;</span>152<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">retinal arteriolar occlusions in, 151<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">salmon-&#173;patch hemorrhage in, 150<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Nonsyndromic panret&#173;i&#173;nal dystrophies, 258–259</p>
			<p class="em-only_endmatter-idx1">North Carolina macular dystrophy, 277, 278<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">NPDR. <span class="italic">See</span> Nonproliferative diabetic retinopathy</p>
			<p class="em-only_endmatter-idx1">NPSR. <span class="italic">See</span> Nonproliferative sickle cell retinopathy</p>
			<p class="em-only_endmatter-idx1"><span class="italic">NR2E3</span> gene, 49, 266</p>
			<p class="em-only_endmatter-idx1">NRTIs. <span class="italic">See</span> Nucleoside reverse transcriptase inhibitors</p>
			<p class="em-only_endmatter-idx1">Nuclear sclerotic cataract, 402, 402<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Nucleoside reverse transcriptase inhibitors (NRTIs), <br />299</p>
			<p class="em-only_endmatter-idx1">Nyctalopia, 290</p>
			<p class="em-only_endmatter-idx1">Nystagmus</p>
			<p class="em-only_endmatter-idx2">visual evoked potentials in, 53</p>
			<p class="em-only_endmatter-idx2">wandering, 266</p>
			<p class="em-only_endmatter-idx-alpha"><span class="italic">OAT</span> gene, 269</p>
			<p class="em-only_endmatter-idx1">Occlusive arterial disease</p>
			<p class="em-only_endmatter-idx2">branch ret&#173;i&#173;nal artery</p>
			<p class="em-only_endmatter-idx3">emboli that cause, 141, 142<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">hypertensive retinopathy and, 122</p>
			<p class="em-only_endmatter-idx3">imaging of, 141<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">management of, 142</p>
			<p class="em-only_endmatter-idx3">multiple, 152<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">in nonproliferative sickle cell retinopathy, 152<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal infarction caused by, 141</p>
			<p class="em-only_endmatter-idx3">in Susac syndrome, 156</p>
			<p class="em-only_endmatter-idx2">branch ret&#173;i&#173;nal vein</p>
			<p class="em-only_endmatter-idx3">aflibercept for, 135</p>
			<p class="em-only_endmatter-idx3">at arteriovenous crossing, 126</p>
			<p class="em-only_endmatter-idx3">bevacizumab for, 135</p>
			<p class="em-only_endmatter-idx3">clinical findings of, 125–127, 126<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">corticosteroids for, 137–138</p>
			<p class="em-only_endmatter-idx3">diabetes mellitus and, 128</p>
			<p class="em-only_endmatter-idx3">fluorescein angiography of, 129<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">glaucoma as risk &#173;factor for, 125</p>
			<p class="em-only_endmatter-idx3">hypertensive retinopathy and, 122</p>
			<p class="em-only_endmatter-idx3">intraret&#173;i&#173;nal hemorrhages associated with, 125, 126<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">macular &#173;laser surgery for, 128</p>
			<p class="em-only_endmatter-idx3">neovascularization in, 125, 128, 129<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">pars plana vitrectomy for, 130</p>
			<p class="em-only_endmatter-idx3">pharmacologic management of, 135–138</p>
			<p class="em-only_endmatter-idx3">prognosis for, 128</p>
			<p class="em-only_endmatter-idx3">ranibizumab for, 135</p>
			<p class="em-only_endmatter-idx3">risk &#173;factors for, 127–128</p>
			<p class="em-only_endmatter-idx3">scatter photocoagulation for, 128–130</p>
			<p class="em-only_endmatter-idx3">spontaneous resolution of, 125</p>
			<p class="em-only_endmatter-idx3">surgical management of, 128–130</p>
			<p class="em-only_endmatter-idx3">treatment of, 128–130</p>
			<p class="em-only_endmatter-idx3">triamcinolone for, 137</p>
			<p class="em-only_endmatter-idx3">vision loss caused by, 128</p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal artery</p>
			<p class="em-only_endmatter-idx3">anti-&#173;VEGF therapy for, 146</p>
			<p class="em-only_endmatter-idx3">&#173;causes of, 144</p>
			<p class="em-only_endmatter-idx3">ciliary artery occlusion with, 144, 145<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">electroretinography findings in, 50</p>
			<p class="em-only_endmatter-idx3">emboli as cause of, 144</p>
			<p class="em-only_endmatter-idx3">&#173;giant cell arteritis as cause of, 145</p>
			<p class="em-only_endmatter-idx3">illustration of, 16<span class="italic">f,</span> 144<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">iris neovascularization in, 146</p>
			<p class="em-only_endmatter-idx3">management of, 146</p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal infarction caused by, 143</p>
			<p class="em-only_endmatter-idx3">spectral-&#173;domain optical coherence tomography of, 144<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">symptoms and signs of, 143</p>
			<p class="em-only_endmatter-idx3">vision loss caused by, 143–144</p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal vein occlusion. <span class="italic">See</span> Central ret&#173;i&#173;nal <br />vein occlusion (CRVO)</p>
			<p class="em-only_endmatter-idx1">Occlusive retinopathy, 300–301</p>
			<p class="em-only_endmatter-idx1">Occult choroidal neovascularization, 72–73</p>
			<p class="em-only_endmatter-idx1">Occult macular dystrophies, 277</p>
			<p class="em-only_endmatter-idx1">Occupational light toxicity, 369</p>
			<p class="em-only_endmatter-idx1">Ocriplasmin, 337, 340</p>
			<p class="em-only_endmatter-idx1">OCT. <span class="italic">See</span> Optical coherence tomography</p>
			<p class="em-only_endmatter-idx1">OCTA. <span class="italic">See</span> Optical coherence tomographic angiography</p>
			<p class="em-only_endmatter-idx1">Ocular albinism</p>
			<p class="em-only_endmatter-idx2">characteristics of, 288</p>
			<p class="em-only_endmatter-idx2">pattern-&#173;appearance visual evoked potentials in, 53</p>
			<p class="em-only_endmatter-idx1">Ocular argyrosis, 306</p>
			<p class="em-only_endmatter-idx1">Ocular expansion, pathologic myopia as cause of, 216</p>
			<p class="em-only_endmatter-idx1">Ocular histoplasmosis syndrome (OHS), choroidal neovascularization caused by, 86–87, 88<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ocular ischemic syndrome (OIS)</p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal vein occlusion versus, 134</p>
			<p class="em-only_endmatter-idx2">course of, 139</p>
			<p class="em-only_endmatter-idx2">definition of, 138</p>
			<p class="em-only_endmatter-idx2">etiology of, 139</p>
			<p class="em-only_endmatter-idx2">ischemic cardiovascular disease associated with, 139</p>
			<p class="em-only_endmatter-idx2">retinopathy caused by, 138</p>
			<p class="em-only_endmatter-idx2">stroke rate in, 139</p>
			<p class="em-only_endmatter-idx2">symptoms and signs of, 138–139</p>
			<p class="em-only_endmatter-idx2">treatment of, 140</p>
			<p class="em-only_endmatter-idx1">Ocular-&#173;retinal developmental disease, genes and loci associated with, 256<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ocular surgery, sympathetic ophthalmia secondary <br />to, 233. <span class="italic">See also </span>Surgery</p>
			<p class="em-only_endmatter-idx1">Ocular trauma. <span class="italic">See</span> Trauma</p>
			<p class="em-only_endmatter-idx1">Ocular Trauma Score, 364, 364<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Oculocutaneous albinism</p>
			<p class="em-only_endmatter-idx2">description of, 288</p>
			<p class="em-only_endmatter-idx2">pattern-&#173;appearance visual evoked potentials in, 53</p>
			<p class="em-only_endmatter-idx1">Oculodentodigital dysplasia syndrome, 282<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Oculodigital reflex, 266</p>
			<p class="em-only_endmatter-idx1">Oguchi disease, 253</p>
			<p class="em-only_endmatter-idx1">“Ohno” sign, 233</p>
			<p class="em-only_endmatter-idx1">OHS. <span class="italic">See</span> Ocular histoplasmosis syndrome</p>
			<p class="em-only_endmatter-idx1">OIS. <span class="italic">See</span> Ocular ischemic syndrome</p>
			<p class="em-only_endmatter-idx1">Olivopontocerebellar atrophy, 282<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Omega-3 long-&#173;chain polyunsaturated fatty acids, 70</p>
			<p class="em-only_endmatter-idx1">OMIM. <span class="italic">See</span> Online Mendelian Inheritance in Man (OMIM) website</p>
			<p class="em-only_endmatter-idx1">ONL. <span class="italic">See</span> Outer nuclear layer</p>
			<p class="em-only_endmatter-idx1">Online Mendelian Inheritance in Man (OMIM) website, 255</p>
			<p class="em-only_endmatter-idx1">Opacities, vitreous</p>
			<p class="em-only_endmatter-idx2">amyloidosis, 348, 349<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">asteroid hyalosis, 346<span class="italic">f,</span> 346–347</p>
			<p class="em-only_endmatter-idx2">bilateral, 348</p>
			<p class="em-only_endmatter-idx2">cholesterolosis, 348</p>
			<p class="em-only_endmatter-idx2">pigment granules, 348</p>
			<p class="em-only_endmatter-idx2">vitrectomy for, 386</p>
			<p class="em-only_endmatter-idx2">vitreous degeneration and detachment associated, 344</p>
			<p class="em-only_endmatter-idx2">vitreous hemorrhage, 347</p>
			<p class="em-only_endmatter-idx1">Open-&#173;angle glaucoma. <span class="italic">See also </span>Glaucoma</p>
			<p class="em-only_endmatter-idx2">in central ret&#173;i&#173;nal vein occlusion, 133</p>
			<p class="em-only_endmatter-idx2">vitrectomy as risk &#173;factor for, 402</p>
			<p class="em-only_endmatter-idx1">Operculated ret&#173;i&#173;nal holes, 315–316</p>
			<p class="em-only_endmatter-idx1">Ophthalmic artery occlusion, 146, 147<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ophthalmic examinations, diabetes mellitus-&#173;related, 93–94, 95<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ophthalmic instrumentation, phototoxicity from, 368–369</p>
			<p class="em-only_endmatter-idx1">Ophthalmoscopy</p>
			<p class="em-only_endmatter-idx2">direct</p>
			<p class="em-only_endmatter-idx3">limitations of, 21</p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal disease evaluations using, 21</p>
			<p class="em-only_endmatter-idx2">indirect</p>
			<p class="em-only_endmatter-idx3">illumination in, 21</p>
			<p class="em-only_endmatter-idx3">posterior vitreous detachment diagnosed using, 309, 331</p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal disease evaluations using, 21–22</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal disease evaluations using, 21–22</p>
			<p class="em-only_endmatter-idx2">scanning &#173;laser. <span class="italic">See</span> Scanning &#173;laser ophthalmoscopy</p>
			<p class="em-only_endmatter-idx1">OPL. <span class="italic">See</span> Outer plexiform layer</p>
			<p class="em-only_endmatter-idx1">Opportunistic infections, 235–236</p>
			<p class="em-only_endmatter-idx1">Optical coherence tomographic angiography (OCTA)</p>
			<p class="em-only_endmatter-idx2">artifacts in, 29, 30<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">choroidal circulation abnormalities, 198</p>
			<p class="em-only_endmatter-idx2">choroidal neovascularization on, 75–76, 76<span class="italic">–&#173;</span>78<span class="italic">f,</span> 192</p>
			<p class="em-only_endmatter-idx2">depth resolution using, 29</p>
			<p class="em-only_endmatter-idx2">diabetic retinopathy on, 93, 94<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">fluorescein angiography versus, 29</p>
			<p class="em-only_endmatter-idx2">macular telangiectasia type 2 on, 163, 164<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">motion artifacts in, 29</p>
			<p class="em-only_endmatter-idx2">projection artifacts in, 29, 30<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">pseudoxanthoma elasticum on, 199<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal capillary layers on, 16</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal disease evaluations using, 28–29</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal vasculature on, 29, 30<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">severity of, 93, 94<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Optical coherence tomography (OCT)</p>
			<p class="em-only_endmatter-idx2">acute idiopathic maculopathy on, 228</p>
			<p class="em-only_endmatter-idx2">acute macular neuroretinopathy on, 228</p>
			<p class="em-only_endmatter-idx2">acute posterior multifocal placoid pigment epitheliopathy on, 221<span class="italic">f,</span> 222</p>
			<p class="em-only_endmatter-idx2">acute zonal occult outer retinopathy on, 227, 227<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">cancer-&#173;associated retinopathy on, 287<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">central serous chorioretinopathy evaluations, 32</p>
			<p class="em-only_endmatter-idx2">choroidal neovascularization on, 192, 194</p>
			<p class="em-only_endmatter-idx2">cystoid macular edema on, 132<span class="italic">f,</span> 157, 158<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">definition of, 25</p>
			<p class="em-only_endmatter-idx2">diabetic macular edema on, 111<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">drusen on, 65–66</p>
			<p class="em-only_endmatter-idx2">enhanced depth imaging, 25</p>
			<p class="em-only_endmatter-idx2">epiret&#173;i&#173;nal membranes on, 335, 383<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">eye movement tracking with, 27</p>
			<p class="em-only_endmatter-idx2">low-&#173;coherence light in, 25</p>
			<p class="em-only_endmatter-idx2">macular hole on, 27<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">myopic macular schisis on, 210<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">nerve fiber layer mea&#173;sure&#173;ment using, 218</p>
			<p class="em-only_endmatter-idx2">nomenclature terminology for, 26–27</p>
			<p class="em-only_endmatter-idx2">peripapillary intrachoroidal cavitations on, 215, 215<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">pigment epithelial detachment on, 74<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">posterior vitreous detachment on, 309, 332</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal disease evaluations using, 25–27, 27<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">solar retinopathy on, 368<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">spectral-&#173;domain</p>
			<p class="em-only_endmatter-idx3">adult-&#173;onset vitelliform maculopathy on, 67–68, <br />68<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">alkyl nitrite findings, 300, 300<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">chloroquine toxicity monitoring uses of, 297</p>
			<p class="em-only_endmatter-idx3">choroidal neovascularization on, 73–75, 75<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">diabetic macular edema on, 109<span class="italic">f,</span> 125</p>
			<p class="em-only_endmatter-idx3">drusen on, 64<span class="italic">f,</span> 65</p>
			<p class="em-only_endmatter-idx3">epiret&#173;i&#173;nal membranes on, 335<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">Gaucher disease on, 291</p>
			<p class="em-only_endmatter-idx3">pathologic myopia on, 90<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">reticular pseudodrusen on, 65<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal layers on, 10–11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">retinitis pigmentosa findings, 263<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">sensitivity of, 26</p>
			<p class="em-only_endmatter-idx3">swept-&#173;source optical coherence tomography versus, 25–26</p>
			<p class="em-only_endmatter-idx2">swept-&#173;source</p>
			<p class="em-only_endmatter-idx3">pathologic myopia findings, 209<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">sensitivity of, 26</p>
			<p class="em-only_endmatter-idx3">spectral-&#173;domain optical coherence tomography versus, 25–26</p>
			<p class="em-only_endmatter-idx2">time-&#173;domain, 25</p>
			<p class="em-only_endmatter-idx2">vitreoret&#173;i&#173;nal traction syndrome on, 337, 337<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">volume rendering, 27, 28<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">X-&#173;linked retinoschisis on, 278, 278<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Optically empty vitreous, hereditary hyaloideoretinopathies with, 342–343, 343<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Optic atrophy, genes and loci associated with, 256<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Optic nerve</p>
			<p class="em-only_endmatter-idx2">conduction delay, visual evoked potentials of, 52</p>
			<p class="em-only_endmatter-idx2">in pathologic myopia, 217–218, 218<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">peripapillary intrachoroidal cavitations, 215, 215<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Optic nerve head (optic disc)</p>
			<p class="em-only_endmatter-idx2">angiomatous lesion of, 242</p>
			<p class="em-only_endmatter-idx2">avulsion of, 365, 365<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">drusen of, 260</p>
			<p class="em-only_endmatter-idx2">edema of, 234, 349</p>
			<p class="em-only_endmatter-idx2">hyperemia of, 232</p>
			<p class="em-only_endmatter-idx2">neovascularization of, 128, 129<span class="italic">f,</span> 170</p>
			<p class="em-only_endmatter-idx2">in pathologic myopia, 217–218, 218<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">subret&#173;i&#173;nal hemorrhage, 355<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Optic neuropathy, hypertensive, 123, 125</p>
			<p class="em-only_endmatter-idx1">Optic pit(s), 328–329, 329<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Optic pit maculopathy, 328–329, 329<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ora bays</p>
			<p class="em-only_endmatter-idx2">definition of, 10</p>
			<p class="em-only_endmatter-idx2">illustration of, 11<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal tears near, 312</p>
			<p class="em-only_endmatter-idx1">Oral contraceptives, central ret&#173;i&#173;nal vein occlusion <br />risks, 134</p>
			<p class="em-only_endmatter-idx1">Ora serrata</p>
			<p class="em-only_endmatter-idx2">anatomy of, 7, 11<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">binocular indirect ophthalmoscopy of, 22</p>
			<p class="em-only_endmatter-idx2">definition of, 10</p>
			<p class="em-only_endmatter-idx1">Oscillary potentials, 43<span class="italic">f,</span> 43–44</p>
			<p class="em-only_endmatter-idx1">Outer nuclear layer (ONL), 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Outer plexiform layer (OPL)</p>
			<p class="em-only_endmatter-idx2">histology of, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">oxygen supply to, 16</p>
			<p class="em-only_endmatter-idx2">paracentral acute &#173;middle maculopathy of, 143</p>
			<p class="em-only_endmatter-idx2">typical degenerative retinoschisis findings, 326</p>
			<p class="em-only_endmatter-idx1">Outer-&#173;schisis-&#173;layer holes, 327, 327<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Outer segments</p>
			<p class="em-only_endmatter-idx2">of cones, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">phagocytosis of, 17</p>
			<p class="em-only_endmatter-idx2">of rods, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Oxalate, 303</p>
			<p class="em-only_endmatter-idx1">Oxygen</p>
			<p class="em-only_endmatter-idx2">hyalocyte consumption of, 7</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal supply of, 16<span class="italic">f,</span> 16–17</p>
			<p class="em-only_endmatter-idx2">supplementation of, retinopathy of prematurity and, 184</p>
			<p class="em-only_endmatter-idx-alpha">P50, 45, 47<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Pachychoroid, 19, 76</p>
			<p class="em-only_endmatter-idx1">Paclitaxel, 301</p>
			<p class="em-only_endmatter-idx1">PAMM. <span class="italic">See</span> Paracentral acute &#173;middle maculopathy</p>
			<p class="em-only_endmatter-idx1">Panel D-15 test (Farnsworth), 55<span class="italic">f,</span> 55–56</p>
			<p class="em-only_endmatter-idx1">Panret&#173;i&#173;nal dystrophies</p>
			<p class="em-only_endmatter-idx2">clinical findings of, 261, 263<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">Coats reaction associated with, 260</p>
			<p class="em-only_endmatter-idx2">nonsyndromic, 258–259</p>
			<p class="em-only_endmatter-idx2">syndromic, 259</p>
			<p class="em-only_endmatter-idx1">Panret&#173;i&#173;nal photocoagulation (PRP)</p>
			<p class="em-only_endmatter-idx2">adverse effects of, 106</p>
			<p class="em-only_endmatter-idx2">applications of, 376–377, 377<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal vein occlusion treated with, 135</p>
			<p class="em-only_endmatter-idx2">idiopathic ret&#173;i&#173;nal vasculitis, aneurysms, and neuroretinitis treated with, 156</p>
			<p class="em-only_endmatter-idx2">iris neovascularization and, 135</p>
			<p class="em-only_endmatter-idx2">macular edema exacerbation by, 379</p>
			<p class="em-only_endmatter-idx2">nonproliferative diabetic retinopathy treated <br />with, 101</p>
			<p class="em-only_endmatter-idx2">oxygen tension affected by, 104</p>
			<p class="em-only_endmatter-idx2">proliferative diabetic retinopathy treated with, 104, 106, 106<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal vein occlusion treated with, 126</p>
			<p class="em-only_endmatter-idx1">Panuveitis. <span class="italic">See also</span> Uveitis</p>
			<p class="em-only_endmatter-idx2">Ebola virus, 247</p>
			<p class="em-only_endmatter-idx2">multifocal choroiditis with, 226<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">in syphilitic uveitis, 241</p>
			<p class="em-only_endmatter-idx2">in toxocariasis, 245</p>
			<p class="em-only_endmatter-idx2">in Vogt-&#173;Koyanagi-&#173;Harada disease, 233</p>
			<p class="em-only_endmatter-idx1">Paracentral acute &#173;middle maculopathy (PAMM), 143</p>
			<p class="em-only_endmatter-idx1">Paracentral scotomas, 228, 367</p>
			<p class="em-only_endmatter-idx1">Parafovea</p>
			<p class="em-only_endmatter-idx2">characteristics of, 10<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">definition of, 9</p>
			<p class="em-only_endmatter-idx1">Parafoveal macula, 9<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Paraneoplastic retinopathies, 286–287</p>
			<p class="em-only_endmatter-idx1">Parasitic infections, 244</p>
			<p class="em-only_endmatter-idx1">Parinaud oculoglandular syndrome, 242</p>
			<p class="em-only_endmatter-idx1">Pars plana, 10</p>
			<p class="em-only_endmatter-idx1">Pars plana vitrectomy. <span class="italic">See also</span> Vitrectomy</p>
			<p class="em-only_endmatter-idx2">branch ret&#173;i&#173;nal vein occlusion treated with, 130</p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal vein occlusion treated with, 135</p>
			<p class="em-only_endmatter-idx2">complications of, 402<span class="italic">t,</span> 402–403</p>
			<p class="em-only_endmatter-idx2">cystoid macular edema treated with, 393, 394<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">diabetic macular edema treated with, 115, 388</p>
			<p class="em-only_endmatter-idx2">diabetic retinopathy complications treated <br />with, 107</p>
			<p class="em-only_endmatter-idx2">epiret&#173;i&#173;nal membranes treated with, 382–383</p>
			<p class="em-only_endmatter-idx2">idiopathic macular holes treated with, <br />384–385, 385<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">indications for, 381</p>
			<p class="em-only_endmatter-idx2">intraocular foreign body removed with, 361</p>
			<p class="em-only_endmatter-idx2">needle perforation/penetration of globe treated <br />with, 396</p>
			<p class="em-only_endmatter-idx2">posteriorly dislocated intraocular lenses treated <br />with, 393</p>
			<p class="em-only_endmatter-idx2">postoperative endophthalmitis treated with</p>
			<p class="em-only_endmatter-idx3">acute-&#173;onset, 388–390, 390<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">bleb-&#173;associated, 390–391, 391<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">chronic (delayed-&#173;onset), 390, 391<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">retained lens fragments &#173;after phacoemulsification treated with, 391–393, 392<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">rhegmatogenous ret&#173;i&#173;nal detachment treated with, 400<span class="italic">f,</span> 400–401</p>
			<p class="em-only_endmatter-idx2">submacular hemorrhage treated with, 385, 386<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">suprachoroidal hemorrhage treated with, 394–395, 395<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">technique for, 381</p>
			<p class="em-only_endmatter-idx2">tractional ret&#173;i&#173;nal detachment treated with, 387–388</p>
			<p class="em-only_endmatter-idx2">vitreous opacities treated with, 386</p>
			<p class="em-only_endmatter-idx1">Pars planitis, 231</p>
			<p class="em-only_endmatter-idx1">Patellar fossa, 7</p>
			<p class="em-only_endmatter-idx1">Pathologic (high) myopia</p>
			<p class="em-only_endmatter-idx2">chorioret&#173;i&#173;nal atrophy in, 214<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">choroidal neovascularization in, 89, 90<span class="italic">f,</span> 211<span class="italic">f,</span> 211–212</p>
			<p class="em-only_endmatter-idx2">choroid in, 212–216, 214<span class="italic">–&#173;</span>215<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">definition of, 207</p>
			<p class="em-only_endmatter-idx2">&#173;factors associated with, 207</p>
			<p class="em-only_endmatter-idx2">glaucoma in, 218, 218<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">global prevalence of, 207</p>
			<p class="em-only_endmatter-idx2">macular holes in, 209</p>
			<p class="em-only_endmatter-idx2">ocular expansion related to, 216</p>
			<p class="em-only_endmatter-idx2">optic nerve in, 217–218, 218<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">prevalence of, 207</p>
			<p class="em-only_endmatter-idx2">prevention of, 207–208</p>
			<p class="em-only_endmatter-idx2">ret&#173;ina in, 207–216, 209<span class="italic">–&#173;</span>215</p>
			<p class="em-only_endmatter-idx2">sclera in, 216–217, 217<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">swept-&#173;source optical coherence tomography of, 209<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">traction effects on ret&#173;i&#173;nal vessels in, 209</p>
			<p class="em-only_endmatter-idx1">Pattern-&#173;appearance stimulation, of visual evoked potentials, 53</p>
			<p class="em-only_endmatter-idx1">Pattern dystrophies, 67, 272, 276<span class="italic">f,</span> 276–277</p>
			<p class="em-only_endmatter-idx1">Pattern electroretinography (PERG), 45–46, 46<span class="italic">–&#173;</span>49<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Pattern-&#173;reversal visual evoked potential, 52, 53<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Patton lines, 201</p>
			<p class="em-only_endmatter-idx1">Paving-&#173;stone degeneration, 313, 314<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">PCIOLs. <span class="italic">See</span> Posteriorly dislocated intraocular lenses</p>
			<p class="em-only_endmatter-idx1">PCV. <span class="italic">See</span> Polypoidal choroidal vasculopathy</p>
			<p class="em-only_endmatter-idx1">PDR. <span class="italic">See</span> Proliferative diabetic retinopathy</p>
			<p class="em-only_endmatter-idx1">PDT. <span class="italic">See</span> Photodynamic therapy</p>
			<p class="em-only_endmatter-idx1">Peau d’orange, 87, 89<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">PED. <span class="italic">See</span> Pigment epithelial detachments</p>
			<p class="em-only_endmatter-idx1">Pegaptanib, for neovascular age-&#173;related macular degeneration, 80</p>
			<p class="em-only_endmatter-idx1">Pelizaeus-&#173;Merzbacher disease, 283<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Pelli-&#173;Robson test, 56–57, 57<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Penetrating ocular injury, sympathetic ophthalmia secondary to, 233. <span class="italic">See also</span> Trauma</p>
			<p class="em-only_endmatter-idx1">Perfluorocarbon (C<span class="CharOverride-1">3</span>F<span class="CharOverride-1">8</span>), 382</p>
			<p class="em-only_endmatter-idx1">Perfluoropropane, 382, 401</p>
			<p class="em-only_endmatter-idx1">PERG. <span class="italic">See</span> Pattern electroretinography</p>
			<p class="em-only_endmatter-idx1">Pericytes, 93</p>
			<p class="em-only_endmatter-idx1">Perifovea</p>
			<p class="em-only_endmatter-idx2">characteristics of, 10<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">definition of, 9</p>
			<p class="em-only_endmatter-idx1">Perifoveal macula, 9<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Peripapillary intrachoroidal cavitations, 215, 215<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Peripheral cystoid degeneration</p>
			<p class="em-only_endmatter-idx2">description of, 314</p>
			<p class="em-only_endmatter-idx2">reticular, 326</p>
			<p class="em-only_endmatter-idx2">typical, 326</p>
			<p class="em-only_endmatter-idx1">Peripheral granuloma, in toxocariasis, 244, 245<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Peripheral neovascularization, vitreous hemorrhage associated with, 232</p>
			<p class="em-only_endmatter-idx1">Peripheral ret&#173;i&#173;na</p>
			<p class="em-only_endmatter-idx2">definition of, 10</p>
			<p class="em-only_endmatter-idx2">excavations, 312–313</p>
			<p class="em-only_endmatter-idx1">Peripheral ret&#173;i&#173;nal neovascularization, 154<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Peripheral vitreous, 7</p>
			<p class="em-only_endmatter-idx1">Periphlebitis, in cytomegalovirus retinitis, 235</p>
			<p class="em-only_endmatter-idx1">Peroxisomal disorders, 290</p>
			<p class="em-only_endmatter-idx1">Per&#173;sis&#173;tent fetal vasculature (PFV), 341–342</p>
			<p class="em-only_endmatter-idx1">Phacoemulsification, vitrectomy for retained lens fragments &#173;after, 391–393, 392<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Phagocytosis</p>
			<p class="em-only_endmatter-idx2">of outer segments, 17</p>
			<p class="em-only_endmatter-idx2">pathologic changes that affect, 17</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium cell, 17</p>
			<p class="em-only_endmatter-idx1">Phakomatoses</p>
			<p class="em-only_endmatter-idx2">definition of, 165</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal cavernous hemangioma, 168, 169<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">von Hippel–&#173;Lindau syndrome, 165–168, 166<span class="italic">–&#173;</span>167<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">Wyburn-&#173;Mason syndrome, 168</p>
			<p class="em-only_endmatter-idx1">Pharmacogenomic testing, for age-&#173;related macular degeneration, 63</p>
			<p class="em-only_endmatter-idx1">Phenothiazines, 297–298, 298<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Phosphodiesterase-5 inhibitors, 304</p>
			<p class="em-only_endmatter-idx1">Photic damage, 367–369, 368<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Photochemical injury, 367</p>
			<p class="em-only_endmatter-idx1">Photocoagulation</p>
			<p class="em-only_endmatter-idx2">anesthesia for, 375</p>
			<p class="em-only_endmatter-idx2">Bruch membrane rupture caused by, 378</p>
			<p class="em-only_endmatter-idx2">choroidal detachment caused by, 379, 379<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">clinically significant diabetic macular edema treated with, 110</p>
			<p class="em-only_endmatter-idx2">Coats disease treated with, 161</p>
			<p class="em-only_endmatter-idx2">complications of, 378–379</p>
			<p class="em-only_endmatter-idx2">diabetic macular edema treated with, 376</p>
			<p class="em-only_endmatter-idx2">Early Treatment Diabetic Retinopathy Study findings for, 100</p>
			<p class="em-only_endmatter-idx2">exudative ret&#173;i&#173;nal detachment caused by, 379</p>
			<p class="em-only_endmatter-idx2">&#173;factors that affect, 373</p>
			<p class="em-only_endmatter-idx2">foveal burns caused by, 378</p>
			<p class="em-only_endmatter-idx2">indications for, 375–377</p>
			<p class="em-only_endmatter-idx2">&#173;lasers used in</p>
			<p class="em-only_endmatter-idx3">alternative systems, 377–378</p>
			<p class="em-only_endmatter-idx3">wavelength of, 373–375</p>
			<p class="em-only_endmatter-idx2">lenses for, 375, 376<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">macular applications of, 375–376</p>
			<p class="em-only_endmatter-idx2">neovascular age-&#173;related macular degeneration treated with, 79</p>
			<p class="em-only_endmatter-idx2">par&#173;ameters for, 375–377</p>
			<p class="em-only_endmatter-idx2">princi&#173;ples of, 373–379</p>
			<p class="em-only_endmatter-idx2">proliferative diabetic retinopathy treated with</p>
			<p class="em-only_endmatter-idx3">description of, 104</p>
			<p class="em-only_endmatter-idx3">in pregnancy, 94</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal arterial macroaneurysms treated with, 147</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal cavernous hemangioma treated with, 168</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal holes caused by, 378</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal lesions caused by, 378–379</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal vascular lesions treated with, 377</p>
			<p class="em-only_endmatter-idx2">retinopathy of prematurity treated with, 186<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">slit-&#173;lamp delivery systems, 377</p>
			<p class="em-only_endmatter-idx2">vitreous hemorrhage caused by, 379</p>
			<p class="em-only_endmatter-idx2">von Hippel–&#173;Lindau syndrome treated with, 167</p>
			<p class="em-only_endmatter-idx1">Photodynamic therapy (PDT). <span class="italic">See also</span> Verteporfin</p>
			<p class="em-only_endmatter-idx2">applications of, 380</p>
			<p class="em-only_endmatter-idx2">central serous chorioretinopathy treated with, 194</p>
			<p class="em-only_endmatter-idx2">choroidal neovascularization treated with, 212, 213<span class="italic">f,</span> <br />380</p>
			<p class="em-only_endmatter-idx2">complications of, 380</p>
			<p class="em-only_endmatter-idx2">half-&#173;fluence, 380</p>
			<p class="em-only_endmatter-idx2">neovascular age-&#173;related macular degeneration <br />treated with, 79</p>
			<p class="em-only_endmatter-idx2">photosensitivity reactions caused by, 380</p>
			<p class="em-only_endmatter-idx2">polypoidal choroidal vasculopathy treated with, 76</p>
			<p class="em-only_endmatter-idx2">ranibizumab added to, 85</p>
			<p class="em-only_endmatter-idx2">steps involved in, 380</p>
			<p class="em-only_endmatter-idx2">von Hippel–&#173;Lindau syndrome treated with, 167</p>
			<p class="em-only_endmatter-idx1">Photophobia, 46, 264</p>
			<p class="em-only_endmatter-idx1">Photopsias. <span class="italic">See also</span> Floaters</p>
			<p class="em-only_endmatter-idx2">electroretinography findings in, 46</p>
			<p class="em-only_endmatter-idx2">in posterior vitreous detachment, 308</p>
			<p class="em-only_endmatter-idx2">in rhegmatogenous ret&#173;i&#173;nal detachment, 320</p>
			<p class="em-only_endmatter-idx1">Photoreceptor(s)</p>
			<p class="em-only_endmatter-idx2">age-&#173;related changes in, 61</p>
			<p class="em-only_endmatter-idx2">cone. <span class="italic">See</span> Cone(s)</p>
			<p class="em-only_endmatter-idx2">density of, 11</p>
			<p class="em-only_endmatter-idx2">distribution of, 11</p>
			<p class="em-only_endmatter-idx2">drusen effects on, 64</p>
			<p class="em-only_endmatter-idx2">iron damage to, 362</p>
			<p class="em-only_endmatter-idx2">rod. <span class="italic">See</span> Rod(s)</p>
			<p class="em-only_endmatter-idx2">as waveguides, 33</p>
			<p class="em-only_endmatter-idx1">Photoreceptor dystrophies</p>
			<p class="em-only_endmatter-idx2">cone, 264–265</p>
			<p class="em-only_endmatter-idx2">cone–&#173;rod, 264–265</p>
			<p class="em-only_endmatter-idx2">rod–&#173;cone, 261–264, 262<span class="italic">–&#173;</span>264<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Phototoxicity from ophthalmic instrumentation, 368–369</p>
			<p class="em-only_endmatter-idx1">PHP. <span class="italic">See</span> Preferential hyperacuity perimetry</p>
			<p class="em-only_endmatter-idx1">PIC. <span class="italic">See</span> Punctate inner choroiditis</p>
			<p class="em-only_endmatter-idx1">PIER study, 80</p>
			<p class="em-only_endmatter-idx1">Pigmented paravenous retinopathy, 263</p>
			<p class="em-only_endmatter-idx1">Pigment epithelial detachments (PEDs)</p>
			<p class="em-only_endmatter-idx2">definition of, 64</p>
			<p class="em-only_endmatter-idx2">drusenoid, 64, 272, 274<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">fibrovascular</p>
			<p class="em-only_endmatter-idx3">anti-&#173;VEGF therapy for, 201<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">description of, 72–73</p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal pigment epithelial tear risks, 82</p>
			<p class="em-only_endmatter-idx2">in hypertensive choroidopathy, 123</p>
			<p class="em-only_endmatter-idx2">optical coherence tomography of, 74<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">serous, 72–73, 74<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">subfoveal, 74<span class="italic">–&#173;</span>75<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Pigment granules, 348</p>
			<p class="em-only_endmatter-idx1">Pigments, in ret&#173;i&#173;nal pigment epithelium, 12<span class="italic">f,</span> 17</p>
			<p class="em-only_endmatter-idx1">Pioglitazone, 301</p>
			<p class="em-only_endmatter-idx1">Planoconcave lenses, 375</p>
			<p class="em-only_endmatter-idx1">Plus disease, 176–177, 176<span class="italic">t</span>, 178<span class="italic">f</span>, 178<span class="italic">t</span>, 179, 179<span class="italic">f</span>, 184t, 186, 186<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Pneumatic displacement, 85</p>
			<p class="em-only_endmatter-idx1">Pneumatic retinopexy, for rhegmatogenous ret&#173;i&#173;nal detachment, 324, 397–398, 398<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">POHS. <span class="italic">See</span> Presumed ocular histoplasmosis syndrome</p>
			<p class="em-only_endmatter-idx1">Polypoidal choroidal vasculopathy (PCV)</p>
			<p class="em-only_endmatter-idx2">central serous chorioretinopathy versus, 193</p>
			<p class="em-only_endmatter-idx2">clinical pre&#173;sen&#173;ta&#173;tion of, 75</p>
			<p class="em-only_endmatter-idx2">definition of, 75</p>
			<p class="em-only_endmatter-idx2">indocyanine green angiography for, 38, 38<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">subret&#173;i&#173;nal hemorrhage associated with, 76</p>
			<p class="em-only_endmatter-idx2">verteporfin for, 76</p>
			<p class="em-only_endmatter-idx1">Pooling, fluorescein, 35, 36<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">PORN. <span class="italic">See</span> Progressive outer retinal necrosis</p>
			<p class="em-only_endmatter-idx1">Positron emission tomography, of uveal lymphoma, 234</p>
			<p class="em-only_endmatter-idx1">Posterior capsular opacification, 260</p>
			<p class="em-only_endmatter-idx1">Posterior chamber intraocular lenses (PCIOLs), 393</p>
			<p class="em-only_endmatter-idx1">Posterior ciliary arteries</p>
			<p class="em-only_endmatter-idx2">anatomy of, 195<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">choroid blood supply from, 19, 20<span class="italic">f,</span> 195<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Posterior per&#173;sis&#173;tent fetal vasculature, 342</p>
			<p class="em-only_endmatter-idx1">Posterior pole granuloma, 245</p>
			<p class="em-only_endmatter-idx1">Posterior segment</p>
			<p class="em-only_endmatter-idx2">anterior segment surgery complications of, vitrectomy for, 388–396</p>
			<p class="em-only_endmatter-idx2">Beh<span class="accent">ç</span>et disease involvement of, 230</p>
			<p class="em-only_endmatter-idx2">blunt trauma to, 353</p>
			<p class="em-only_endmatter-idx2">&#173;laser effects on, 374</p>
			<p class="em-only_endmatter-idx1">Posterior uveal bleeding syndrome, 75</p>
			<p class="em-only_endmatter-idx1">Posterior uveitis</p>
			<p class="em-only_endmatter-idx2">electroretinography findings in, 44</p>
			<p class="em-only_endmatter-idx2">intermediate uveitis, 231</p>
			<p class="em-only_endmatter-idx1">Posterior vitreoschisis, 332–333</p>
			<p class="em-only_endmatter-idx1">Posterior vitreous detachment (PVD)</p>
			<p class="em-only_endmatter-idx2">age-&#173;related, 307–308</p>
			<p class="em-only_endmatter-idx2">anatomy of, 331</p>
			<p class="em-only_endmatter-idx2">atrophic holes presenting with, 318</p>
			<p class="em-only_endmatter-idx2">cholesterolosis and, 348</p>
			<p class="em-only_endmatter-idx2">conditions associated with, 307</p>
			<p class="em-only_endmatter-idx2">definition of, 331</p>
			<p class="em-only_endmatter-idx2">diagnosis of, 331</p>
			<p class="em-only_endmatter-idx2">epiret&#173;i&#173;nal membranes. <span class="italic">See</span> Epiret&#173;i&#173;nal membranes (ERM)</p>
			<p class="em-only_endmatter-idx2">examination of, 309</p>
			<p class="em-only_endmatter-idx2">fibroglial tissue in, 331</p>
			<p class="em-only_endmatter-idx2">floaters associated with, 308–309</p>
			<p class="em-only_endmatter-idx2">idiopathic macular holes, 337–339, 338<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">imaging of, 308<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">indirect ophthalmoscopy of, 309, 331</p>
			<p class="em-only_endmatter-idx2">management of, 309</p>
			<p class="em-only_endmatter-idx2">myopia macular retinoschisis in, 209</p>
			<p class="em-only_endmatter-idx2">nonproliferative diabetic retinopathy progression affected by, 102</p>
			<p class="em-only_endmatter-idx2">optical coherence tomography of, 309, 332</p>
			<p class="em-only_endmatter-idx2">in pars plana vitrectomy for diabetic macular <br />edema, 115</p>
			<p class="em-only_endmatter-idx2">pathologic conditions caused by, 332</p>
			<p class="em-only_endmatter-idx2">photopsias associated with, 308</p>
			<p class="em-only_endmatter-idx2">prevalence of, 331</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal breaks associated with, 309</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal tears caused by, 307, 308<span class="italic">f,</span> <br />309</p>
			<p class="em-only_endmatter-idx2">risk &#173;factors for, 309</p>
			<p class="em-only_endmatter-idx2">signs and symptoms of, 308</p>
			<p class="em-only_endmatter-idx2">slit-&#173;lamp biomicroscopy of, 331</p>
			<p class="em-only_endmatter-idx2">vitrectomy for, 333<span class="italic">f,</span> 359</p>
			<p class="em-only_endmatter-idx2">vitreomacular adhesions, 336, 336<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">vitreomacular traction syndrome, 332, 332<span class="italic">f,</span> 336<span class="italic">t,</span> 336–337, 337<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">vitreous hemorrhage associated with, 309</p>
			<p class="em-only_endmatter-idx1">Postoperative endophthalmitis, 388–391, 390<span class="italic">–&#173;</span>391<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Posttraumatic endophthalmitis, 362–363</p>
			<p class="em-only_endmatter-idx1">Precortical vitreous pocket, 7, 8<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Prednisone, for herpetic retinitis, 238<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Preeclampsia, 197<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Preferential hyperacuity perimetry (PHP), 69</p>
			<p class="em-only_endmatter-idx1">Pregnancy</p>
			<p class="em-only_endmatter-idx2">diabetic retinopathy in</p>
			<p class="em-only_endmatter-idx3">progression of, 93–94</p>
			<p class="em-only_endmatter-idx3">proliferative, 94</p>
			<p class="em-only_endmatter-idx2">fluorescein angiography in, 36</p>
			<p class="em-only_endmatter-idx2"><span class="italic">Toxoplasma gondii</span> exposure, 243</p>
			<p class="em-only_endmatter-idx2">Zika virus exposure during, 247</p>
			<p class="em-only_endmatter-idx1">Premacular bursa, 7, 8<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Prepapillary vascular loops, 341, 341<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Preret&#173;i&#173;nal macular fibrosis, 335</p>
			<p class="em-only_endmatter-idx1">Preret&#173;i&#173;nal tract, 7</p>
			<p class="em-only_endmatter-idx1">Presumed ocular histoplasmosis syndrome (POHS), 87</p>
			<p class="em-only_endmatter-idx1">Prethreshold disease (retinopathy of prematurity), 178<span class="italic">t,</span> 179, 185</p>
			<p class="em-only_endmatter-idx1">Primary vitreoret&#173;i&#173;nal lymphoma, 233–234</p>
			<p class="em-only_endmatter-idx1">Procainamide, 300</p>
			<p class="em-only_endmatter-idx1">Progressive outer ret&#173;i&#173;nal necrosis (PORN) syndrome, 236–237, 237<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Projection artifact, 29, 30<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Proliferative diabetic retinopathy (PDR)</p>
			<p class="em-only_endmatter-idx2">anti-&#173;VEGF therapy for, 103–104, 386</p>
			<p class="em-only_endmatter-idx2">complications of, 103–108</p>
			<p class="em-only_endmatter-idx2">definition of, 91–92</p>
			<p class="em-only_endmatter-idx2">description of, 91–92</p>
			<p class="em-only_endmatter-idx2">extraret&#173;i&#173;nal fibrovascular proliferation associated with, 102</p>
			<p class="em-only_endmatter-idx2">high-&#173;risk characteristics of, 103</p>
			<p class="em-only_endmatter-idx2">&#173;laser surgery for, 104–107</p>
			<p class="em-only_endmatter-idx2">management of, 103–108</p>
			<p class="em-only_endmatter-idx2">neovascular proliferation associated with, 102</p>
			<p class="em-only_endmatter-idx2">neovascularization in, 151</p>
			<p class="em-only_endmatter-idx2">nonproliferative diabetic retinopathy progression <br />to, 101</p>
			<p class="em-only_endmatter-idx2">nonsurgical management of, 103–104</p>
			<p class="em-only_endmatter-idx2">optical coherence tomography angiography of, 94<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">panret&#173;i&#173;nal photocoagulation for, 104, 106, 106<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">photocoagulation for, 94</p>
			<p class="em-only_endmatter-idx2">in pregnancy, 94</p>
			<p class="em-only_endmatter-idx2">proangiogenic &#173;factors in, 102</p>
			<p class="em-only_endmatter-idx2">proliferative sickle cell retinopathy versus, 151</p>
			<p class="em-only_endmatter-idx2">ranibizumab for, 104</p>
			<p class="em-only_endmatter-idx2">scatter photocoagulation for, 116</p>
			<p class="em-only_endmatter-idx2">severe carotid artery occlusive disease associated with, 98</p>
			<p class="em-only_endmatter-idx2">severity of, 95<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">stages of, 102</p>
			<p class="em-only_endmatter-idx2">ste&#173;roids for, 103–104</p>
			<p class="em-only_endmatter-idx2">surgical management of, 104–107</p>
			<p class="em-only_endmatter-idx2">tractional ret&#173;i&#173;nal detachment caused by, 103, 108, 387–388</p>
			<p class="em-only_endmatter-idx2">vitreous hemorrhage caused by, 103, 103<span class="italic">f,</span> 107–108, 386–387</p>
			<p class="em-only_endmatter-idx1">Proliferative vitreoretinopathy (PVR), 320, 323<span class="italic">f,</span> 323<span class="italic">t,</span> 323–324</p>
			<p class="em-only_endmatter-idx1"><span class="italic">Propionibacterium acnes,</span> 390</p>
			<p class="em-only_endmatter-idx1">Protanomalous dichromatism, 250<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Protanomalous trichromatism, 250<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Protan red-&#173;green color deficiency, 54</p>
			<p class="em-only_endmatter-idx1">Protein C deficiency, 134</p>
			<p class="em-only_endmatter-idx1">Protein S deficiency, 134</p>
			<p class="em-only_endmatter-idx1">PRP. <span class="italic">See</span> Panret&#173;i&#173;nal photocoagulation</p>
			<p class="em-only_endmatter-idx1"><span class="italic">PRPH2</span> gene, 272, 273<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Pseudodrusen</p>
			<p class="em-only_endmatter-idx2">characteristics of, 200, 200<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">imaging of, 200</p>
			<p class="em-only_endmatter-idx2">in pseudoxanthoma elasticum, 198</p>
			<p class="em-only_endmatter-idx2">reticular, 65<span class="italic">f,</span> 65–66</p>
			<p class="em-only_endmatter-idx2">scanning &#173;laser ophthalmoscopy of, 24</p>
			<p class="em-only_endmatter-idx1">Pseudoisochromatic plates, for color vision testing, <br />54, 55<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Pseudophakia, ret&#173;i&#173;nal detachment risks associated with, 319</p>
			<p class="em-only_endmatter-idx1">Pseudophakic cystoid macular edema</p>
			<p class="em-only_endmatter-idx2">definition of, 157</p>
			<p class="em-only_endmatter-idx2">imaging of, 394<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">optical coherence tomography of, 158<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">pars plana vitrectomy for, 394<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Pseudo-&#173;POHS. <span class="italic">See</span> Pseudo-&#173;presumed ocular histoplasmosis syndrome</p>
			<p class="em-only_endmatter-idx1">Pseudo-&#173;presumed ocular histoplasmosis syndrome (pseudo-&#173;POHS), 225</p>
			<p class="em-only_endmatter-idx1">Pseudoxanthoma elasticum (PXE)</p>
			<p class="em-only_endmatter-idx2">angioid streaks and, 87, 89<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">Bruch membrane calcification in, 19</p>
			<p class="em-only_endmatter-idx2">optical coherence tomographic angiography of, <br />199<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">pseudodrusen in, 198</p>
			<p class="em-only_endmatter-idx1">Psychophysical testing</p>
			<p class="em-only_endmatter-idx2">color vision, 54–56, 55<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">contrast sensitivity, 56–57, 57<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">dark adaptometry, 57–58</p>
			<p class="em-only_endmatter-idx2">tests used in, 53–54</p>
			<p class="em-only_endmatter-idx1">Punctate inner choroiditis (PIC), 225</p>
			<p class="em-only_endmatter-idx1">Pupillary-&#173;block glaucoma, in retinopathy of prematurity, 181</p>
			<p class="em-only_endmatter-idx1">Purtscher flecken, 171</p>
			<p class="em-only_endmatter-idx1">Purtscherlike retinopathy, 171–173, 172<span class="italic">f,</span> 173<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Purtscher retinopathy, 171–173, 173<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">PVD. <span class="italic">See</span> Posterior vitreous detachment</p>
			<p class="em-only_endmatter-idx1">PVR. <span class="italic">See</span> Proliferative vitreoretinopathy</p>
			<p class="em-only_endmatter-idx1">PXE. <span class="italic">See</span> Pseudoxanthoma elasticum</p>
			<p class="em-only_endmatter-idx-alpha">Qua&#173;dru&#173;ple therapy, for toxoplasmic <br />retinochoroiditis, 243</p>
			<p class="em-only_endmatter-idx1">Quinine, 301</p>
			<p class="em-only_endmatter-idx-alpha">Raccoons, 246</p>
			<p class="em-only_endmatter-idx1">Race</p>
			<p class="em-only_endmatter-idx2">age-&#173;related macular degeneration and, 62</p>
			<p class="em-only_endmatter-idx2">polypoidal choroidal vasculopathy and, 75</p>
			<p class="em-only_endmatter-idx2">sickle cell hemoglobinopathies and, 149, 154</p>
			<p class="em-only_endmatter-idx2">systemic lupus erythematosus and, 230</p>
			<p class="em-only_endmatter-idx2">Vogt-&#173;Koyanagi-&#173;Harada disease and, 232</p>
			<p class="em-only_endmatter-idx1">Radial peripapillary capillary network, 16</p>
			<p class="em-only_endmatter-idx1">Radiation</p>
			<p class="em-only_endmatter-idx2">ionizing, retinopathy caused by exposure to, 170<span class="italic">f,</span> 170–171</p>
			<p class="em-only_endmatter-idx2">primary vitreoret&#173;i&#173;nal lymphoma treated with, 234</p>
			<p class="em-only_endmatter-idx1">Radiation retinopathy, 170<span class="italic">f,</span> 170–171</p>
			<p class="em-only_endmatter-idx1">Ranibizumab</p>
			<p class="em-only_endmatter-idx2">bevacizumab and, comparison between, 83, 84<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">branch ret&#173;i&#173;nal vein occlusion treated with, 135</p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal vein occlusion treated with, 135</p>
			<p class="em-only_endmatter-idx2">clinical &#173;trials of, 82<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">diabetic macular edema treated with, 111–112, 112<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">diabetic retinopathy treated with, 102</p>
			<p class="em-only_endmatter-idx2">neovascular age-&#173;related macular degeneration treated with, 80–82, 82<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">photodynamic therapy and, 85</p>
			<p class="em-only_endmatter-idx2">proliferative diabetic retinopathy treated with, 104</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal vein occlusion treated with, 135</p>
			<p class="em-only_endmatter-idx1"><span class="italic">R9AP</span> gene, 49</p>
			<p class="em-only_endmatter-idx1">Rapid plasma reagin (RPR) test, 241</p>
			<p class="em-only_endmatter-idx1">RAPs. <span class="italic">See</span> Ret&#173;i&#173;nal angiomatous proliferations</p>
			<p class="em-only_endmatter-idx1"><span class="italic">RDH5</span> gene, 252</p>
			<p class="em-only_endmatter-idx1">Red-&#173;green color deficiency</p>
			<p class="em-only_endmatter-idx2">anomaloscope of, 54</p>
			<p class="em-only_endmatter-idx2">types of, 54</p>
			<p class="em-only_endmatter-idx1">Red &#173;laser, 374</p>
			<p class="em-only_endmatter-idx1">Refsum disease, 283<span class="italic">t,</span> 286, 290</p>
			<p class="em-only_endmatter-idx1">Renal diseases, ret&#173;i&#173;nal degeneration associated with, 285</p>
			<p class="em-only_endmatter-idx1">Retained lens fragments &#173;after phacoemulsification, 391–393, 392<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Reticular degenerative retinoschisis, 326–327</p>
			<p class="em-only_endmatter-idx1">Reticular peripheral cystoid degeneration, 326</p>
			<p class="em-only_endmatter-idx1">Reticular pseudodrusen, 65<span class="italic">f,</span> 65–66</p>
			<p class="em-only_endmatter-idx1">Reticular-&#173;type pattern dystrophy, 276, 276<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Reticulum cell sarcoma. <span class="italic">See</span> Primary vitreoret&#173;i&#173;nal lymphoma</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;na</p>
			<p class="em-only_endmatter-idx2">angiomas of, 168</p>
			<p class="em-only_endmatter-idx2">blood supply to, 140</p>
			<p class="em-only_endmatter-idx2">circulation of, 16<span class="italic">f,</span> 16–17</p>
			<p class="em-only_endmatter-idx2">drug-&#173;induced toxicity of</p>
			<p class="em-only_endmatter-idx3">alkyl nitrites, 300, 300<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">chloroquine derivatives, 295–297, 296<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">clofazimine, 298</p>
			<p class="em-only_endmatter-idx3">deferoxamine, 298–299</p>
			<p class="em-only_endmatter-idx3">dideoxyinosine, 299</p>
			<p class="em-only_endmatter-idx3">hydroxychloroquine, 295–297, 296<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">MEK inhibitors, 299, 299<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">nucleoside reverse transcriptase inhibitors, 299</p>
			<p class="em-only_endmatter-idx3">phenothiazines, 297–298, 298<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">electro-&#173;oculography of, 50–51, 51<span class="italic">–&#173;</span>52<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">electrophysiologic testing of, 41–42</p>
			<p class="em-only_endmatter-idx2">electroretinography of. <span class="italic">See</span> Electroretinography (ERG)</p>
			<p class="em-only_endmatter-idx2">equatorial, 9–10</p>
			<p class="em-only_endmatter-idx2">hemangioblastomas of, in von Hippel–&#173;Lindau syndrome, 165–166, 166<span class="italic">f,</span> 168</p>
			<p class="em-only_endmatter-idx2">inflammation of</p>
			<p class="em-only_endmatter-idx3">acute ret&#173;i&#173;nal necrosis, 236, 236<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">cat-&#173;scratch disease, 242–243, 243<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">cytomegalovirus retinitis, 235–236</p>
			<p class="em-only_endmatter-idx3">diffuse unilateral subacute neuroretinitis, 246</p>
			<p class="em-only_endmatter-idx3">endogenous bacterial endophthalmitis, 237–239, 238<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">fungal endophthalmitis, 239, 239<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">infectious &#173;causes, 235–247</p>
			<p class="em-only_endmatter-idx3">Lyme disease, 245–246</p>
			<p class="em-only_endmatter-idx3">necrotizing herpetic retinitis, 236–237, 236<span class="italic">–&#173;</span>237<span class="italic">f,</span> 238<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">noninfectious &#173;causes, 219–234</p>
			<p class="em-only_endmatter-idx3">progressive outer ret&#173;i&#173;nal necrosis syndrome, 236–237, 237<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">syphilitic chorioretinitis, 241–242, 242<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">toxocariasis, 244–245, 245<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">toxoplasmic retinochoroiditis, 243–244, 244<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">tuberculosis, 240–241, 241<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">West Nile virus chorioretinitis, 246, 247<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">white dot syndromes as cause of. <span class="italic">See</span> White dot syndromes</p>
			<p class="em-only_endmatter-idx3">yeast endophthalmitis, 239–240, 240<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">layers of</p>
			<p class="em-only_endmatter-idx3">blood supply to, 140</p>
			<p class="em-only_endmatter-idx3">external limiting membrane, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">ganglion cell layer, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">Henle fiber layer, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">imaging of, 10–11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">inner nuclear layer, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">inner plexiform layer, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">internal limiting membrane, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">&#173;middle limiting membrane, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">nerve fiber layer, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">optical coherence tomography angiography of, 29</p>
			<p class="em-only_endmatter-idx3">outer nuclear layer, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">outer plexiform layer, 11, 12<span class="italic">f,</span> 16</p>
			<p class="em-only_endmatter-idx3">oxygen supply to, 16</p>
			<p class="em-only_endmatter-idx2">lesions of, 378–379</p>
			<p class="em-only_endmatter-idx2">light-&#173;related injury to, 367</p>
			<p class="em-only_endmatter-idx2">metabolic needs of, 20</p>
			<p class="em-only_endmatter-idx2">neurosensory, 9–17</p>
			<p class="em-only_endmatter-idx2">noninfectious inflammation of</p>
			<p class="em-only_endmatter-idx3">acute idiopathic maculopathy, 228–229</p>
			<p class="em-only_endmatter-idx3">acute macular neuroretinopathy, 228, 229<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">acute zonal occult outer retinopathy, 226–228, <br />227<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">white dot syndromes. <span class="italic">See</span> White dot syndromes</p>
			<p class="em-only_endmatter-idx2">oxygen supply to, 16<span class="italic">f,</span> 16–17</p>
			<p class="em-only_endmatter-idx2">in pathologic myopia, 207–216, 209<span class="italic">–&#173;</span>215<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">peripheral, 10</p>
			<p class="em-only_endmatter-idx2">psychophysical testing of. <span class="italic">See</span> Psychophysical testing</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium separation of, 17</p>
			<p class="em-only_endmatter-idx2">surface of, in exudative ret&#173;i&#173;nal detachment, 326</p>
			<p class="em-only_endmatter-idx2">thickness of, in pathologic myopia, 208</p>
			<p class="em-only_endmatter-idx2">topography of, 9<span class="italic">f,</span> 9–10</p>
			<p class="em-only_endmatter-idx2">vascularization of, 180</p>
			<p class="em-only_endmatter-idx2">vascular occlusion of, 231</p>
			<p class="em-only_endmatter-idx2">vasculature of, 16<span class="italic">f,</span> 16–17</p>
			<p class="em-only_endmatter-idx2">vasculature of, optical coherence tomography angiography of, 29, 30<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">venous pressure in, 125</p>
			<p class="em-only_endmatter-idx2">visual evoked cortical potentials of, 52–53</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal angiomatous proliferations (RAPs), 72, 78<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal arterial macroaneurysms, 147–148, 148<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal artery occlusion</p>
			<p class="em-only_endmatter-idx2">branch. <span class="italic">See</span> Branch ret&#173;i&#173;nal artery occlusion (BRAO)</p>
			<p class="em-only_endmatter-idx2">capillary ret&#173;i&#173;nal arteriole obstruction, 140<span class="italic">f,</span> 140–141</p>
			<p class="em-only_endmatter-idx2">central. <span class="italic">See</span> Central ret&#173;i&#173;nal artery occlusion (CRAO)</p>
			<p class="em-only_endmatter-idx2">cilioret&#173;i&#173;nal artery occlusion, 143</p>
			<p class="em-only_endmatter-idx2">ophthalmic artery occlusion, 146, 147<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">paracentral acute &#173;middle maculopathy, 143</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal breaks</p>
			<p class="em-only_endmatter-idx2">aphakia and, 319</p>
			<p class="em-only_endmatter-idx2">asymptomatic, 318</p>
			<p class="em-only_endmatter-idx2">classification of, 315</p>
			<p class="em-only_endmatter-idx2">cryotherapy of, as prophylactic treatment, 317</p>
			<p class="em-only_endmatter-idx2">definition of, 314</p>
			<p class="em-only_endmatter-idx2">description of, 396</p>
			<p class="em-only_endmatter-idx2">lattice degeneration and, 310</p>
			<p class="em-only_endmatter-idx2">Lincoff rules for finding, 320, 322<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">posterior vitreous detachment and, 309</p>
			<p class="em-only_endmatter-idx2">prophylactic treatment of, 317<span class="italic">t,</span> 317–320</p>
			<p class="em-only_endmatter-idx2">pseudophakia and, 319</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal detachment caused by</p>
			<p class="em-only_endmatter-idx3">illustration of, 318<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">prophylactic treatment to prevent, 317<span class="italic">t,</span> 317–320</p>
			<p class="em-only_endmatter-idx3">rhegmatogenous, 314–315, 320, 322<span class="italic">f,</span> 324</p>
			<p class="em-only_endmatter-idx2">significance of, 314</p>
			<p class="em-only_endmatter-idx2">symptomatic, 318</p>
			<p class="em-only_endmatter-idx2">traumatic, 315–316, 316<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">vitreoret&#173;i&#173;nal traction as cause of, 315</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal capillaries</p>
			<p class="em-only_endmatter-idx2">nonperfusion of, in diabetic retinopathy, 101</p>
			<p class="em-only_endmatter-idx2">perifoveal, 157</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal degeneration</p>
			<p class="em-only_endmatter-idx2">amino acid disorders that cause, 293</p>
			<p class="em-only_endmatter-idx2">autoimmune &#173;causes of, 286–287</p>
			<p class="em-only_endmatter-idx2">cancer-&#173;associated retinopathy as cause of, 286, 287<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">dental diseases associated with, 286</p>
			<p class="em-only_endmatter-idx2">dermatologic diseases associated with, 286</p>
			<p class="em-only_endmatter-idx2">gastrointestinal diseases associated with, 285–286</p>
			<p class="em-only_endmatter-idx2">liver diseases associated with, 285</p>
			<p class="em-only_endmatter-idx2">melanoma-&#173;associated retinopathy as cause of, 286</p>
			<p class="em-only_endmatter-idx2">metabolic diseases that cause</p>
			<p class="em-only_endmatter-idx3">abetalipoproteinemia, 289–290</p>
			<p class="em-only_endmatter-idx3">albinism, 288</p>
			<p class="em-only_endmatter-idx3">central ner&#173;vous system, 288–292</p>
			<p class="em-only_endmatter-idx3">lysosomal, 291–292, 292<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">mucopolysaccharidoses, 290–291</p>
			<p class="em-only_endmatter-idx3">neuronoid ceroid lipofuscinoses, 289, 290<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">Niemann-&#173;Pick disease, 291</p>
			<p class="em-only_endmatter-idx3">peroxisomal disorders, 290</p>
			<p class="em-only_endmatter-idx3">Refsum disease, 290</p>
			<p class="em-only_endmatter-idx3">Tay-&#173;Sachs disease, 291, 292<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">vitamin A deficiency, 289–290</p>
			<p class="em-only_endmatter-idx3">Zellweger syndrome, 290</p>
			<p class="em-only_endmatter-idx2">mitochondrial disorders that cause, 293–294</p>
			<p class="em-only_endmatter-idx2">neuromuscular disorders associated with, 285</p>
			<p class="em-only_endmatter-idx2">paraneoplastic retinopathies that cause, 286–287</p>
			<p class="em-only_endmatter-idx2">renal diseases associated with, 285</p>
			<p class="em-only_endmatter-idx2">systemic disorders associated with</p>
			<p class="em-only_endmatter-idx3">Bardet-&#173;Biedl syndrome, 281, 282<span class="italic">t,</span> 284, 284<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">Leber congenital amaurosis, 281</p>
			<p class="em-only_endmatter-idx3">list of, 282<span class="italic">–&#173;</span>283<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">overview of, 281</p>
			<p class="em-only_endmatter-idx3">Usher syndrome, 284</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal detachment</p>
			<p class="em-only_endmatter-idx2">&#173;after cataract surgery, 319</p>
			<p class="em-only_endmatter-idx2">central serous chorioretinopathy as cause of, 189, 191</p>
			<p class="em-only_endmatter-idx2">chronic, 324<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">classification of, 320</p>
			<p class="em-only_endmatter-idx2">cobblestone degeneration and, 313, 314<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">diagnostic features of, 320, 321<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">differential diagnosis of</p>
			<p class="em-only_endmatter-idx3">description of, 320</p>
			<p class="em-only_endmatter-idx3">retinoschisis, 326–328</p>
			<p class="em-only_endmatter-idx2">exudative</p>
			<p class="em-only_endmatter-idx3">&#173;causes of, 320</p>
			<p class="em-only_endmatter-idx3">diagnostic features of, 321<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">in familial exudative vitreoretinopathy, 343</p>
			<p class="em-only_endmatter-idx3">imaging of, 325<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">management of, 325–326</p>
			<p class="em-only_endmatter-idx3">photocoagulation as cause of, 379</p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal surface in, 326</p>
			<p class="em-only_endmatter-idx3">subret&#173;i&#173;nal fluid findings in, 326</p>
			<p class="em-only_endmatter-idx2">in fellow eye, 319</p>
			<p class="em-only_endmatter-idx2">lattice degeneration and, 309–311, 310<span class="italic">–&#173;</span>311<span class="italic">f,</span> <br />316<span class="italic">f,</span> 319</p>
			<p class="em-only_endmatter-idx2">lesions not predisposing to, 313–314</p>
			<p class="em-only_endmatter-idx2">lesions predisposing to, 309–312, 310<span class="italic">–&#173;</span>313<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">macular hole as cause of, 330, 330<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">macular lesions associated with, 328–329</p>
			<p class="em-only_endmatter-idx2">management of, 324, 324<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">meridional folds and, 312, 313<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">optic pit maculopathy and, 328–329, 329<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">paving-&#173;stone degeneration and, 313, 314<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">peripheral cystoid degeneration and, 314</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelial hyperplasia and, <br />313–314</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelial hypertrophy and, 314</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal tear progression to, 347</p>
			<p class="em-only_endmatter-idx2">in retinoschisis, 328</p>
			<p class="em-only_endmatter-idx2">rhegmatogenous (RRD)</p>
			<p class="em-only_endmatter-idx3">chronic, 324<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">complex, 401</p>
			<p class="em-only_endmatter-idx3">definition of, 396</p>
			<p class="em-only_endmatter-idx3">diagnostic features of, 320, 321<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">floaters associated with, 320</p>
			<p class="em-only_endmatter-idx3">incidence of, 320</p>
			<p class="em-only_endmatter-idx3">intraocular pressure in, 320</p>
			<p class="em-only_endmatter-idx3">lattice degeneration associated with, 310</p>
			<p class="em-only_endmatter-idx3">“macula-&#173;off,” 401</p>
			<p class="em-only_endmatter-idx3">macular hole as cause of, 330, 330<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">management of, 324, 324<span class="italic">f,</span> 397</p>
			<p class="em-only_endmatter-idx3">pigmented demarcation lines with, 324</p>
			<p class="em-only_endmatter-idx3">pneumatic retinopexy for, 324, 397–398, 398<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">proliferative vitreoretinopathy associated with, 320, 323<span class="italic">f,</span> 323<span class="italic">t,</span> 323–324</p>
			<p class="em-only_endmatter-idx3">reattachment surgery for, 401–402</p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal breaks as cause of, 314–315, 396</p>
			<p class="em-only_endmatter-idx3">retinoschisis versus, 327<span class="italic">t,</span> 320, 322<span class="italic">f</span>, 327–328</p>
			<p class="em-only_endmatter-idx3">risk &#173;factors for, 396</p>
			<p class="em-only_endmatter-idx3">scatter photocoagulation as cause of, 155</p>
			<p class="em-only_endmatter-idx3">scleral buckling for, 324, 398–400, 399<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">Shafer sign, 320</p>
			<p class="em-only_endmatter-idx3">surgical repair of, 397–401, 398<span class="italic">–&#173;</span>400<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">tractional ret&#173;i&#173;nal detachment versus, 325</p>
			<p class="em-only_endmatter-idx3">vision loss caused by, 128</p>
			<p class="em-only_endmatter-idx3">vitrectomy for, 324, 400<span class="italic">f,</span> 400–401</p>
			<p class="em-only_endmatter-idx3">word origin of, 320</p>
			<p class="em-only_endmatter-idx2">serous</p>
			<p class="em-only_endmatter-idx3">in intraocular lymphoma, 234</p>
			<p class="em-only_endmatter-idx3">MEK inhibitors as cause of, 299</p>
			<p class="em-only_endmatter-idx2">in sickle cell retinopathy, 155</p>
			<p class="em-only_endmatter-idx2">subclinical, 319–320</p>
			<p class="em-only_endmatter-idx2">tractional</p>
			<p class="em-only_endmatter-idx3">&#173;causes of, 320</p>
			<p class="em-only_endmatter-idx3">description of, 286</p>
			<p class="em-only_endmatter-idx3">diagnostic features of, 321<span class="italic">t,</span> 325</p>
			<p class="em-only_endmatter-idx3">in familial exudative vitreoretinopathy, 343</p>
			<p class="em-only_endmatter-idx3">imaging of, 387<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">management of, 325</p>
			<p class="em-only_endmatter-idx3">pathophysiology of, 387</p>
			<p class="em-only_endmatter-idx3">in proliferative diabetic retinopathy, 103, 108, 387–388</p>
			<p class="em-only_endmatter-idx3">rhegmatogenous ret&#173;i&#173;nal detachment versus, 325</p>
			<p class="em-only_endmatter-idx3">vitrectomy for, 325, 387–388</p>
			<p class="em-only_endmatter-idx2">trauma-&#173;induced, 317</p>
			<p class="em-only_endmatter-idx2">vitreoret&#173;i&#173;nal tufts and, 311–312, 312<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">vitreous contraction as cause of, 349</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal dialyses, 315</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal disease</p>
			<p class="em-only_endmatter-idx2">arterial macroaneurysms, 147–148, 148<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">arterial occlusive</p>
			<p class="em-only_endmatter-idx3">branch ret&#173;i&#173;nal artery occlusion. <span class="italic">See</span> Branch ret&#173;i&#173;nal artery occlusion (BRAO)</p>
			<p class="em-only_endmatter-idx3">capillary ret&#173;i&#173;nal arteriole obstruction, 140<span class="italic">f,</span> 140–141</p>
			<p class="em-only_endmatter-idx3">central ret&#173;i&#173;nal artery occlusion. <span class="italic">See</span> Central ret&#173;i&#173;nal artery occlusion (CRAO)</p>
			<p class="em-only_endmatter-idx3">cilioret&#173;i&#173;nal artery occlusion, 143</p>
			<p class="em-only_endmatter-idx3">ophthalmic artery occlusion, 146, 147<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">paracentral acute &#173;middle maculopathy, 143</p>
			<p class="em-only_endmatter-idx2">imaging modalities for</p>
			<p class="em-only_endmatter-idx3">adaptive optics imaging, 33</p>
			<p class="em-only_endmatter-idx3">fluorescein angiography, 33–38, 34<span class="italic">f,</span> 36<span class="italic">–&#173;</span>37<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">fundus autofluorescence, 29, 31–33</p>
			<p class="em-only_endmatter-idx3">fundus camera imaging, 22–23, 23<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">indirect ophthalmoscopy, 21–22</p>
			<p class="em-only_endmatter-idx3">indocyanine green angiography, 38–39</p>
			<p class="em-only_endmatter-idx3">ophthalmoscopy, 21–22</p>
			<p class="em-only_endmatter-idx3">optical coherence tomography, 25–27, 27<span class="italic">f. See also</span> Optical coherence tomography</p>
			<p class="em-only_endmatter-idx3">optical coherence tomography angiography, 28–29</p>
			<p class="em-only_endmatter-idx3">scanning &#173;laser ophthalmoscopy, 24</p>
			<p class="em-only_endmatter-idx3">ultrasonography, 39–40</p>
			<p class="em-only_endmatter-idx2">vascular</p>
			<p class="em-only_endmatter-idx3">branch ret&#173;i&#173;nal vein occlusion. <span class="italic">See</span> Branch ret&#173;i&#173;nal vein occlusion (BRVO)</p>
			<p class="em-only_endmatter-idx3">cavernous hemangioma, 168, 169<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">central ret&#173;i&#173;nal vein occlusion. <span class="italic">See</span> Central ret&#173;i&#173;nal vein occlusion (CRVO)</p>
			<p class="em-only_endmatter-idx3">Coats disease, 159–161, 160<span class="italic">f,</span> 326</p>
			<p class="em-only_endmatter-idx3">cystoid macular edema. <span class="italic">See</span> Cystoid macular edema (CME)</p>
			<p class="em-only_endmatter-idx3">hypertension, 121–125, 122<span class="italic">–&#173;</span>124<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">macular telangiectasia. <span class="italic">See</span> Macular telangiectasia</p>
			<p class="em-only_endmatter-idx3">ocular ischemic syndrome, 138–140, 139<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">Purtscherlike retinopathy, 171–173, 172<span class="italic">f,</span> 173<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">Purtscher retinopathy, 171–173, 173<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">radiation retinopathy, 170<span class="italic">f,</span> 170–171</p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal vein occlusion. <span class="italic">See</span> Ret&#173;i&#173;nal vein occlusion (RVO)</p>
			<p class="em-only_endmatter-idx3">sickle cell retinopathy. <span class="italic">See</span> Sickle cell retinopathy</p>
			<p class="em-only_endmatter-idx3">systemic arterial hypertension, 121–125, 122<span class="italic">–&#173;</span>124<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">Terson syndrome, 173</p>
			<p class="em-only_endmatter-idx3">Valsalva retinopathy, 171</p>
			<p class="em-only_endmatter-idx3">vasculitis, 155<span class="italic">f,</span> 155–156</p>
			<p class="em-only_endmatter-idx3">von Hippel–&#173;Lindau syndrome, 165–168, <br />166<span class="italic">–&#173;</span>167<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">Wyburn-&#173;Mason syndrome, 168</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal dystrophies</p>
			<p class="em-only_endmatter-idx2">classification of, 255</p>
			<p class="em-only_endmatter-idx2">hereditary</p>
			<p class="em-only_endmatter-idx3">bilateral symmetric involvement of, 258</p>
			<p class="em-only_endmatter-idx3">blindness concerns of patients with, 260</p>
			<p class="em-only_endmatter-idx3">cystoid macular edema in, 260, 260<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">diagnostic considerations for, 258–259</p>
			<p class="em-only_endmatter-idx3">enhanced S-&#173;cone disease, 266, 267<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">genes and loci associated with, 256<span class="italic">–&#173;</span>257<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">gene therapy for, 260, 266</p>
			<p class="em-only_endmatter-idx3">ge&#173;ne&#173;tic considerations for, 259</p>
			<p class="em-only_endmatter-idx3">inheritance patterns for, 259</p>
			<p class="em-only_endmatter-idx3">Leber congenital amaurosis, 265–266</p>
			<p class="em-only_endmatter-idx3">management of, 259–260, 260<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">molecular ge&#173;ne&#173;tic testing for, 259</p>
			<p class="em-only_endmatter-idx3">rod–&#173;cone dystrophies, 261–264, 262<span class="italic">–&#173;</span>264<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">stem cell therapy for, 260</p>
			<p class="em-only_endmatter-idx2">inner, 278–279</p>
			<p class="em-only_endmatter-idx2">sporadic, 263</p>
			<p class="em-only_endmatter-idx2">X-&#173;linked retinoschisis, 278<span class="italic">f,</span> 278–279</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal edema, myopia choroidal neovascularization <br />as cause of, 212</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal folds</p>
			<p class="em-only_endmatter-idx2">in familial exudative vitreoretinopathy, 343, 345<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">fixed, 326</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal ganglion cells, 45</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal grafts, 340</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal hemorrhages</p>
			<p class="em-only_endmatter-idx2">in abusive head trauma, 366, 366<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">in carotid occlusive disease, 138</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal holes</p>
			<p class="em-only_endmatter-idx2">atrophic</p>
			<p class="em-only_endmatter-idx3">definition of, 315</p>
			<p class="em-only_endmatter-idx3">lattice degeneration with, 310, 311<span class="italic">f,</span> 316<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal detachment secondary to, 310</p>
			<p class="em-only_endmatter-idx2">description of, 378</p>
			<p class="em-only_endmatter-idx2">operculated, 315–316</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal ischemia, 140</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal pigment epithelium (RPE)</p>
			<p class="em-only_endmatter-idx2">abnormalities of</p>
			<p class="em-only_endmatter-idx3">in age-&#173;related macular degeneration, 66–67</p>
			<p class="em-only_endmatter-idx3">central serous chorioretinopathy as cause of, 67</p>
			<p class="em-only_endmatter-idx3">focal atrophy, 66</p>
			<p class="em-only_endmatter-idx3">geographic atrophy, 64, 66, 67<span class="italic">f,</span> 68</p>
			<p class="em-only_endmatter-idx3">hyperpigmentation, 68</p>
			<p class="em-only_endmatter-idx3">pattern dystrophies, 67</p>
			<p class="em-only_endmatter-idx2">age-&#173;related changes in, 62</p>
			<p class="em-only_endmatter-idx2">anatomy of, 17–19, 18<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">atrophy of, 106<span class="italic">f,</span> 294<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">barrier functions of, 18</p>
			<p class="em-only_endmatter-idx2">cells of</p>
			<p class="em-only_endmatter-idx3">bis-&#173;retinoid accumulation in, 31</p>
			<p class="em-only_endmatter-idx3">description of, 17, 20</p>
			<p class="em-only_endmatter-idx3">in epiret&#173;i&#173;nal membranes, 334</p>
			<p class="em-only_endmatter-idx3">fluorescein angiography of, 34</p>
			<p class="em-only_endmatter-idx3">pigment-&#173;laden, 66</p>
			<p class="em-only_endmatter-idx2">degeneration of, 258</p>
			<p class="em-only_endmatter-idx2">depigmentation of, 227, 293</p>
			<p class="em-only_endmatter-idx2">detachment of. <span class="italic">See</span> Pigment epithelial detachments (PEDs)</p>
			<p class="em-only_endmatter-idx2">drugs that affect</p>
			<p class="em-only_endmatter-idx3">alkyl nitrites, 300, 300<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">chloroquine derivatives, 295–297, 296<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">chlorpromazine, 297</p>
			<p class="em-only_endmatter-idx3">clofazimine, 298</p>
			<p class="em-only_endmatter-idx3">deferoxamine, 298–299</p>
			<p class="em-only_endmatter-idx3">dideoxyinosine, 299</p>
			<p class="em-only_endmatter-idx3">MEK inhibitors, 299, 299<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">nucleoside reverse transcriptase inhibitors, 299</p>
			<p class="em-only_endmatter-idx3">phenothiazines, 297–298</p>
			<p class="em-only_endmatter-idx3">thioridazine, 297</p>
			<p class="em-only_endmatter-idx2">electro-&#173;oculography of, 50</p>
			<p class="em-only_endmatter-idx2">functions of, 17–18</p>
			<p class="em-only_endmatter-idx2">hyperpigmentation of, 106<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">hyperplasia of</p>
			<p class="em-only_endmatter-idx3">around ret&#173;i&#173;nal tuft, 312</p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal detachment and, 313–314</p>
			<p class="em-only_endmatter-idx2">hypertrophy of, 314</p>
			<p class="em-only_endmatter-idx2">leaks from, 190, 190<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">lipofuscin in, 32</p>
			<p class="em-only_endmatter-idx2">lipofuscin-&#173;like material, 270, 270<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">nummular loss of, 204</p>
			<p class="em-only_endmatter-idx2">pigmentation of, 214, 277</p>
			<p class="em-only_endmatter-idx2">pigments in</p>
			<p class="em-only_endmatter-idx3">description of, 12<span class="italic">f,</span> 17</p>
			<p class="em-only_endmatter-idx3">mottling of, 79, 87, 90<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">progressive atrophy of, 66</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal separation from, 17</p>
			<p class="em-only_endmatter-idx2">siderosis bulbi effects on, 362</p>
			<p class="em-only_endmatter-idx2">standing potential, 50, 51<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">Stargardt disease findings, 270, 270<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">tears of</p>
			<p class="em-only_endmatter-idx3">autofluorescence of, 31, 32<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">in choroidal neovascularization, 31</p>
			<p class="em-only_endmatter-idx3">fibrovascular pigment epithelial detachment <br />as risk for, 82</p>
			<p class="em-only_endmatter-idx2">thermal injury to, 367</p>
			<p class="em-only_endmatter-idx2">&#173;water transport in, 18</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal precipitates, 241</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal sclopetaria, 356–358, 357<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal tears. <span class="italic">See also</span> Retinal breaks</p>
			<p class="em-only_endmatter-idx2">chorioret&#173;i&#173;nal adhesions around, using &#173;laser retinopexy, 377</p>
			<p class="em-only_endmatter-idx2">classification of, 315</p>
			<p class="em-only_endmatter-idx2">flap, 315, 318–319</p>
			<p class="em-only_endmatter-idx2">&#173;giant, 315</p>
			<p class="em-only_endmatter-idx2">horseshoe-&#173;shaped, 316, 323<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">mechanisms of, 308<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">ora bays and, 312</p>
			<p class="em-only_endmatter-idx2">peripheral ret&#173;i&#173;nal excavations and, 312–313</p>
			<p class="em-only_endmatter-idx2">posterior vitreous detachment as cause of, 307, 308<span class="italic">f,</span> 309</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal detachment progression of, 347</p>
			<p class="em-only_endmatter-idx2">ultrasonography of, 39</p>
			<p class="em-only_endmatter-idx2">in vitreous hemorrhage, 347</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal tufts, 311–312, 312<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal vascular sheathing, 231<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal vasculitis, 155<span class="italic">f,</span> 155–156</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal vein occlusion (RVO)</p>
			<p class="em-only_endmatter-idx2">aflibercept for, 135</p>
			<p class="em-only_endmatter-idx2">anti-&#173;VEGF drugs for, 126, 136–137</p>
			<p class="em-only_endmatter-idx2">bevacizumab for, 135</p>
			<p class="em-only_endmatter-idx2">branch (BRVO)</p>
			<p class="em-only_endmatter-idx3">aflibercept for, 135</p>
			<p class="em-only_endmatter-idx3">at arteriovenous crossing, 126</p>
			<p class="em-only_endmatter-idx3">bevacizumab for, 135</p>
			<p class="em-only_endmatter-idx3">clinical findings of, 125–127, 126<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">corticosteroids for, 137–138</p>
			<p class="em-only_endmatter-idx3">diabetes mellitus and, 128</p>
			<p class="em-only_endmatter-idx3">fluorescein angiography of, 129<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">glaucoma as risk &#173;factor for, 125</p>
			<p class="em-only_endmatter-idx3">hypertensive retinopathy and, 122</p>
			<p class="em-only_endmatter-idx3">intraret&#173;i&#173;nal hemorrhages associated with, 125, </p>
			<p class="em-only_endmatter-idx3">126<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">macular &#173;laser surgery for, 128</p>
			<p class="em-only_endmatter-idx3">neovascularization in, 125, 128, 129<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">pars plana vitrectomy for, 130</p>
			<p class="em-only_endmatter-idx3">pharmacologic management of, 135–138</p>
			<p class="em-only_endmatter-idx3">prognosis for, 128</p>
			<p class="em-only_endmatter-idx3">ranibizumab for, 135</p>
			<p class="em-only_endmatter-idx3">risk &#173;factors for, 127–128</p>
			<p class="em-only_endmatter-idx3">scatter photocoagulation for, 128–130</p>
			<p class="em-only_endmatter-idx3">spontaneous resolution of, 125</p>
			<p class="em-only_endmatter-idx3">surgical management of, 128–130</p>
			<p class="em-only_endmatter-idx3">treatment of, 128–130</p>
			<p class="em-only_endmatter-idx3">triamcinolone for, 137</p>
			<p class="em-only_endmatter-idx3">vision loss caused by, 128</p>
			<p class="em-only_endmatter-idx2">central (CRVO)</p>
			<p class="em-only_endmatter-idx3">aflibercept for, 135</p>
			<p class="em-only_endmatter-idx3">age and, 133</p>
			<p class="em-only_endmatter-idx3">bevacizumab for, 135</p>
			<p class="em-only_endmatter-idx3">&#173;causes of, 133–134</p>
			<p class="em-only_endmatter-idx3">chronic changes caused by, 127<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">cilioret&#173;i&#173;nal artery occlusion caused by, 143</p>
			<p class="em-only_endmatter-idx3">clinical findings of, 127<span class="italic">f,</span> 130</p>
			<p class="em-only_endmatter-idx3">complications of, 135</p>
			<p class="em-only_endmatter-idx3">corticosteroids for, 137–138</p>
			<p class="em-only_endmatter-idx3">cystoid macular edema caused by, 136<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">differential diagnosis of, 134</p>
			<p class="em-only_endmatter-idx3">diuretic and, 134</p>
			<p class="em-only_endmatter-idx3">electroretinography findings in, 50</p>
			<p class="em-only_endmatter-idx3">evaluation of, 134–135</p>
			<p class="em-only_endmatter-idx3">follow-up for, 134</p>
			<p class="em-only_endmatter-idx3">hypercoagulable conditions presenting with, 134</p>
			<p class="em-only_endmatter-idx3">hypertensive retinopathy and, 122</p>
			<p class="em-only_endmatter-idx3">hyperviscosity retinopathy versus, 134</p>
			<p class="em-only_endmatter-idx3">intraocular pressure in, 133</p>
			<p class="em-only_endmatter-idx3">iris neovascularization in, 133, 135</p>
			<p class="em-only_endmatter-idx3">ischemic, 132<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">macular &#173;laser surgery for, 135</p>
			<p class="em-only_endmatter-idx3">management of, 134–135</p>
			<p class="em-only_endmatter-idx3">neovascularization in, 125</p>
			<p class="em-only_endmatter-idx3">nonischemic, 130, 131<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">ocular ischemic syndrome versus, 134</p>
			<p class="em-only_endmatter-idx3">open-&#173;angle glaucoma in, 133</p>
			<p class="em-only_endmatter-idx3">oral contraceptives and, 134</p>
			<p class="em-only_endmatter-idx3">panret&#173;i&#173;nal photocoagulation for, 135</p>
			<p class="em-only_endmatter-idx3">pars plana vitrectomy for, 135</p>
			<p class="em-only_endmatter-idx3">pharmacologic management of, 135–138</p>
			<p class="em-only_endmatter-idx3">progression of, follow-up for, 134</p>
			<p class="em-only_endmatter-idx3">ranibizumab for, 135</p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal microvascular changes in, 125, 127<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">risk &#173;factors for, 133–134</p>
			<p class="em-only_endmatter-idx3">spontaneous resolution of, 125</p>
			<p class="em-only_endmatter-idx3">treatment of, 135</p>
			<p class="em-only_endmatter-idx3">vision loss caused by, 130</p>
			<p class="em-only_endmatter-idx3">vitreous hemorrhage secondary to, 135</p>
			<p class="em-only_endmatter-idx2">cystoid macular edema caused by, 135, 136<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">dexamethasone implant for, 137</p>
			<p class="em-only_endmatter-idx2">glaucoma as risk &#173;factor for, 125</p>
			<p class="em-only_endmatter-idx2">improvements in, 125</p>
			<p class="em-only_endmatter-idx2">intravitreal corticosteroids for, 137–138</p>
			<p class="em-only_endmatter-idx2">ocular examination for, 125</p>
			<p class="em-only_endmatter-idx2">panret&#173;i&#173;nal photocoagulation for, 126</p>
			<p class="em-only_endmatter-idx2">pharmacologic management of, 135–138</p>
			<p class="em-only_endmatter-idx2">ranibizumab for, 135</p>
			<p class="em-only_endmatter-idx2">spontaneous resolution of, 125</p>
			<p class="em-only_endmatter-idx2">triamcinolone for, 137</p>
			<p class="em-only_endmatter-idx1">Retinitis</p>
			<p class="em-only_endmatter-idx2">Chikungunya virus, 247</p>
			<p class="em-only_endmatter-idx2">cytomegalovirus, 235–236, 238<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">foveomacular. <span class="italic">See</span> Solar retinopathy</p>
			<p class="em-only_endmatter-idx2">necrotizing herpetic, 236–237, 236<span class="italic">–&#173;</span>237<span class="italic">f,</span> 238<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">in neuroretinitis, 242</p>
			<p class="em-only_endmatter-idx2">solar. <span class="italic">See</span> Solar retinopathy</p>
			<p class="em-only_endmatter-idx1">Retinitis pigmentosa (RP). <span class="italic">See also</span> Rod–&#173;cone dystrophies</p>
			<p class="em-only_endmatter-idx2">autofluorescence imaging of, 261</p>
			<p class="em-only_endmatter-idx2">clinical pre&#173;sen&#173;ta&#173;tion of, 261</p>
			<p class="em-only_endmatter-idx2">congenital stationary night blindness versus, 251</p>
			<p class="em-only_endmatter-idx2">cystoid macular edema associated with, 260</p>
			<p class="em-only_endmatter-idx2">electroretinography findings in, 44, 261</p>
			<p class="em-only_endmatter-idx2">fundal findings in, 261, 262<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">genes and loci associated with, 257<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">hearing loss and, 284</p>
			<p class="em-only_endmatter-idx2">management of, 264</p>
			<p class="em-only_endmatter-idx2">nutritional supplements for, 264</p>
			<p class="em-only_endmatter-idx2">sectorial, 263, 264<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">sine pigmento, 261</p>
			<p class="em-only_endmatter-idx2">spectral-&#173;domain optical coherence tomography findings, 263<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">unilateral, 263</p>
			<p class="em-only_endmatter-idx2">visual fields in, 263<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">X-&#173;linked, 50</p>
			<p class="em-only_endmatter-idx1">Retinitis punctata albescens, 258, 258<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Retinochoroiditis</p>
			<p class="em-only_endmatter-idx2">necrotizing, 243</p>
			<p class="em-only_endmatter-idx2">in syphilitic uveitis, 241</p>
			<p class="em-only_endmatter-idx2">toxoplasmic, 243–244, 244<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Retinopathy</p>
			<p class="em-only_endmatter-idx2">acute zonal occult outer, 226–228, 227<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">arteriosclerotic, 122</p>
			<p class="em-only_endmatter-idx2">autoimmune, 286</p>
			<p class="em-only_endmatter-idx2">cancer-&#173;associated, 286, 287<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2"><span class="italic">CRB1</span>-&#173;related, 258</p>
			<p class="em-only_endmatter-idx2">crystalline</p>
			<p class="em-only_endmatter-idx3">cause of, 302–304, 303<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">drugs that cause, 302–304</p>
			<p class="em-only_endmatter-idx3">tamoxifen as cause of, 303, 304<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">West African, 303–304, 305<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">diabetic. <span class="italic">See</span> Diabetic retinopathy</p>
			<p class="em-only_endmatter-idx2">hypertensive, 121–123, 122<span class="italic">f,</span> 124<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">hyperviscosity, 134</p>
			<p class="em-only_endmatter-idx2">melanoma-&#173;associated, 286</p>
			<p class="em-only_endmatter-idx2">occlusive, 300–301</p>
			<p class="em-only_endmatter-idx2">ocular ischemic syndrome as cause of, 138</p>
			<p class="em-only_endmatter-idx2">pigmentary, 282<span class="italic">–&#173;</span>283<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">pigmented paravenous, 263</p>
			<p class="em-only_endmatter-idx2">Purtscher, 171–173, 173<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">Purtscherlike, 171–173, 172<span class="italic">f,</span> 173<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">radiation, 170<span class="italic">f,</span> 170–171</p>
			<p class="em-only_endmatter-idx2">sickle cell. <span class="italic">See</span> Sickle cell retinopathy</p>
			<p class="em-only_endmatter-idx2">solar, 277, 367, 368<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">syndromic/systemic diseases associated with, 257<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">thioridazine as cause of, 297</p>
			<p class="em-only_endmatter-idx2">Valsalva, 171</p>
			<p class="em-only_endmatter-idx1">Retinopathy of prematurity (ROP)</p>
			<p class="em-only_endmatter-idx2">aggressive posterior, 177</p>
			<p class="em-only_endmatter-idx2">angle-&#173;closure glaucoma in, 181</p>
			<p class="em-only_endmatter-idx2">birth weight and, 182</p>
			<p class="em-only_endmatter-idx2">blindness caused by, 182</p>
			<p class="em-only_endmatter-idx2">cicatricial, 181</p>
			<p class="em-only_endmatter-idx2">classification of, 175–179, 176<span class="italic">t,</span> 178<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">clinically significant, 184<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">conditions associated with, 181–182</p>
			<p class="em-only_endmatter-idx2">definition of, 175</p>
			<p class="em-only_endmatter-idx2">diet and, 184–185</p>
			<p class="em-only_endmatter-idx2">end stage of, 175</p>
			<p class="em-only_endmatter-idx2">epidemiology of, 175</p>
			<p class="em-only_endmatter-idx2">familial exudative vitreoretinopathy versus, 344</p>
			<p class="em-only_endmatter-idx2">incidence of, in premature infants, 182</p>
			<p class="em-only_endmatter-idx2">in infants, 175</p>
			<p class="em-only_endmatter-idx2">insulin growth factor-1 levels and, 182</p>
			<p class="em-only_endmatter-idx2">late sequelae of, 181–182</p>
			<p class="em-only_endmatter-idx2">natu&#173;ral course of, 181</p>
			<p class="em-only_endmatter-idx2">neovascularization in, 180–181</p>
			<p class="em-only_endmatter-idx2">oxygen supplementation and, 184</p>
			<p class="em-only_endmatter-idx2">pathophysiology of, 180–182</p>
			<p class="em-only_endmatter-idx2">posterior per&#173;sis&#173;tent fetal vasculature versus, 342</p>
			<p class="em-only_endmatter-idx2">prethreshold disease, 178<span class="italic">t,</span> 179, 185</p>
			<p class="em-only_endmatter-idx2">prevention of, 184–185</p>
			<p class="em-only_endmatter-idx2">pupillary-&#173;block glaucoma in, 181</p>
			<p class="em-only_endmatter-idx2">risk &#173;factors for, 184–185</p>
			<p class="em-only_endmatter-idx2">screening of</p>
			<p class="em-only_endmatter-idx3">birth weight–&#173;based criteria for, 182</p>
			<p class="em-only_endmatter-idx3">criteria for, 182–183</p>
			<p class="em-only_endmatter-idx3">discontinuation of, criteria for, 183</p>
			<p class="em-only_endmatter-idx3">fundus photographic, 184</p>
			<p class="em-only_endmatter-idx3">intervals for, 183</p>
			<p class="em-only_endmatter-idx2">sequelae of, 181–182</p>
			<p class="em-only_endmatter-idx2">severity of, 176<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">spontaneous regression of, 181</p>
			<p class="em-only_endmatter-idx2">stage 1, 176, 176<span class="italic">f,</span> 180</p>
			<p class="em-only_endmatter-idx2">stage 2, 176, 176<span class="italic">f,</span> 180</p>
			<p class="em-only_endmatter-idx2">stage 3, 176, 177<span class="italic">f,</span> 180</p>
			<p class="em-only_endmatter-idx2">stage 4, 176, 177<span class="italic">f,</span> 180, 187–188</p>
			<p class="em-only_endmatter-idx2">stage 5, 188</p>
			<p class="em-only_endmatter-idx2">terminology for, 175–176, 176<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">threshold disease, 177, 178<span class="italic">t,</span> 179, 180<span class="italic">f,</span> 181, 185</p>
			<p class="em-only_endmatter-idx2">treatment of</p>
			<p class="em-only_endmatter-idx3">anti-&#173;VEGF drugs, 186–187</p>
			<p class="em-only_endmatter-idx3">bevacizumab, 186–187</p>
			<p class="em-only_endmatter-idx3">cryoablation, 185–186</p>
			<p class="em-only_endmatter-idx3">intravitreal injections, 187</p>
			<p class="em-only_endmatter-idx3">&#173;laser surgery, 185–186</p>
			<p class="em-only_endmatter-idx3">overview of, 185</p>
			<p class="em-only_endmatter-idx3">photocoagulation, 186<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">scleral buckling surgery, 187–188</p>
			<p class="em-only_endmatter-idx3">vitrectomy, 187–188</p>
			<p class="em-only_endmatter-idx2">weight, IGF-1, neonatal ROP algorithm for, 182</p>
			<p class="em-only_endmatter-idx1">Retinopexy</p>
			<p class="em-only_endmatter-idx2">&#173;laser, 376–377</p>
			<p class="em-only_endmatter-idx2">pneumatic, for rhegmatogenous ret&#173;i&#173;nal detachment, 397–398, 398<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Retinoschisin, 279</p>
			<p class="em-only_endmatter-idx1">Retinoschisis</p>
			<p class="em-only_endmatter-idx2">bullous, 326</p>
			<p class="em-only_endmatter-idx2">demarcation lines in, 328</p>
			<p class="em-only_endmatter-idx2">imaging of, 327<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">outer-&#173;schisis-&#173;layer holes associated with, 327, 327<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">reticular degenerative, 326–327</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal detachments and, 326–328</p>
			<p class="em-only_endmatter-idx2">rhegmatogenous ret&#173;i&#173;nal detachment versus, 327<span class="italic">t,</span> 327–328</p>
			<p class="em-only_endmatter-idx2">typical degenerative, 326</p>
			<p class="em-only_endmatter-idx1">Retrolental fibroplasia. <span class="italic">See</span> Retinopathy of prematurity (ROP)</p>
			<p class="em-only_endmatter-idx1"><span class="italic">RGS9</span> gene, 49</p>
			<p class="em-only_endmatter-idx1">Rhegmatogenous ret&#173;i&#173;nal detachment (RRD)</p>
			<p class="em-only_endmatter-idx2">chronic, 324<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">complex, 401</p>
			<p class="em-only_endmatter-idx2">definition of, 396</p>
			<p class="em-only_endmatter-idx2">diagnostic features of, 320, 321<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">floaters associated with, 320</p>
			<p class="em-only_endmatter-idx2">incidence of, 320</p>
			<p class="em-only_endmatter-idx2">intraocular pressure in, 320</p>
			<p class="em-only_endmatter-idx2">lattice degeneration associated with, 310</p>
			<p class="em-only_endmatter-idx2">“macula-&#173;off,” 401</p>
			<p class="em-only_endmatter-idx2">macular hole as cause of, 330, 330<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">management of, 324, 324<span class="italic">f,</span> 397</p>
			<p class="em-only_endmatter-idx2">pigmented demarcation lines with, 324</p>
			<p class="em-only_endmatter-idx2">pneumatic retinopexy for, 324, 397–398, 398<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">proliferative vitreoretinopathy associated with, 320, 323<span class="italic">f</span>, 323<span class="italic">t</span>, 323–324</p>
			<p class="em-only_endmatter-idx2">reattachment surgery for, 401–402</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal breaks as cause of, 314–315, 320, 322<span class="italic">f,</span> 396</p>
			<p class="em-only_endmatter-idx2">retinoschisis versus, 327<span class="italic">t,</span> 327–328</p>
			<p class="em-only_endmatter-idx2">risk &#173;factors for, 396</p>
			<p class="em-only_endmatter-idx2">scatter photocoagulation as cause of, 155</p>
			<p class="em-only_endmatter-idx2">scleral buckling for, 324, 398–400, 399<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">Shafer sign, 320</p>
			<p class="em-only_endmatter-idx2">surgical repair of, 397–401, 398<span class="italic">–&#173;</span>400<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">tractional ret&#173;i&#173;nal detachment versus, 325</p>
			<p class="em-only_endmatter-idx2">vision loss caused by, 128</p>
			<p class="em-only_endmatter-idx2">vitrectomy for, 324, 400<span class="italic">f,</span> 400–401</p>
			<p class="em-only_endmatter-idx2">word origin of, 320</p>
			<p class="em-only_endmatter-idx1">Rheopheresis, 71</p>
			<p class="em-only_endmatter-idx1">Rhodopsin, 252, 264</p>
			<p class="em-only_endmatter-idx1">Rifabutin, 305</p>
			<p class="em-only_endmatter-idx1">Rifampin, for cat-&#173;scratch disease, 243</p>
			<p class="em-only_endmatter-idx1">Rituximab, for primary vitreoret&#173;i&#173;nal lymphoma, 234</p>
			<p class="em-only_endmatter-idx1"><span class="italic">RLBP1</span> gene, 252</p>
			<p class="em-only_endmatter-idx1">Rod(s)</p>
			<p class="em-only_endmatter-idx2">density of, 11–12</p>
			<p class="em-only_endmatter-idx2">in foveal center, 11</p>
			<p class="em-only_endmatter-idx2">inner segments of, 11–12, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">light-&#173;sensitive molecules in, 12</p>
			<p class="em-only_endmatter-idx2">outer segments of, 11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">schematic diagram of, 14<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Rod–&#173;cone dystrophies. <span class="italic">See also</span> Retinitis pigmentosa</p>
			<p class="em-only_endmatter-idx2">in Bardet-&#173;Biedl syndrome, 284</p>
			<p class="em-only_endmatter-idx2">characteristics of, 261–264, 262<span class="italic">–&#173;</span>264<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">conventional testing of, 261</p>
			<p class="em-only_endmatter-idx2">electroretinography evaluations, 46, 47<span class="italic">f,</span> 261</p>
			<p class="em-only_endmatter-idx2">imaging of, 262<span class="italic">–&#173;</span>264<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">macula-&#173;spared, 46, 47<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Rod monochromatism, 250, 250<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">ROP. <span class="italic">See</span> Retinopathy of prematurity</p>
			<p class="em-only_endmatter-idx1">Rosiglitazone, 301</p>
			<p class="em-only_endmatter-idx1">RP. <span class="italic">See</span> Retinitis pigmentosa</p>
			<p class="em-only_endmatter-idx1">RPE. <span class="italic">See</span> Ret&#173;i&#173;nal pigment epithelium</p>
			<p class="em-only_endmatter-idx1"><span class="italic">RPE65</span> gene, 266</p>
			<p class="em-only_endmatter-idx1">RPR. <span class="italic">See</span> Rapid plasma reagin (RPR) test</p>
			<p class="em-only_endmatter-idx1">RRD. <span class="italic">See</span> Rhegmatogenous retinal detachment</p>
			<p class="em-only_endmatter-idx1"><span class="italic">RS1</span> gene, 279</p>
			<p class="em-only_endmatter-idx1">Rush disease, 177, 178<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">RVO. <span class="italic">See</span> Retinal vein occlusion</p>
			<p class="em-only_endmatter-idx-alpha"><span class="italic">SAG</span> gene, 253</p>
			<p class="em-only_endmatter-idx1">SAILOR study, 81</p>
			<p class="em-only_endmatter-idx1">Salmon-&#173;patch hemorrhage, 150, 150<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Sanfilippo syndrome, 282<span class="italic">t,</span> 291</p>
			<p class="em-only_endmatter-idx1">Sarcoidosis, 134, 231, 231<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Sattler layer, 19</p>
			<p class="em-only_endmatter-idx1">Scanning &#173;laser ophthalmoscopy (SLO)</p>
			<p class="em-only_endmatter-idx2">angiography versus, 24</p>
			<p class="em-only_endmatter-idx2">blue excitation light used by, 31</p>
			<p class="em-only_endmatter-idx2">choroidal nevi on, 24</p>
			<p class="em-only_endmatter-idx2">digital resolution of, 24</p>
			<p class="em-only_endmatter-idx2">ellipsoidal mirror in, 24</p>
			<p class="em-only_endmatter-idx2">epiret&#173;i&#173;nal membrane on, 334<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">pseudodrusen on, 24</p>
			<p class="em-only_endmatter-idx2">resolution of, 24</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal disease evaluations, 24</p>
			<p class="em-only_endmatter-idx2">wavelengths in, 24</p>
			<p class="em-only_endmatter-idx1">Scatter photocoagulation. <span class="italic">See also</span> Photocoagulation</p>
			<p class="em-only_endmatter-idx2">branch ret&#173;i&#173;nal vein occlusion treated with, <br />128–130</p>
			<p class="em-only_endmatter-idx2">sickle cell retinopathy treated with, 155</p>
			<p class="em-only_endmatter-idx2">vitreoret&#173;i&#173;nal surgery for, 155</p>
			<p class="em-only_endmatter-idx1">Scheie syndrome, 282<span class="italic">t,</span> 290–291</p>
			<p class="em-only_endmatter-idx1">Schisis, macular, 328</p>
			<p class="em-only_endmatter-idx1">Schlaegel lines, 225</p>
			<p class="em-only_endmatter-idx1">Sclera</p>
			<p class="em-only_endmatter-idx2">anatomy of, 20</p>
			<p class="em-only_endmatter-idx2">indentation of, 310<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">laceration of, 359</p>
			<p class="em-only_endmatter-idx2">in pathologic myopia, 216–217, 217<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">permeability of, 20</p>
			<p class="em-only_endmatter-idx2">rupture of, 352, 358</p>
			<p class="em-only_endmatter-idx2">thickness of, 20, 216</p>
			<p class="em-only_endmatter-idx2">traumatic injuries to, 352, 358</p>
			<p class="em-only_endmatter-idx1">Scleral buckles, 201</p>
			<p class="em-only_endmatter-idx1">Scleral buckling</p>
			<p class="em-only_endmatter-idx2">complications of, 400</p>
			<p class="em-only_endmatter-idx2">intraocular pressure affected by, 399</p>
			<p class="em-only_endmatter-idx2">retinopathy of prematurity treated with, 187–188</p>
			<p class="em-only_endmatter-idx2">rhegmatogenous ret&#173;i&#173;nal detachment treated with, 324, 398–400, 399<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Scleral fixation, 393</p>
			<p class="em-only_endmatter-idx1">S cone, 54</p>
			<p class="em-only_endmatter-idx1">S-&#173;cone monochromatism, 250</p>
			<p class="em-only_endmatter-idx1">Scotomas</p>
			<p class="em-only_endmatter-idx2">absolute, 327</p>
			<p class="em-only_endmatter-idx2">central, 86, 265</p>
			<p class="em-only_endmatter-idx2">paracentral, 228, 367</p>
			<p class="em-only_endmatter-idx2">retinoschisis as cause of, 327</p>
			<p class="em-only_endmatter-idx1">SDH. <span class="italic">See</span> Shape-discrimination hyperacuity</p>
			<p class="em-only_endmatter-idx1">SD-OCT. <span class="italic">See</span> Spectral-domain optical coherence tomography</p>
			<p class="em-only_endmatter-idx1">Sea-&#173;blue histiocyte syndrome, 291</p>
			<p class="em-only_endmatter-idx1">Sea fan neovascularization, 151, 153<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Sectorial retinitis pigmentosa, 263, 264<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Segmental phlebitis, 232</p>
			<p class="em-only_endmatter-idx1">Septic emboli, 141</p>
			<p class="em-only_endmatter-idx1">Serous pigment epithelial detachment, 72–73, 74<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Serous ret&#173;i&#173;nal detachment</p>
			<p class="em-only_endmatter-idx2">in intraocular lymphoma, 234</p>
			<p class="em-only_endmatter-idx2">MEK inhibitors as cause of, 299</p>
			<p class="em-only_endmatter-idx1">Serpiginous choroidopathy, 220<span class="italic">t,</span> 222–223, 223<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">SF<span class="CharOverride-1">6</span>. <span class="italic">See</span> Sulfur hex&#173;a&#173;fluor&#173;ide</p>
			<p class="em-only_endmatter-idx1">Shafer sign, 320, 348</p>
			<p class="em-only_endmatter-idx1">Shaken baby syndrome, 365–366, 366<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Shape-&#173;discrimination hyperacuity (SDH), 69</p>
			<p class="em-only_endmatter-idx1">Shimmering, electroretinography findings in, 46</p>
			<p class="em-only_endmatter-idx1">Sickle cell disease, proliferative sickle cell retinopathy complications in, 150</p>
			<p class="em-only_endmatter-idx1">Sickle cell hemoglobin C disease (SC)</p>
			<p class="em-only_endmatter-idx2">ocular findings in, 153<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">proliferative sickle cell retinopathy complications in, 150</p>
			<p class="em-only_endmatter-idx1">Sickle cell hemoglobinopathies</p>
			<p class="em-only_endmatter-idx2">description of, 149</p>
			<p class="em-only_endmatter-idx2">incidence of, 149<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">ocular abnormalities in, 154</p>
			<p class="em-only_endmatter-idx2">racial predilection of, 149, 154</p>
			<p class="em-only_endmatter-idx1">Sickle cell retinopathy</p>
			<p class="em-only_endmatter-idx2">management of, 154–155</p>
			<p class="em-only_endmatter-idx2">nonproliferative</p>
			<p class="em-only_endmatter-idx3">branch ret&#173;i&#173;nal artery occlusions in, 152<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">characteristics of, 149–150</p>
			<p class="em-only_endmatter-idx3">imaging of, 150<span class="italic">–&#173;</span>152<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">retinal arteriolar occlusions in, 151<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">salmon-&#173;patch hemorrhage in, 150<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">proliferative</p>
			<p class="em-only_endmatter-idx3">complications of, 150</p>
			<p class="em-only_endmatter-idx3">proliferative diabetic retinopathy versus, 151</p>
			<p class="em-only_endmatter-idx3">scatter photocoagulation for, 155</p>
			<p class="em-only_endmatter-idx3">sea fan neovascularization associated with, <br />151, 153<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">stages of, 150–151</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal detachment secondary to, 155</p>
			<p class="em-only_endmatter-idx2">scatter photocoagulation for, 155</p>
			<p class="em-only_endmatter-idx2">thalassemia as cause of, 149</p>
			<p class="em-only_endmatter-idx1">Siderosis bulbi, 362, 363<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Siegrist streaks, 123, 198</p>
			<p class="em-only_endmatter-idx1">Sildenafil, 299, 304</p>
			<p class="em-only_endmatter-idx1">Silicone oil, 401</p>
			<p class="em-only_endmatter-idx1">Silver, 306</p>
			<p class="em-only_endmatter-idx1">Skin, fluorescein angiography effects on, 36</p>
			<p class="em-only_endmatter-idx1">Slit-&#173;lamp biomicroscopy</p>
			<p class="em-only_endmatter-idx2">operculated holes on, 318</p>
			<p class="em-only_endmatter-idx2">posterior vitreous detachment diagnosis using, 331</p>
			<p class="em-only_endmatter-idx1">SLO. <span class="italic">See</span> Scanning &#173;laser ophthalmoscopy</p>
			<p class="em-only_endmatter-idx1">Snowballs, in intermediate uveitis, 231</p>
			<p class="em-only_endmatter-idx1">Snowbanks, in intermediate uveitis, 231–232, 245</p>
			<p class="em-only_endmatter-idx1">“Snowflakes,” 326</p>
			<p class="em-only_endmatter-idx1">Soft drusen, 65, 68, 75, 200<span class="italic">f,</span> 272</p>
			<p class="em-only_endmatter-idx1">Soft exudates, 122</p>
			<p class="em-only_endmatter-idx1">Solar retinitis. <span class="italic">See</span> Solar retinopathy</p>
			<p class="em-only_endmatter-idx1">Solar retinopathy, 277, 367, 368<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Sorsby macular dystrophy, 275<span class="italic">f,</span> 275–276</p>
			<p class="em-only_endmatter-idx1">Spatial frequency, 56, 57<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Spectral-&#173;domain optical coherence tomography (SD-OCT)</p>
			<p class="em-only_endmatter-idx2">adult-&#173;onset vitelliform maculopathy on, 67–68, 68<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">alkyl nitrite findings, 300, 300<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal artery occlusion on, 144<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">chloroquine toxicity monitoring uses of, 297</p>
			<p class="em-only_endmatter-idx2">choroidal neovascularization on, 73–75, 75<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">commotio ret&#173;i&#173;nae on, 353</p>
			<p class="em-only_endmatter-idx2">diabetic macular edema on, 109<span class="italic">f,</span> 125</p>
			<p class="em-only_endmatter-idx2">drusen on, 64<span class="italic">f,</span> 65</p>
			<p class="em-only_endmatter-idx2">epiret&#173;i&#173;nal membranes on, 335<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">Gaucher disease on, 291</p>
			<p class="em-only_endmatter-idx2">pathologic myopia on, 90<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">reticular pseudodrusen on, 65<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal layers on, 10–11, 12<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">retinitis pigmentosa findings, 263<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">sensitivity of, 26</p>
			<p class="em-only_endmatter-idx2">swept-&#173;source optical coherence tomography versus, 25–26</p>
			<p class="em-only_endmatter-idx2">vitreomacular traction on, 332<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Spinocerebellar degeneration, 282<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Staining, hyperfluorescence and, 35</p>
			<p class="em-only_endmatter-idx1">Standing potential, 50, 51<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1"><span class="italic">Staphylococcus</span> spp</p>
			<p class="em-only_endmatter-idx2">endogenous bacterial endophthalmitis caused by, 238</p>
			<p class="em-only_endmatter-idx2">postoperative endophthalmitis caused by, 389</p>
			<p class="em-only_endmatter-idx1">Staphyloma, 209, 216, 217<span class="italic">f,</span> 330</p>
			<p class="em-only_endmatter-idx1">Stargardt disease</p>
			<p class="em-only_endmatter-idx2"><span class="italic">ABCA4</span> gene mutations as cause of, 271</p>
			<p class="em-only_endmatter-idx2">clinical findings of, 269–270, 270<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">description of, 31, 44</p>
			<p class="em-only_endmatter-idx2">electroretinography findings in, 48<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">fluorescein angiography findings, 269–270, 270<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">fundus autofluorescence findings, 270</p>
			<p class="em-only_endmatter-idx2">phenotype of, 269</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium findings in, 270, 270<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">visual acuity in, 269</p>
			<p class="em-only_endmatter-idx1">“Starry night” sign, in Vogt-&#173;Koyanagi-&#173;Harada <br />disease, 232</p>
			<p class="em-only_endmatter-idx1">Static dyschromatopsia, 249</p>
			<p class="em-only_endmatter-idx1">Steinert disease, 282<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Stereopsis, binocular indirect ophthalmoscopes for, 22</p>
			<p class="em-only_endmatter-idx1">Stickler syndrome, 282<span class="italic">t,</span> 309, 342–343, 343<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1"><span class="italic">Streptococcus</span> spp</p>
			<p class="em-only_endmatter-idx2">endophthalmitis caused by</p>
			<p class="em-only_endmatter-idx3">bleb-&#173;associated, 391</p>
			<p class="em-only_endmatter-idx3">endogenous bacterial, 238</p>
			<p class="em-only_endmatter-idx3">postoperative, 389</p>
			<p class="em-only_endmatter-idx2"><span class="italic">S viridans,</span> 404</p>
			<p class="em-only_endmatter-idx1">Stroke, in ocular ischemic syndrome patients, 139</p>
			<p class="em-only_endmatter-idx1">Sturge-&#173;Weber syndrome, 202</p>
			<p class="em-only_endmatter-idx1">Subarachnoid hemorrhage, 173</p>
			<p class="em-only_endmatter-idx1">Subclinical ret&#173;i&#173;nal detachment, 319–320</p>
			<p class="em-only_endmatter-idx1">Subfoveal pigment epithelial detachment, 74<span class="italic">–&#173;</span>75<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Subhyaloid hemorrhage, 173</p>
			<p class="em-only_endmatter-idx1">Submacular hemorrhage</p>
			<p class="em-only_endmatter-idx2">in neovascular age-&#173;related macular degeneration, <br />85, 385</p>
			<p class="em-only_endmatter-idx2">posttraumatic, 354<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">vitrectomy for, 385, 386<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Subret&#173;i&#173;nal drusenoid deposits, 65, 65<span class="italic">f,</span> 200</p>
			<p class="em-only_endmatter-idx1">Subret&#173;i&#173;nal fibrosis, in multifocal choroiditis, 226, 226<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Subret&#173;i&#173;nal fluid</p>
			<p class="em-only_endmatter-idx2">in central serous chorioretinopathy, 76</p>
			<p class="em-only_endmatter-idx2">in choroidal neovascularization, 71</p>
			<p class="em-only_endmatter-idx2">in exudative ret&#173;i&#173;nal detachment, 326</p>
			<p class="em-only_endmatter-idx2">optic pit and, 329<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Subret&#173;i&#173;nal hemorrhage</p>
			<p class="em-only_endmatter-idx2">choroidal neovascularization versus, 211</p>
			<p class="em-only_endmatter-idx2">in polypoidal choroidal vasculopathy, 76</p>
			<p class="em-only_endmatter-idx1">Subret&#173;i&#173;nal hyperreflective material (SHRM), 75</p>
			<p class="em-only_endmatter-idx1">Subret&#173;i&#173;nal neovascularization, 162, 164</p>
			<p class="em-only_endmatter-idx1">Subret&#173;i&#173;nal space</p>
			<p class="em-only_endmatter-idx2">fluorophore accumulation in, 32</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium-&#173;mediated dehydration of, 18</p>
			<p class="em-only_endmatter-idx1">Sub-&#173;Tenon space, 20</p>
			<p class="em-only_endmatter-idx1">“Sugiura” sign, 233</p>
			<p class="em-only_endmatter-idx1">Sulfadiazine, for toxoplasmic retinochoroiditis, 243</p>
			<p class="em-only_endmatter-idx1">Sulfur hex&#173;a&#173;fluor&#173;ide (SF<span class="CharOverride-1">6</span>), 382</p>
			<p class="em-only_endmatter-idx1">“Sunset glow” sign, 232<span class="italic">f,</span> 232–233</p>
			<p class="em-only_endmatter-idx1">Superficial vascular plexus, 16</p>
			<p class="em-only_endmatter-idx1">Supertraction crescent, 210</p>
			<p class="em-only_endmatter-idx1">Suprachoroidal hemorrhage, 394–395, 395<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Surgery. <span class="italic">See also</span> Cataract surgery; &#173;Laser surgery</p>
			<p class="em-only_endmatter-idx2">diabetic macular edema treated with, 114–115</p>
			<p class="em-only_endmatter-idx2">endophthalmitis &#173;after, 388–391, 390<span class="italic">–&#173;</span>391<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">intraocular foreign bodies removed with, 360–362</p>
			<p class="em-only_endmatter-idx2">macular holes managed with, 339–340</p>
			<p class="em-only_endmatter-idx2">neovascular age-&#173;related macular degeneration <br />treated with, 85–86</p>
			<p class="em-only_endmatter-idx2">open-&#173;globe injuries managed with, 359–360</p>
			<p class="em-only_endmatter-idx2">rhegmatogenous ret&#173;i&#173;nal detachment treated with, 397–401, 398<span class="italic">–&#173;</span>400<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">sympathetic ophthalmia secondary to, 233</p>
			<p class="em-only_endmatter-idx2">vitreous loss during, 349</p>
			<p class="em-only_endmatter-idx1">Susac syndrome, 156</p>
			<p class="em-only_endmatter-idx1">SUSTAIN study, 81</p>
			<p class="em-only_endmatter-idx1">Swept-&#173;source optical coherence tomography (SS–OCT)</p>
			<p class="em-only_endmatter-idx2">pathologic myopia findings, 209<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">sensitivity of, 26</p>
			<p class="em-only_endmatter-idx2">spectral-&#173;domain optical coherence tomography versus, 25–26</p>
			<p class="em-only_endmatter-idx1">Sympathetic ophthalmia</p>
			<p class="em-only_endmatter-idx2">characteristics of, 233</p>
			<p class="em-only_endmatter-idx2">trauma as cause of, 364–365</p>
			<p class="em-only_endmatter-idx2">Vogt-&#173;Koyanagi-&#173;Harada disease versus, 232</p>
			<p class="em-only_endmatter-idx1">Symptomatic ret&#173;i&#173;nal breaks, 318</p>
			<p class="em-only_endmatter-idx1">Synchysis scintillans, 348</p>
			<p class="em-only_endmatter-idx1">Syndromic panret&#173;i&#173;nal dystrophies, 259</p>
			<p class="em-only_endmatter-idx1">Syneresis, vitreous, 307, 316</p>
			<p class="em-only_endmatter-idx1">Syphilis</p>
			<p class="em-only_endmatter-idx2">acute syphilitic posterior placoid chorioretinitis caused by, 241</p>
			<p class="em-only_endmatter-idx2">uveitis caused by, 241</p>
			<p class="em-only_endmatter-idx1">Syphilitic chorioretinitis, 241–242, 242<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Systemic lupus erythematosus</p>
			<p class="em-only_endmatter-idx2">description of, 134</p>
			<p class="em-only_endmatter-idx2">procainamide as cause of, 300</p>
			<p class="em-only_endmatter-idx2">vasculitis associated with, 230–231, 231<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx-alpha">Tadalafil, 304</p>
			<p class="em-only_endmatter-idx1">Talc emboli, 141, 303</p>
			<p class="em-only_endmatter-idx1">Tamoxifen, 302–303, 304<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Taxanes, 301</p>
			<p class="em-only_endmatter-idx1">Tay-&#173;Sachs disease, 291, 292<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">T cells, CD4<span class="symbol">+</span>, 235</p>
			<p class="em-only_endmatter-idx1">Telangiectasia. <span class="italic">See also</span> Macular telangiectasia</p>
			<p class="em-only_endmatter-idx2">aneurysmal, 161</p>
			<p class="em-only_endmatter-idx2">juxtafoveal, 161</p>
			<p class="em-only_endmatter-idx1">Terson syndrome, 366</p>
			<p class="em-only_endmatter-idx1">Tessellation, 214</p>
			<p class="em-only_endmatter-idx1">Thalassemia, 149, 149<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Thermal &#173;laser, for neovascular age-&#173;related macular degeneration, 79</p>
			<p class="em-only_endmatter-idx1">Thioridazine, 297</p>
			<p class="em-only_endmatter-idx1">3-&#173;mirror lens, 22</p>
			<p class="em-only_endmatter-idx1">Threshold disease (retinopathy of prematurity), 177, 178<span class="italic">t,</span> 179, 180<span class="italic">f,</span> 181, 185</p>
			<p class="em-only_endmatter-idx1">Thrombi, comma-&#173;shaped, 154</p>
			<p class="em-only_endmatter-idx1">Thrombosis, ret&#173;i&#173;nal vasculitis versus, 156</p>
			<p class="em-only_endmatter-idx1">Thrombotic thrombocytopenic purpura, 195</p>
			<p class="em-only_endmatter-idx1">Tick-&#173;borne diseases, 245–246</p>
			<p class="em-only_endmatter-idx1">Tilted disc syndrome, 217</p>
			<p class="em-only_endmatter-idx1"><span class="italic">TIMP3</span> gene, 275–276</p>
			<p class="em-only_endmatter-idx1">Topiramate</p>
			<p class="em-only_endmatter-idx2">choroidal swelling caused by, 201</p>
			<p class="em-only_endmatter-idx2">myopia caused by, 305</p>
			<p class="em-only_endmatter-idx1">Topography, ret&#173;i&#173;nal, 9<span class="italic">f,</span> 9–10</p>
			<p class="em-only_endmatter-idx1"><span class="italic">Toxocara canis,</span> 244, 246</p>
			<p class="em-only_endmatter-idx1"><span class="italic">Toxocara catti,</span> 244, 246</p>
			<p class="em-only_endmatter-idx1">Toxocariasis, 244–245, 245<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1"><span class="italic">Toxoplasma gondii</span></p>
			<p class="em-only_endmatter-idx2">definition of, 243</p>
			<p class="em-only_endmatter-idx2">retinochoroiditis caused by, 243–244, 244<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">TP-&#173;PA. <span class="italic">See Treponema pallidum</span> particle agglutination assay</p>
			<p class="em-only_endmatter-idx1">Tractional ret&#173;i&#173;nal detachment. <span class="italic">See also</span> Retinal detachment</p>
			<p class="em-only_endmatter-idx2">description of, 286</p>
			<p class="em-only_endmatter-idx2">diagnostic features of, 321<span class="italic">t,</span> 325</p>
			<p class="em-only_endmatter-idx2">in familial exudative vitreoretinopathy, 343</p>
			<p class="em-only_endmatter-idx2">imaging of, 387<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">management of, 325</p>
			<p class="em-only_endmatter-idx2">pathophysiology of, 387</p>
			<p class="em-only_endmatter-idx2">in proliferative diabetic retinopathy, 103, 108, 387–388</p>
			<p class="em-only_endmatter-idx2">rhegmatogenous ret&#173;i&#173;nal detachment versus, 325</p>
			<p class="em-only_endmatter-idx2">vitrectomy for, 325, 387–388</p>
			<p class="em-only_endmatter-idx1">Transconjunctival cryopexy, 398</p>
			<p class="em-only_endmatter-idx1">Transmission defect, hyperfluorescence in, 36</p>
			<p class="em-only_endmatter-idx1">Transpupillary thermotherapy (TTT), 380</p>
			<p class="em-only_endmatter-idx1">11-&#173;<span class="italic">trans-&#173;</span>retinal, 31</p>
			<p class="em-only_endmatter-idx1">11-&#173;<span class="italic">trans-&#173;</span>retinaldehyde, 17</p>
			<p class="em-only_endmatter-idx1">Transscleral cryopexy, 398</p>
			<p class="em-only_endmatter-idx1">Trauma</p>
			<p class="em-only_endmatter-idx2">abusive head, 365–366, 366<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">blunt, 315, 353–358, 354<span class="italic">–&#173;</span>357<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">in &#173;children, 316–317</p>
			<p class="em-only_endmatter-idx2">choroidal rupture, 354–355, 354<span class="italic">–&#173;</span>356<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">classification of, 351</p>
			<p class="em-only_endmatter-idx2">closed-&#173;globe, 351–352</p>
			<p class="em-only_endmatter-idx2">commotio ret&#173;i&#173;nae, 353, 354<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">endophthalmitis &#173;after, 362–363</p>
			<p class="em-only_endmatter-idx2">evaluation of patient &#173;after, 351–353, 352<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">fibrocellular proliferation secondary to, 315</p>
			<p class="em-only_endmatter-idx2">handheld laser-&#173;pointer injury, 369</p>
			<p class="em-only_endmatter-idx2">in infants, 316–317</p>
			<p class="em-only_endmatter-idx2">intraocular pressure evaluations, 352</p>
			<p class="em-only_endmatter-idx2">laser-&#173;pointer injury, 369</p>
			<p class="em-only_endmatter-idx2">macular hole caused by, 355–357, 356<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">microsurgery for, 351</p>
			<p class="em-only_endmatter-idx2">occupational light toxicity, 369</p>
			<p class="em-only_endmatter-idx2">Ocular Trauma Score, 364, 364<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">open-&#173;globe</p>
			<p class="em-only_endmatter-idx3">description of, 351–352</p>
			<p class="em-only_endmatter-idx3">intraocular foreign bodies, 351–352, 360–362, 361<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">lacerating injuries, 358</p>
			<p class="em-only_endmatter-idx3">needle perforation/penetration, 358, 395<span class="italic">f,</span> 395–396</p>
			<p class="em-only_endmatter-idx3">penetrating injuries, 358</p>
			<p class="em-only_endmatter-idx3">prognosis for, 363–364</p>
			<p class="em-only_endmatter-idx3">scleral rupture, 358</p>
			<p class="em-only_endmatter-idx2">optic nerve head avulsion caused by, 365, 365<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">photic damage, 367–369, 368<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">phototoxicity from ophthalmic instrumentation, 368–369</p>
			<p class="em-only_endmatter-idx2">prognosis &#173;after, 363–364</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal breaks caused by, 315–316, 316<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal detachments caused by, 317</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal sclopetaria, 356–358, 357<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">scleral rupture, 352</p>
			<p class="em-only_endmatter-idx2">submacular hemorrhage secondary to, 354<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">sympathetic ophthalmia secondary to, 364–365</p>
			<p class="em-only_endmatter-idx2">vitreous hemorrhage secondary to, 357</p>
			<p class="em-only_endmatter-idx2">whiplash, 356–357</p>
			<p class="em-only_endmatter-idx2">in young patients, 316–317</p>
			<p class="em-only_endmatter-idx1"><span class="italic">Treponema pallidum</span> particle agglutination assay <br />(TP-PA), 241</p>
			<p class="em-only_endmatter-idx1">Triamcinolone acetonide</p>
			<p class="em-only_endmatter-idx2">branch ret&#173;i&#173;nal vein occlusion treated with, 137</p>
			<p class="em-only_endmatter-idx2">diabetic macular edema treated with, 113</p>
			<p class="em-only_endmatter-idx2">uveal effusion syndrome treated with, 203</p>
			<p class="em-only_endmatter-idx1">Trichromatism, 249</p>
			<p class="em-only_endmatter-idx1">Trimethoprim-&#173;sulfamethoxazole, for toxoplasmic retinochoroiditis, 243–244</p>
			<p class="em-only_endmatter-idx1">Tritanomalous dichromatism, 250<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Tritanomalous trichromatism, 250<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">TTT. <span class="italic">See</span> Transpupillary thermotherapy</p>
			<p class="em-only_endmatter-idx1">Tubercular serpiginous-&#173;like choroiditis, 222</p>
			<p class="em-only_endmatter-idx1">Tuberculosis, ocular, 240–241, 241<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Tunica vasculosa lentis, 186, 340–341</p>
			<p class="em-only_endmatter-idx1">Typical degenerative retinoschisis, 326</p>
			<p class="em-only_endmatter-idx1">Typical peripheral cystoid degeneration, 326</p>
			<p class="em-only_endmatter-idx-alpha">UKPDS. <span class="italic">See</span> United Kingdom Prospective Diabetes Study</p>
			<p class="em-only_endmatter-idx1">Ultrasonography</p>
			<p class="em-only_endmatter-idx2">applications of, 40</p>
			<p class="em-only_endmatter-idx2">contact B-&#173;scan, 39, 39<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">intraocular foreign body evaluations, 352</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal disease evaluations using, 39–40</p>
			<p class="em-only_endmatter-idx1">Ultrasound biomicroscopy</p>
			<p class="em-only_endmatter-idx2">anterior chamber evaluations, 40</p>
			<p class="em-only_endmatter-idx2">ciliary body evaluations, 40</p>
			<p class="em-only_endmatter-idx1">Umbo</p>
			<p class="em-only_endmatter-idx2">anatomy of, 9, 9<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">characteristics of, 10<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">United Kingdom Prospective Diabetes Study (UKPDS), 96–97</p>
			<p class="em-only_endmatter-idx1">Urinary tract infections, <span class="italic">Escherichia coli</span> as cause of, 238</p>
			<p class="em-only_endmatter-idx1">Usher syndrome</p>
			<p class="em-only_endmatter-idx2">clinical features of, 283<span class="italic">t,</span> 284</p>
			<p class="em-only_endmatter-idx2">description of, 259</p>
			<p class="em-only_endmatter-idx2">genes and loci associated with, 257<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">types of, 284</p>
			<p class="em-only_endmatter-idx1">Uveal effusion syndrome, 203, 204<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Uveal lymphoma, 234, 235<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Uveal thickening, 234, 235<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Uveitis</p>
			<p class="em-only_endmatter-idx2">in Beh<span class="accent">ç</span>et disease, 230</p>
			<p class="em-only_endmatter-idx2">birdshot</p>
			<p class="em-only_endmatter-idx3">characteristics of, 220<span class="italic">t,</span> 224–225, 225<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">uveal lymphoma and, 234</p>
			<p class="em-only_endmatter-idx2">immune recovery, 235</p>
			<p class="em-only_endmatter-idx2">indocyanine green angiography of, 38–39</p>
			<p class="em-only_endmatter-idx2">intermediate, 231–232</p>
			<p class="em-only_endmatter-idx2">intraocular lymphoma and, 233–234</p>
			<p class="em-only_endmatter-idx2">in Lyme disease, 245</p>
			<p class="em-only_endmatter-idx2"><span class="italic">Mycobacterium tuberculosis,</span> 240</p>
			<p class="em-only_endmatter-idx2">syphilitic, 241</p>
			<p class="em-only_endmatter-idx2">in toxocariasis, 245</p>
			<p class="em-only_endmatter-idx-alpha">Valacyclovir, for herpetic retinitis, 238<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Valsalva retinopathy, 171</p>
			<p class="em-only_endmatter-idx1">Vancomycin, 300</p>
			<p class="em-only_endmatter-idx1">Variable expressivity, 255</p>
			<p class="em-only_endmatter-idx1">Varicella-&#173;zoster virus (VZV), necrotizing retinitis caused by, 236–237, 236<span class="italic">–&#173;</span>237<span class="italic">f,</span> 238<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Vascular endothelial growth &#173;factor (VEGF)</p>
			<p class="em-only_endmatter-idx2">choroidal neovascularization concentrations of, 80</p>
			<p class="em-only_endmatter-idx2">isoforms of, 80</p>
			<p class="em-only_endmatter-idx2">therapy inhibiting. <span class="italic">See</span> Anti-VEGF therapy</p>
			<p class="em-only_endmatter-idx1">Vascular filling defects, in fluorescein angiography, 35</p>
			<p class="em-only_endmatter-idx1">Vasculature, ret&#173;i&#173;nal, 16<span class="italic">f,</span> 16–17</p>
			<p class="em-only_endmatter-idx1">Vasculitis</p>
			<p class="em-only_endmatter-idx2">inflammatory, 230<span class="italic">t,</span> 230–231, 231<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">lupus, 230–231, 231<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal, 155<span class="italic">f,</span> 155–156</p>
			<p class="em-only_endmatter-idx1">VECP. <span class="italic">See</span> Visual evoked cortical potential</p>
			<p class="em-only_endmatter-idx1">VEGF. <span class="italic">See</span> Vascular endothelial growth &#173;factor</p>
			<p class="em-only_endmatter-idx1"><span class="italic">VEGFR1</span> gene, 82</p>
			<p class="em-only_endmatter-idx1"><span class="italic">VEGFR2</span> gene, 82</p>
			<p class="em-only_endmatter-idx1">VEGF Trap, 82. <span class="italic">See also</span> Aflibercept</p>
			<p class="em-only_endmatter-idx1">Venous beading, in nonproliferative diabetic retinopathy, 100<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">VEPs. <span class="italic">See</span> Visual evoked potentials</p>
			<p class="em-only_endmatter-idx1">Verteporfin. <span class="italic">See also</span> Photodynamic therapy (PDT)</p>
			<p class="em-only_endmatter-idx2">central serous chorioretinopathy treated with, 194</p>
			<p class="em-only_endmatter-idx2">complications of, 380</p>
			<p class="em-only_endmatter-idx2">neovascular age-&#173;related macular degeneration <br />treated with, 79</p>
			<p class="em-only_endmatter-idx2">polypoidal choroidal vasculopathy treated with, 76</p>
			<p class="em-only_endmatter-idx2">von Hippel–&#173;Lindau syndrome treated with, 167</p>
			<p class="em-only_endmatter-idx1">VIEW 1 study, 83</p>
			<p class="em-only_endmatter-idx1">VIEW 2 study, 83</p>
			<p class="em-only_endmatter-idx1">Vigabatrin, 305</p>
			<p class="em-only_endmatter-idx1">Visceral larval migrans, 244</p>
			<p class="em-only_endmatter-idx1">Vision loss</p>
			<p class="em-only_endmatter-idx2">arteritic &#173;causes of, 195</p>
			<p class="em-only_endmatter-idx2">branch ret&#173;i&#173;nal vein occlusion as cause of, 128</p>
			<p class="em-only_endmatter-idx2">&#173;causes of, 346</p>
			<p class="em-only_endmatter-idx2">central ret&#173;i&#173;nal artery occlusion as cause of, 143–144</p>
			<p class="em-only_endmatter-idx2">in diffuse unilateral subacute neuroretinitis, 246</p>
			<p class="em-only_endmatter-idx2">fungal endophthalmitis as cause of, 239</p>
			<p class="em-only_endmatter-idx2">rhegmatogenous ret&#173;i&#173;nal detachment as cause of, 128</p>
			<p class="em-only_endmatter-idx2">in toxocariasis, 245</p>
			<p class="em-only_endmatter-idx2">vitreous hemorrhage as cause of, 346</p>
			<p class="em-only_endmatter-idx1">Visual acuity</p>
			<p class="em-only_endmatter-idx2">in central serous chorioretinopathy, 190</p>
			<p class="em-only_endmatter-idx2">ranibizumab effects on, 80</p>
			<p class="em-only_endmatter-idx1">Visual evoked cortical potential (VECP), 52</p>
			<p class="em-only_endmatter-idx1">Visual evoked potentials (VEPs)</p>
			<p class="em-only_endmatter-idx2">albinism evaluations, 288</p>
			<p class="em-only_endmatter-idx2">in &#173;children, 53</p>
			<p class="em-only_endmatter-idx2">delayed, 52–53</p>
			<p class="em-only_endmatter-idx2">demyelinating optic neuritis findings, 52</p>
			<p class="em-only_endmatter-idx2">description of, 52</p>
			<p class="em-only_endmatter-idx2">flash, 52</p>
			<p class="em-only_endmatter-idx2">flash stimulation for, 53</p>
			<p class="em-only_endmatter-idx2">in nystagmus, 53</p>
			<p class="em-only_endmatter-idx2">optic nerve conduction delay diagnosis with, 52</p>
			<p class="em-only_endmatter-idx2">pattern-&#173;appearance stimulation, 53</p>
			<p class="em-only_endmatter-idx2">pattern electroretinography and, 45–46</p>
			<p class="em-only_endmatter-idx2">pattern-&#173;reversal, 52, 53<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Visual field defects, in acute zonal occult outer retinopathy, 227</p>
			<p class="em-only_endmatter-idx1">Vitamin A deficiency, 261, 289–290</p>
			<p class="em-only_endmatter-idx1">Vitamins, for age-&#173;related macular degeneration, 69, 70<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Vitelliform exudative macular detachment, 272, 274<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Vitelliform macular dystrophy</p>
			<p class="em-only_endmatter-idx2">description of, 32</p>
			<p class="em-only_endmatter-idx2">electro-&#173;oculography findings in, 51</p>
			<p class="em-only_endmatter-idx1">Vitiliginous chorioretinitis. <span class="italic">See</span> Birdshot uveitis</p>
			<p class="em-only_endmatter-idx1">Vitrectomy. <span class="italic">See also</span> Pars plana vitrectomy</p>
			<p class="em-only_endmatter-idx2">complications of, 402<span class="italic">t,</span> 402–403</p>
			<p class="em-only_endmatter-idx2">cystoid macular edema treated with, 159, 393, 394<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">delayed, 360</p>
			<p class="em-only_endmatter-idx2">diabetic macular edema treated with, 388</p>
			<p class="em-only_endmatter-idx2">diabetic retinopathy complications treated with, 107</p>
			<p class="em-only_endmatter-idx2">epiret&#173;i&#173;nal membranes treated with, 382–383</p>
			<p class="em-only_endmatter-idx2">idiopathic macular holes treated with, 384–385, 385<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">immediate, 359</p>
			<p class="em-only_endmatter-idx2">indications for, 359, 381</p>
			<p class="em-only_endmatter-idx2">instrumentation used in, 381–382</p>
			<p class="em-only_endmatter-idx2">needle perforation/penetration of globe treated <br />with, 396</p>
			<p class="em-only_endmatter-idx2">open-&#173;angle glaucoma risks secondary to, 402</p>
			<p class="em-only_endmatter-idx2">open-&#173;globe injuries treated with, 359–360</p>
			<p class="em-only_endmatter-idx2">posteriorly dislocated intraocular lenses treated <br />with, 393</p>
			<p class="em-only_endmatter-idx2">posterior vitreous detachment treated with, 333<span class="italic">f,</span> 359</p>
			<p class="em-only_endmatter-idx2">postoperative endophthalmitis treated with</p>
			<p class="em-only_endmatter-idx3">acute-&#173;onset, 388–390, 390<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">bleb-&#173;associated, 390–391, 391<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">chronic (delayed-&#173;onset), 390, 391<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">retained lens fragments &#173;after phacoemulsification treated with, 391–393, 392<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">retinopathy of prematurity treated with, 187</p>
			<p class="em-only_endmatter-idx2">rhegmatogenous ret&#173;i&#173;nal detachment treated with, 324, 400<span class="italic">f,</span> 400–401</p>
			<p class="em-only_endmatter-idx2">smaller-&#173;gauge instrumentation used in, 382</p>
			<p class="em-only_endmatter-idx2">submacular hemorrhage treated with, 385, 386<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">suprachoroidal hemorrhage treated with, 394–395, 395<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">technique for, 381</p>
			<p class="em-only_endmatter-idx2">tractional ret&#173;i&#173;nal detachment treated with, 325, 387–388</p>
			<p class="em-only_endmatter-idx2">visualization aids used in, 381–382</p>
			<p class="em-only_endmatter-idx2">vitreous hemorrhage treated with, 366, 386–387</p>
			<p class="em-only_endmatter-idx2">vitreous opacities treated with, 348, 386</p>
			<p class="em-only_endmatter-idx1">Vitreomacular adhesions, 336, 336<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Vitreomacular traction (VMT) syndrome</p>
			<p class="em-only_endmatter-idx2">description of, 332, 332<span class="italic">f,</span> 336<span class="italic">t,</span> 336–337, 337<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">epiret&#173;i&#173;nal membranes versus, 382–383</p>
			<p class="em-only_endmatter-idx2">vitrectomy for, 382–384, 384<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Vitreoret&#173;i&#173;nal adhesions, 337</p>
			<p class="em-only_endmatter-idx1">Vitreoret&#173;i&#173;nal lymphoma, primary, 233–234</p>
			<p class="em-only_endmatter-idx1">Vitreoret&#173;i&#173;nal tufts, 311–312, 312<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Vitreous</p>
			<p class="em-only_endmatter-idx2">anatomy of, 7–9, 8<span class="italic">f,</span> 331</p>
			<p class="em-only_endmatter-idx2">ascorbate levels in, 9</p>
			<p class="em-only_endmatter-idx2">attachments of, 7</p>
			<p class="em-only_endmatter-idx2">canals in, 7</p>
			<p class="em-only_endmatter-idx2">cisterns in, 7</p>
			<p class="em-only_endmatter-idx2">collagen fibers in, 7, 344</p>
			<p class="em-only_endmatter-idx2">composition of, 7, 331</p>
			<p class="em-only_endmatter-idx2">cytomegalovirus retinitis findings, 235</p>
			<p class="em-only_endmatter-idx2">definition of, 331</p>
			<p class="em-only_endmatter-idx2">degeneration of, 344</p>
			<p class="em-only_endmatter-idx2">developmental abnormalities of</p>
			<p class="em-only_endmatter-idx3">per&#173;sis&#173;tent fetal vasculature, 341–342</p>
			<p class="em-only_endmatter-idx3">prepapillary vascular loops, 341, 341<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">tunica vasculosa lentis, 340–341</p>
			<p class="em-only_endmatter-idx2">enhanced depth imaging optical coherence tomography of, 25</p>
			<p class="em-only_endmatter-idx2">familial exudative vitreoretinopathy of, 343–344, 345<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">hereditary hyaloideoretinopathies with optically empty vitreous, 342–343, 343<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">hyalocytes in, 7</p>
			<p class="em-only_endmatter-idx2">liquefaction of, 316–317, 344</p>
			<p class="em-only_endmatter-idx2">opacities of</p>
			<p class="em-only_endmatter-idx3">amyloidosis, 348, 349<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">asteroid hyalosis, 346<span class="italic">f,</span> 346–347</p>
			<p class="em-only_endmatter-idx3">bilateral, 348</p>
			<p class="em-only_endmatter-idx3">cholesterolosis, 348</p>
			<p class="em-only_endmatter-idx3">pigment granules, 348</p>
			<p class="em-only_endmatter-idx3">vitrectomy for, 386</p>
			<p class="em-only_endmatter-idx3">vitreous degeneration and detachment associated, 344</p>
			<p class="em-only_endmatter-idx3">vitreous hemorrhage, 347</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal cavernous hemangioma bleeding into, 168</p>
			<p class="em-only_endmatter-idx2">surgery-&#173;related abnormalities of, 349–350</p>
			<p class="em-only_endmatter-idx2">syneresis of, 307, 316</p>
			<p class="em-only_endmatter-idx2">traction, 208</p>
			<p class="em-only_endmatter-idx2">void of, 7</p>
			<p class="em-only_endmatter-idx1">Vitreous base</p>
			<p class="em-only_endmatter-idx2">avulsion of, 315, 316<span class="italic">f,</span> 331</p>
			<p class="em-only_endmatter-idx2">posterior border of, 10</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal dialyses at, 315</p>
			<p class="em-only_endmatter-idx2">vitreous gel attachment to, 307</p>
			<p class="em-only_endmatter-idx1">Vitreous body</p>
			<p class="em-only_endmatter-idx2">anatomy of, 8<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">anterior surface of, 7, 8<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">topographic areas of, 7</p>
			<p class="em-only_endmatter-idx1">Vitreous detachment</p>
			<p class="em-only_endmatter-idx2">perifoveal, 337</p>
			<p class="em-only_endmatter-idx2">posterior</p>
			<p class="em-only_endmatter-idx3">age-&#173;related, 307–308</p>
			<p class="em-only_endmatter-idx3">anatomy of, 331</p>
			<p class="em-only_endmatter-idx3">atrophic holes presenting with, 318</p>
			<p class="em-only_endmatter-idx3">cholesterolosis and, 348</p>
			<p class="em-only_endmatter-idx3">conditions associated with, 307</p>
			<p class="em-only_endmatter-idx3">definition of, 331</p>
			<p class="em-only_endmatter-idx3">diagnosis of, 331</p>
			<p class="em-only_endmatter-idx3">epiret&#173;i&#173;nal membranes. <span class="italic">See</span> Epiret&#173;i&#173;nal membranes (ERM)</p>
			<p class="em-only_endmatter-idx3">examination of, 309</p>
			<p class="em-only_endmatter-idx3">fibroglial tissue in, 331</p>
			<p class="em-only_endmatter-idx3">floaters associated with, 308–309</p>
			<p class="em-only_endmatter-idx3">idiopathic macular holes, 337–339, 338<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">imaging of, 308<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">indirect ophthalmoscopy of, 309, 331</p>
			<p class="em-only_endmatter-idx3">management of, 309</p>
			<p class="em-only_endmatter-idx3">myopia macular retinoschisis in, 209</p>
			<p class="em-only_endmatter-idx3">nonproliferative diabetic retinopathy progression affected by, 102</p>
			<p class="em-only_endmatter-idx3">optical coherence tomography of, 309, 332</p>
			<p class="em-only_endmatter-idx3">in pars plana vitrectomy for diabetic macular edema, 115</p>
			<p class="em-only_endmatter-idx3">pathologic conditions caused by, 332</p>
			<p class="em-only_endmatter-idx3">photopsias associated with, 308</p>
			<p class="em-only_endmatter-idx3">prevalence of, 331</p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal breaks associated with, 309</p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal tears caused by, 307, 308<span class="italic">f,</span> 309</p>
			<p class="em-only_endmatter-idx3">risk &#173;factors for, 309</p>
			<p class="em-only_endmatter-idx3">signs and symptoms of, 308</p>
			<p class="em-only_endmatter-idx3">slit-&#173;lamp biomicroscopy of, 331</p>
			<p class="em-only_endmatter-idx3">vitrectomy for, 333<span class="italic">f,</span> 359</p>
			<p class="em-only_endmatter-idx3">vitreomacular adhesions, 336, 336<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx3">vitreomacular traction syndrome, 332, 332<span class="italic">f,</span> 336<span class="italic">t,</span> 336–337, 337<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx3">vitreous hemorrhage associated with, 309</p>
			<p class="em-only_endmatter-idx1">Vitreous gel</p>
			<p class="em-only_endmatter-idx2">age-&#173;related changes in, 331</p>
			<p class="em-only_endmatter-idx2">attachment of, to vitreous base, 307</p>
			<p class="em-only_endmatter-idx2">composition of, 7</p>
			<p class="em-only_endmatter-idx1">Vitreous hemorrhage</p>
			<p class="em-only_endmatter-idx2">in central ret&#173;i&#173;nal vein occlusion, 135</p>
			<p class="em-only_endmatter-idx2">echography for, 347</p>
			<p class="em-only_endmatter-idx2">peripheral neovascularization, 232</p>
			<p class="em-only_endmatter-idx2">photocoagulation as cause of, 379</p>
			<p class="em-only_endmatter-idx2">in polypoidal choroidal vasculopathy, 75</p>
			<p class="em-only_endmatter-idx2">posterior vitreous detachment and, 309</p>
			<p class="em-only_endmatter-idx2">in proliferative diabetic retinopathy, 103, 103<span class="italic">f,</span> 107–108, 386–387</p>
			<p class="em-only_endmatter-idx2">trauma-&#173;related, 357</p>
			<p class="em-only_endmatter-idx2">treatment of, 309</p>
			<p class="em-only_endmatter-idx2">in Valsalva retinopathy, 171</p>
			<p class="em-only_endmatter-idx2">vision loss caused by, 346</p>
			<p class="em-only_endmatter-idx2">vitrectomy for, 366, 386–387</p>
			<p class="em-only_endmatter-idx1">VKH disease. <span class="italic">See</span> Vogt-&#173;Koyanagi-&#173;Harada (VKH) disease</p>
			<p class="em-only_endmatter-idx1">VMT. <span class="italic">See </span>Vitreomacular traction (VMT) syndrome</p>
			<p class="em-only_endmatter-idx1">Vogt-&#173;Koyanagi-&#173;Harada (VKH) disease, 232<span class="italic">f,</span> 232–233</p>
			<p class="em-only_endmatter-idx1">Volume rendering</p>
			<p class="em-only_endmatter-idx2">B-&#173;scans versus, 27</p>
			<p class="em-only_endmatter-idx2">macular telangiectasia on, 31</p>
			<p class="em-only_endmatter-idx1">von Hippel–&#173;Lindau (VHL) syndrome, 165–168, 166<span class="italic">–&#173;</span>167<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Voriconazole</p>
			<p class="em-only_endmatter-idx2">fungal endophthalmitis treated with, 239</p>
			<p class="em-only_endmatter-idx2">yeast endophthalmitis treated with, 240</p>
			<p class="em-only_endmatter-idx1">Vortex veins, in choroid, 19</p>
			<p class="em-only_endmatter-idx1">VZV. <span class="italic">See</span> Varicella-&#173;zoster virus</p>
			<p class="em-only_endmatter-idx-alpha">Waardenburg syndrome, 282<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Wagner disease, 342–343</p>
			<p class="em-only_endmatter-idx1">Wagner hereditary vitreoret&#173;i&#173;nal degeneration, 282<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx1">Wandering nystagmus, 266</p>
			<p class="em-only_endmatter-idx1">Watershed defects, 198</p>
			<p class="em-only_endmatter-idx1">&#173;Water transport, in ret&#173;i&#173;nal pigment epithelium, 18</p>
			<p class="em-only_endmatter-idx1">Wegener granulomatosis. <span class="italic">See</span> Granulomatosis with polyangiitis</p>
			<p class="em-only_endmatter-idx1">Weight, IGF-1, neonatal ROP (WINROP) <br />algorithm, 182</p>
			<p class="em-only_endmatter-idx1">Weiss ring, 308<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">WESDR. <span class="italic">See</span> Wisconsin Epidemiologic Study of Diabetic Retinopathy</p>
			<p class="em-only_endmatter-idx1">West African crystalline retinopathy, 303–304, 305<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">West Nile virus chorioretinitis, 246, 247<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">“Wet” age-&#173;related macular degeneration. <span class="italic">See</span> Neovascular (“wet”) age-&#173;related macular degeneration</p>
			<p class="em-only_endmatter-idx1">Whiplash injuries, 356–357</p>
			<p class="em-only_endmatter-idx1">White dot syndromes</p>
			<p class="em-only_endmatter-idx2">acute posterior multifocal placoid pigment epitheliopathy, 220<span class="italic">t,</span> 221<span class="italic">f,</span> 221–222</p>
			<p class="em-only_endmatter-idx2">birdshot uveitis, 220<span class="italic">t,</span> 224–225, 225<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">characteristics of, 220<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">multifocal choroiditis, 220<span class="italic">t,</span> 225–226, 226<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">multifocal choroiditis and panuveitis syndrome, <br />220<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">multiple evanescent, 220<span class="italic">t,</span> 223–224, 224<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">punctate inner choroidopathy, 220<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">serpiginous choroidopathy, 220<span class="italic">t,</span> 222–223, 223<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Wide-&#173;angle fluorescein angiography</p>
			<p class="em-only_endmatter-idx2">description of, 36, 37<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx2">von Hippel–&#173;Lindau syndrome on, 167, 167<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Wilson disease, 362</p>
			<p class="em-only_endmatter-idx1">Win&#173;dow defect, hyperfluorescence in, 36</p>
			<p class="em-only_endmatter-idx1">Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), 92</p>
			<p class="em-only_endmatter-idx1">Wyburn-&#173;Mason syndrome, 168</p>
			<p class="em-only_endmatter-idx-alpha">Xanthophyll, 373, 374<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Xanthopsia, 305</p>
			<p class="em-only_endmatter-idx1">X-&#173;linked cone dystrophy, 253<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">X-&#173;linked congenital stationary night blindness, 252</p>
			<p class="em-only_endmatter-idx1">X-&#173;linked retinitis pigmentosa, electroretinography findings in, 50</p>
			<p class="em-only_endmatter-idx1">X-&#173;linked retinoschisis (XLRS)</p>
			<p class="em-only_endmatter-idx2">characteristics of, 278<span class="italic">f,</span> 278–279</p>
			<p class="em-only_endmatter-idx2">electroretinography findings in, 46, 47<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">XLRS. <span class="italic">See</span> X-&#173;linked retinoschisis</p>
			<p class="em-only_endmatter-idx-alpha">Yeast endophthalmitis, 239–240, 240<span class="italic">f</span></p>
			<p class="em-only_endmatter-idx1">Yellow &#173;laser, 374</p>
			<p class="em-only_endmatter-idx-alpha">Zeaxanthin</p>
			<p class="em-only_endmatter-idx2">age-&#173;related macular degeneration managed with, 70<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">description of, 367</p>
			<p class="em-only_endmatter-idx1">Zellweger syndrome, 283<span class="italic">t,</span> 290</p>
			<p class="em-only_endmatter-idx1">Zika virus chorioretinitis, 247</p>
			<p class="em-only_endmatter-idx1">Zinc</p>
			<p class="em-only_endmatter-idx2">age-&#173;related macular degeneration managed with, <br />69, 70<span class="italic">t</span></p>
			<p class="em-only_endmatter-idx2">in intraocular foreign body, 362</p>
			<p class="em-only_endmatter-idx1">Zonulae occludentes, 17</p>
			<p class="em-only_endmatter-idx1">Zonular traction ret&#173;i&#173;nal tufts, 311, 312<span class="italic">f</span></p>
		</div>
	</body>
</html>
